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Abstract 
Background: Pneumococcal colonisation, although usually asymptomatic, is key to the 
pathogenesis of invasive disease. Colonisation is infrequently detected in older adults, 
despite their high rates of pneumococcal disease; this may relate to sampling from the 
wrong site or reliance on culture-based rather than molecular diagnostic methods.  Anti-
pneumococcal immunity (including responses to vaccination) declines with age, but the 
immunogenicity of colonisation in older adults has not been studied. Alongside innate 
immunity, three specific defence mechanisms exist against pneumococcal disease: herd 
immunity, adaptive immunity (conferred by natural or vaccine-induced antibodies) and 
antibiotics.  Current pneumococcal vaccines confer incomplete protection against 
pneumococcal disease in older adults.   
Research Questions: 
1. Can experimental human pneumococcal colonisation be safely established in older 
adults? 
2. What is the rate of experimental colonisation in older adults?  
3. Do anti-pneumococcal antibodies (natural or post-vaccination) prevent 
experimental colonisation in older adults? 
4. Is experimental colonisation immunogenic in older adults? 
5. What is the optimal sampling site and diagnostic methodology for detecting 
colonisation in older adults? 
6. What do colonisation studies of the general adult population reveal about herd 
immunity and pneumococcal antimicrobial resistance in the community? 
Findings: Experimental colonisation was established in 39% of volunteers (n = 25/64) with 
no adverse events. Experimental colonisation was unaffected by previous pneumococcal 
polysaccharide vaccination or baseline anti-capsular antibody levels.  Although the rate of 
experimental colonisation was similar to that of younger volunteers in previous studies, the 
immune responses were markedly different: older adults did not demonstrate serotype-
specific immune boosting following pneumococcal colonisation.  Furthermore, 
pneumococcal challenge without colonisation led to a drop in specific antibody levels.  
Nasal wash culture appeared to be the optimal detection strategy compared with 
molecular testing of nasal wash, oropharyngeal swab or saliva.   
In a review of all prospective experimental human pneumococcal colonisation volunteers 
between 2010 and 2017, community-acquired colonisation was identified at baseline in 
6.5% (n = 52/795) using nasal wash culture. The commonest serotype was 3 (a vaccine 
serotype), but otherwise non-vaccine serotypes predominated.  There were no changes in 
serotype distribution over time.  15% of isolates (n = 8/52, all identified in 2015 or later) 
were resistant to at least one of the antibiotics tested.   
Conclusions: Experimental pneumococcal colonisation is feasible and safe in older people.   
However, the immunological effects are different to those identified in younger adults in 
previous studies.  We found no evidence that the niche of colonisation changes with age.  
Nasal wash culture detected higher-than-expected rates of community-acquired 
colonisation in young adults, with the dominance of non-vaccine serotypes suggesting that 
the limits of herd immunity have been reached.  New pneumococcal vaccines are needed 
for older adults, and the experimental colonisation model could be used in early phase 
testing of candidate vaccines.  If such vaccines continue to rely on serotype-specific 
protection, then community colonisation studies could inform the serotype composition.   
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1 Introduction 
Streptococcus pneumoniae (the pneumococcus), a gram-positive, encapsulated, aerobic 
diplococcal bacterium, is responsible for high levels of morbidity and mortality across the 
globe.  Throughout history, humans have suffered from pneumococcal disease and the 
pneumococcus has evolved in parallel with us (1).  Over 90 different pneumococcal 
serotypes, defined by capsular polysaccharide (CPS) have been reported, and these vary 
substantially in their propensities to cause colonisation and/or disease (2, 3).  Serotype 
distributions vary substantially across populations, age-groups and time periods (4, 5).  This 
Introduction comprises an overview of pneumococcal disease and colonisation, followed by 
our three main defences against pneumococcal disease: natural immunity, vaccination and 
antibiotics.   
1.1 The burden of pneumococcal disease in adults 
1.1.1 Pneumococcal pneumonia 
Community-acquired pneumonia (CAP) is the sixth biggest cause of death in the UK; it kills 
29,000 people and leads to over 200,000 hospitalizations and 2.3 million bed days each 
year (6).  The pneumococcus is the single commonest identifiable bacterial cause of CAP, 
accounting for 40% of cases in the UK (7).  In resource-limited settings, the burden of 
pneumococcal CAP is even higher (8, 9).  Pneumococcal infections are particularly 
problematic for people aged over 65, who have up to a five-fold increase in the incidence 
and mortality of pneumococcal CAP relative to those aged under 65 (10, 11).   In the United 
States, an estimated 600,000 episodes of pneumococcal CAP occur annually, with a total 
cost to society of US$4.85bn (12); hospitalizations for pneumococcal CAP are predicted to 
increase by nearly 100% by the year 2040, with 87% of this increase accounted for by the 
older people (13).   
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1.1.2 Pneumococcal meningitis 
Pneumococcal meningitis frequently results in death or long-term sequelae, with mortality 
rates exceeding 30% in some settings (14).  Although pneumococcal meningitis is a global 
disease affecting all age-groups, it has substantially higher mortality in older people (15).  In 
resource-rich settings, the pneumococcus has become the commonest cause of adult 
bacterial meningitis (particularly in older people), following the reduction in meningococcal 
disease due to childhood vaccination campaigns (16, 17).  In the African meningitis belt, 
outbreaks of pneumococcal meningitis occur in parallel with seasonal outbreaks of 
meningococcal disease in teenagers and young adults (18).  With the successful roll-out of 
effective serogroup A meningococcal vaccines, there are concerns that the pneumococcus 
will become the predominant causative organism of meningitis in Africa as well (19). 
1.1.3 Pneumococcal bacteraemia 
Pneumococcal bacteraemia is associated with substantial mortality whether in isolation or 
when associated with confirmed organ infection, and is associated with increased incidence 
and mortality in older people (20, 21).   
1.2 The importance of pneumococcal colonisation 
The link between pneumococcal nasopharyngeal colonisation (or carriage) and the 
subsequent development of all forms of pneumococcal disease is generally accepted. This 
is supported by both experimental data (murine models of meningitis) and epidemiologic 
studies (children with otitis media and adults with pneumonia) (22-24).  Children aged 
under two years have high rates (over 60%) of nasopharyngeal pneumococcal colonisation 
(25, 26). Up to 15% of colonisation episodes progress to clinical disease (particularly otitis 
media) before an immune response can clear the pathogen, which could be explained by 
the lack of a robust anti-polysaccharide immune response in young children (23, 27, 28).  
5 
 
Colonisation rates fall with increasing age, particularly in well-resourced settings, with rates 
in young adults generally <10% (29, 30).   
Colonised children are a reservoir of pneumococci, which can then spread to other children 
and adults in their household (31, 32).  This mechanism has been postulated as the main 
source of pneumococcal disease in communities; hence, childhood vaccination 
programmes that reduce colonisation are said to induce “herd immunity” (33).  For these 
reasons, epidemiologic and vaccine impact studies focus on children and their families 
rather than a random population sample (32, 34). However, adults also contribute to 
pneumococcal transmission (31), and excluding the general adult population from 
colonisation studies can miss important trends and reservoirs of colonisation (35).   
1.2.1 The definition and determination of colonisation 
A large pan-European study recently reported a pneumococcal carriage prevalence of 1.9% 
in individuals aged >10 years, with a prevalence of 1.2% in UK adults (30).  However, this 
study utilized nasal rather than nasopharyngeal swabs, in order to improve participant 
uptake.  Deep nasopharyngeal swabs are recommended to identify pneumococcal 
colonisation (36).  In adults, the addition of oropharyngeal swabs may increase diagnostic 
sensitivity—a World Health Organisation (WHO) working group concluded that pairing oral 
swabs with nasopharyngeal samples was desirable but not mandatory (36).  Nasal wash 
(instillation and retrieval of sterile saline via the nasal cavity) is another acceptable method 
for pneumococcal detection, with equivalent or superior sensitivity to nasopharyngeal 
swabs (36, 37).  There is no consensus regarding the relevance of samples from other 
niches and the diagnostic methods applied to such samples.  
1.2.2 Pneumococcal colonisation in older adults: a controversial topic 
Table 1.1 lists examples of studies that attempted to define the rate of pneumococcal 
colonisation in older adults (defined as either >60 or >65 years in different studies) . Much 
6 
 
of the variation between these studies can be explained by the different sampling sites—
nasopharyngeal, oropharyngeal or saliva—and detection methods—classical culture, 
quantitative polymerase chain reaction (qPCR) or some combination of the two.   
Table 1.1: Examples of studies attempting to define the rate of pneumococcal colonization in older people  
Reference Year Country Number 
sampled 
Age 
(years) 
Site  Analysis Rate of 
detection of 
pneumococci, 
n (%) 
(32) 2015 UK 599 NR NP Classical 
microbiology 
13 (2.2%) 
(38) 
 
2015 USA 210 81.4 
(6.3)* 
NP Classical 
microbiology 
4 (1.9%) 
(39) 
 
2014 Portugal 3,361 74.56 
(8.2)* 
NP Classical 
microbiology 
with qPCR 
confirmation 
of positive 
specimens 
61 (1.8%) 
OP 15 (0.4%) 
Overall  76 (2.3%) 
(40) 
 
2012 Belgium 503 80.3 
(10.0)* 
NP 
 
Classical 
microbiology 
21 (4.2%) 
(41) 
 
2016 Italy 417 73.97 
(6.66)* 
OP qPCR 41 (9.8%) 
(42) 2013 Italy 283 NR NP Culture-
enriched 
qPCR 
53 (18.7%) 
(43) 2016 Nether-
lands 
330 72.7 
(68.7—
79.0)† 
NP Classical 
microbiology 
16 (5%) 
qPCR 32 (10%) 
OP Classical 
microbiology 
16 (5%) 
 qPCR 58 (18%) 
Overall   75 (23%) 
(44) 2015 Nether-
lands 
270** 69 
(NR)* 
NP Culture-
enriched 
qPCR 
13 (5%) 
OP 31 (11%) 
Saliva 76 (28%) 
Overall  91 (34%)†† 
All studies enrolled community-dwelling adults 
NP: Nasopharyngeal; NR: Not reported; OP: Oropharyngeal; qPCR: quantitative polymerase chain reaction 
* Mean (SD) 
† Median (IQR) 
**135 subjects, sampled both pre and post influenza-like illness. At a participant level, 65/135 (48%) tested 
positive on at least one occasion.   
††Subjects could test positive by one or both methods, hence “overall” does not equal the sum total of the 
separate methods 
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Our understanding of pneumococcal colonisation, disease susceptibility and natural 
immunity in children, young adults and murine models derives from traditional bacterial 
culture methods in nasopharyngeal specimens (23, 45).  For example, salivary qPCR in 
children can suggest rates of colonisation approaching 100% (46), but this has yet to be 
correlated with immunological endpoints (such as the generation or boosting of anti-
capsular antibodies), incidence of clinical disease or protection against future acquisition.   
While studies of nasopharyngeal swab cultures from older adults have shown lower rates 
of colonisation than in children (1.8—4.2%) (38-40), the addition of oral swabs and the 
combination of traditional culture and qPCR can estimate rates of colonisation (if defined 
as ≥1 sample from any site testing positive by any method) to as high as 23% in an older 
population (43), or 34% if saliva is also sampled (44).   False positive qPCR results from 
other oral streptococci are also a concern, although steps have been taken to increase the 
test specificity in recent studies, for example by performing qPCR against two rather than 
one pneumococcal gene target (47).   
Thus, although classical microbiological analysis on nasopharyngeal samples from older 
adults does not have as high a yield as molecular analysis of oral or salivary specimens, it 
has the advantage of allowing a more direct comparison with previous studies.  The choice 
of diagnostic sampling method must always be guided by the research question. One 
cannot simply state that qPCR is “more sensitive” than culture, as the clinicopathological 
significance of qPCR-positive, culture-negative colonisation may not be equivalent to that 
of culture-positive colonisation.  For example, a qPCR-positive, culture-negative result 
might imply low-density pneumococcal colonisation (48), which could have lower potential 
to cause disease or spread to other hosts (24).  Similarly, the detection of pneumococcal 
DNA in the oropharynx may not represent the presence of viable pneumococci.   
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Most importantly, high nasopharyngeal colonisation rates in older people (23%, as defined 
by classical culture) have been demonstrated during an outbreak in a nursing home (49), 
suggesting that culture-positive nasopharyngeal colonisation may be a clinically relevant 
measurement in this population.   
In this thesis, for the reasons outlined above and to be consistent when comparing studies 
of children, adults, older adults and mice, we define colonisation as the isolation of 
pneumococci from the nasopharynx by culture-based methods unless otherwise stated.   
1.2.3 Risk factors for pneumococcal colonisation 
Studies in industrialised countries have consistently identified regular contact with children 
aged <5 years as the biggest risk factor for pneumococcal colonisation (30, 32). Other 
factors, (including sex, crowding, environment and cigarette smoking) have been 
inconsistently associated with colonisation in different studies (4, 50-52).  Similarly, reports 
differ regarding whether antibiotic therapy in the weeks preceding sampling is associated 
with reduced risk of pneumococcal colonisation (50, 53), although recent antibiotics have 
been associated with increased risk of colonisation by antibiotic-resistant pneumococci in 
children (54-56).   
1.3 The relationship between colonisation and immunity 
Pneumococcal colonisation may be a necessary evil: exposure to pneumococcal antigens 
via repeated episodes of colonisation is key to acquiring and sustaining anti-pneumococcal 
immunity.   
Throughout childhood, adolescence and early adulthood, immunity against pneumococcus 
improves with age.  Colonisation rates fall with increasing age, along with a corresponding 
reduction in pneumococcal disease (25). It seems that repeated colonisation episodes lead 
to the development of protective immunity against the most prevalent circulating 
pneumococcal serotypes (anti-CPS antibodies are specific to a given serotype) (57).  
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Following the maturation of the immune system and multiple episodes of colonisation, 
young adults have well-functioning immune systems and established serotype-specific 
immunologic memory (29).   
Naturally-acquired immunity is multifactorial: non-serotype-specific anti-pneumococcal 
immunity develops alongside serotype-specific immunity in children, through mechanisms 
that have not been entirely elucidated (58).  In young infants with immature anti-CPS 
responses, epidemiological studies have suggested that non-serotype-specific immunity 
predominates, while serotype-specific immunity comes to the fore in older children (59) 
(57).  In adulthood, both epidemiologic and controlled human infection studies have 
suggested that serotype-specific immunity plays a major role in controlling colonisation (29, 
60).  We hypothesize that anti-pneumococcal immunity in older adults is more akin to that 
of young adults than to that of infants.  
Young adults experience very low morbidity and mortality from pneumococcal disease (e.g. 
3.1 cases annually per 100,000 population, versus 38.6 cases per 100,000 population in 
children aged under one year) (15), and their serotype-specific immunity is boosted by 
occasional episodes of asymptomatic colonisation (29, 31, 60).  However, in old age, a 
paradox emerges: while nasopharyngeal colonisation is less common in older adults (Table 
1.1), they are at extremely high risk of pneumococcal disease.   
One hypothesis suggests that the same mechanism (immunosenescence) determines 
increasing disease susceptibility with reduced colonisation: increased circulating levels of 
pro-inflammatory cytokines (“inflammaging”) could lead to clearance of colonisation 
before a natural boosting of pre-existing immunity could take place (61-63).  Equally but 
oppositely, inflammaging-induced chronic activation of inflammatory pathways can result 
in impaired upregulation of inflammation in response to pneumococcal challenge: a murine 
study found that baseline levels of upper respiratory tract pro-inflammatory cytokines (e.g. 
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toll-like receptor 1 and interleukin 1β) were higher in older than younger mice, but that 
pneumococcal colonisation resulted in increased levels of these cytokines in younger but 
not older mice [Krone 2013].   
An alternative line of enquiry explores that hypothesis that colonisation is under-detected 
in older people (e.g. due to poor choice of sampling site and/or method) and that it is a 
precursor to disease, which cannot be prevented by the senescent immune system.  
Mucosal immunity may be more durable than systemic humoral immunity (to be discussed 
in detail later)—this could explain a protection against colonisation but susceptibility to 
invasive disease. Regardless, older adults are clearly at high risk of pneumococcal disease, 
and therefore their natural anti-pneumococcal immunity must differ from that of younger 
adults.  Declines in both innate and adaptive immunity combined with increased rates of 
comorbidities all contribute to this (64), but we will focus here on antibody-mediated 
immunity.  
1.3.1 Naturally-acquired pneumococcal CPS antibodies 
Natural immunity arises following episodic colonisation.  Colonisation leads to increased 
serum levels of anti-pneumococcal antibodies, which are detectable in all adults (65, 66).  
In this section we will discuss their role in the control of pneumococcal disease.  Anti-CPS 
antibodies are the most widely-studied antibodies and are the direct effectors of vaccine-
induced protection, and therefore we focus on these.  The importance of anti-
pneumococcal antibodies is further supported by the first effective treatment for 
pneumococcal disease: passive immunotherapy, i.e. the transfer of specific immune serum 
from naturally-immune donors or immunized animals to patients with pneumococcal 
pneumonia (67).   
In addition to antibodies generated by natural colonisation, others have reported on 
naturally-arising polyvalent antibodies (often IgM) with potent anti-pneumococcal activity 
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(68)—whether these antibodies are analogous to those that arise following colonisation is 
unclear.  Furthermore, it is possible that these antibodies undergo refinement and 
increased specification over time, stimulated by antigen presentation (69).  In this thesis we 
define naturally-acquired antibodies as those that arise following pneumococcal exposure.   
Anti-CPS antibodies bind to the pneumococcal capsule and opsonise the bacteria, 
improving phagocytosis and downstream killing.  In addition, antibodies can promote an 
innate immune response by activating the classical complement pathway; in murine 
models this appears to be the dominant complement pathway in anti-pneumococcal 
immunity and is mediated via natural IgM rather than IgG (70).   
1.3.2 Protective antibodies are a product of nasopharyngeal colonisation 
Anti-CPS antibodies are particularly effective in control of bloodstream infections: passive 
transfer of human antibodies (generated following experimentally-induced colonisation) 
was protective in a murine model of lethal bacteraemia (60).  Passive transfer of pre-
colonisation serum from the same human volunteers conferred a lesser survival benefit. In 
a separate murine lethal challenge model, CD4-deficient knockout mice were able to 
mount a protective antibody response following experimental colonisation and survive 
subsequent bacteraemic challenge, whereas antibody-deficient knockout mice had no 
survival benefit from prior colonisation (71).  Experimental colonisation of mice also 
generated a protective response against subsequent pneumonia (45).  However, this 
experiment found that all arms of the innate and adaptive immune systems were required 
for protection: depletion of any of B-cells, neutrophils or CD4 T-cells eliminated the 
protective response.  This suggests that the control of mucosal disease is more complex 
than the control of bloodstream disease.  Thus, based on the evidence accumulated from a 
combination of murine and human challenge models, antibodies induced by pneumococcal 
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colonisation have been shown to confer protection against bacteraemia and contribute to 
protection against pneumonia.   
1.3.3 Clearance of colonisation is a multifaceted process 
Antibodies have an important role in the protection against becoming colonised. In mice, 
passive transfer of antibodies led to agglutination of bacteria following intranasal 
challenge, which caused the bacteria to clump and become more vulnerable to mucociliary 
clearance (72).  Pneumococcal antibody-mediated agglutination has also been 
demonstrated in humans following vaccination with pneumococcal conjugate vaccine (PCV) 
(73).  In this study, naturally-acquired antibodies were present in the nasopharynx prior to 
vaccination, but not in sufficient levels to induce agglutination.   Murine studies have 
suggested that the clearance of established colonisation is primarily mediated by CD4 T-
cells and interleukin 17 (IL-17), with a possible contribution from anti-protein antibodies 
(74-76). Thus, it appears that anti-CPS antibodies generated during a colonisation episode 
do not have a role in its clearance, though they may be protective against the future 
acquisition of colonisation and subsequent development of disease.  This role of anti-CPS 
antibodies is supported by clinical studies demonstrating a reduction in vaccine-serotype 
pneumococcal colonisation in vaccinated children, reaching virtual elimination in some 
countries (77). The functional importance of anti-CPS antibodies is summarized in Figure 
1.1.   
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Figure 1.1: Anti-capsular antibodies facilitate pneumococcal killing and can prevent colonisation 
(Prior to submission, this figure was published in a review article based on this chapter (78), included in this 
thesis as Appendix 10) 
1.3.4 Antibodies as a marker of pneumococcal exposure 
Colonisation-associated boosting of serotype-specific anti-CPS antibodies has been 
harnessed by researchers as a surrogate marker of pneumococcal colonisation (29, 79).  
Antibody titres vary markedly between individuals and between serotypes, so 
“seroincidence” estimation compares titres from two timepoints to assess for 
pneumococcal colonisation during the intervening period.  Seroincidence can only estimate 
carriage rates for the most common serotypes, as it is generally not practical to measure 
antibodies against all 96 serotypes.  Despite these limitations, seroincidence correlated well 
with observed colonisation rates in children in one study (79).   
1.3.5 Why does lifelong pneumococcal exposure not protect older people? 
If pneumococcal colonisation leads to the generation of antibodies, and these antibodies 
are protective against reacquisition of pneumococcus, then older people should be 
particularly well protected against pneumococcal disease.  Clearly this is not the case, and 
several explanations have been proposed.  Vaccine-induced antipneumococcal antibodies 
wane over time, and require booster vaccines in order to maintain protective levels. 
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Perhaps colonisation-induced antibodies may require boosting by regular episodes of 
colonisation (60), and this is too infrequent in older populations for boosting to occur.  
Otherwise, the defect in antibody-mediated immunity lies either with the B-cells 
responsible for secreting the antibodies, or with the antibodies themselves.  Although our 
focus here is on anti-capsular antibodies, other facets of the immune system can also be 
implicated, including T cell control of B cell responses (64), and alteration in neutrophil 
function with age (80).   
1.3.5.1 B cell populations are altered in older people 
IgM memory B-cells, which function in a T cell-independent manner, are a key component 
of antipneumococcal defences (69). A study found that IgM memory B-cells are less 
abundant in older than in younger adults (81).  In addition, aged IgM memory B-cells were 
determined to be functionally inferior in this same study, with a reduced capacity for 
antibody secretion and plasma cell differentiation.  Pneumococcal polysaccharide 
vaccination of the older volunteers led to some improvement in IgM levels and IgM 
memory B cell percentages, but not to the same degree as in younger subjects.  B1 cells are 
another potential culprit; these cells are responsible for producing naturally-acquired anti-
CPS antibodies (while T cell-dependent adaptive antibodies are generated by B2 cells). 
Levels of B1 cells are reduced in older adults (reviewed in (82)).  This is an emerging field, 
and there is a dearth of human studies relevant to this topic outside of the context of 
vaccination—we will explore this in a later section.   
1.3.5.2 Antibodies decline and lose functional efficacy with age.   
Population-based studies have shown that natural anti-CPS IgG and IgM levels fall with age 
(65, 83, 84).  Figure 1.2 shows a schematic of anti-CPS antibody levels and function at 
different ages relative to rates of pneumococcal colonisation and disease.  Antibody 
function (i.e. opsonic activity, or ability to target pathogens for phagocytosis) can vary 
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markedly between individuals; populations with high rates of pneumococcal colonisation 
and disease have higher serum opsonic activity than lower-risk populations, even when 
matched for age and antibody level (85).  For this reason, opsonophagocytic killing activity 
(measured by exposing pneumococci to antibodies of different research subjects, in the 
presence of standardised populations of neutrophils and complement) is a stronger 
correlate of protection than crude antibody levels (86). It is therefore of great importance 
that the naturally-acquired anti-CPS antibodies of older people have less opsonic activity 
than those of young people.  In one study, the concentration of natural serotype-specific 
IgG required for opsonophagocytic killing (defined in the study as phagocytosis of 50% of 
target pneumococci) was up to twice as high in an unvaccinated older population when 
compared with a young population—differences in IgG function between young and old 
were even more substantial than differences in concentrations (80).  Similar, though less 
pronounced differences were seen for IgM. The authors noted that serotype-specific IgM 
concentrations and opsonic activity were poorly correlated, unlike those of IgG. When the 
decline in antibody level and function are combined, this strongly suggests that antibody 
defects are responsible for (or at least contribute towards) the age-related increase in 
vulnerability to pneumococcus.   
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Figure 1.2: Schematic of pneumococcal disease rates, pneumococcal colonisation rates and pneumococcal 
antibody activity in different age groups.  
(Prior to submission, this figure was published in a review article based on this chapter (78), included in this 
thesis as Appendix 10) 
Impaired opsonic functionality relative to antibody levels is seen in immunosuppression 
secondary to a wide variety of aetiologies.  For example, (although not directly comparable 
to an aged population), it is notable that anti-CPS IgG levels in human immunodeficiency 
virus-infected individuals (who have high rates of pneumococcal colonisation as well as 
disease) have reduced anti-CPS IgG opsonic activity when compared with HIV-uninfected 
subjects, even though anti-CPS IgG levels are higher in those with HIV (87).   
An observational study provides some clinical context and supports the hypothesis that 
reduced opsonic functionality in anti-CPS antibodies is a risk factor for pneumococcal 
disease in older people. Sera from patients in the acute and convalescent stages of various 
types of pneumococcal disease were compared with age-matched controls (88).  Only 27% 
of subjects with pneumococcal disease had IgG to their infecting serotype at time of 
presentation (compared to 37% of controls and 42% of colonised subjects).  Furthermore, 
acute antibodies from infected subjects had significantly lower opsonic activity than those 
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of controls or colonised subjects and were less protective via passive transfer in a lethal 
murine challenge model (20% survival vs 100%).  Sixty-two percent of convalescent sera 
had detectable IgG following pneumococcal disease, which demonstrated good function in 
>50% of patients.  Important limitations of this study include substantial loss to follow-up 
between the acute and convalescent phases, no reporting of ages, and no pre-disease 
antibody levels, the last of which means we cannot rule out the possibility of antibody 
sequestration in diseased tissues as an explanation for low circulating levels.   
The functional efficacy of antibodies can also be quantified via antibody avidity.  However, 
avidity does not always correlate with opsonophagocytic activity (89).  Studies differ on 
whether anti-pneumococcal antibody avidity falls with age or rises following vaccination 
(89)(90)(91).  Indeed, one study found that higher levels of antibody avidity correlated with 
increased severity of pneumonia (91); the authors suggested that the increased avidity 
reflected greater lifetime exposure to pneumococci (and hence increased affinity 
maturation over time) in older people who were naturally at risk of severe pneumonia, or 
alternatively boosted avidity during the initial phase of pneumococcal infection.  They 
concluded that avidity was a poor surrogate for susceptibility to pneumococcal disease.   
Most of the more detailed studies of antibody functionality in older people have been 
conducted in the context of vaccination. Vaccination is an obvious strategy to restore 
waning natural anti-CPS immunity.   
1.4 Vaccines against pneumococcal disease 
Vaccination with purified pneumococcal CPS was first described in 1934 (92), with the first 
report of clinical efficacy emerging following its use to halt an outbreak of serotype 1 
pneumococcal pneumonia in Massachusetts in 1938 (93).  A 14-valent pneumococcal 
polysaccharide vaccine (PPV) was formally licensed in 1977, and PPV23 denotes the current 
23-valent formulation, licensed in 1983.   
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Polysaccharide vaccines are not immunogenic in children aged <2 years (94).  However, 
conjugation of the polysaccharide to a protein carrier molecule can overcome this 
limitation (reviewed in (95)).  The pneumococcal protein-conjugated vaccine (PCV) has 
excellent immunogenicity and efficacy in children: a seven-valent conjugate vaccine was 
introduced in the USA in 2000 and in the UK in 2006; the most recent formulation is the 13-
valent PCV13, introduced in the UK in 2010.   
In addition to conferring direct protection against pneumococcal disease in children, 
childhood vaccination programs generate herd protection by reducing colonisation and 
thus halting transmission at a population level (33).  However, serotype replacement has 
abrogated much of this benefit in many settings (96, 97).  Even without significant levels of 
serotype replacement, vaccine type disease remains common in older people after 
childhood vaccination programs are established (98), and residual non-vaccine-type disease 
will persist as a public health problem (16).   
In the USA, current recommendations for adults aged over 65 years advise vaccination with 
PCV13 followed by PPV23 (99).  In the UK, PPV23 is recommended in older adults, but the 
addition of PCV13 was not deemed to be cost-effective, and the use of PPV23 is to be kept 
under review (100).  Recommendations in other Western European countries vary 
considerably (101).   
1.4.1 Current pneumococcal vaccine strategies provide poor protection in older 
adults 
The discrepancies in national vaccination policies stem from the poor (and disputed) 
efficacy of these vaccines in older people.  A Cochrane review in 2013 concluded that 
PPV23 effectively prevents pneumococcal bacteraemia and meningitis, including in older 
adults (102). It has minimal effect at the mucosal level, and thus has not been shown to 
reduce rates of colonisation.  The Cochrane review found no effect of PPV23 on rates of 
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(non-bacteraemic) pneumococcal CAP or all-cause pneumonia, partially due to the 
substantial heterogeneity of studies that were included.  Nonetheless, some individual 
studies—including both observational studies and well-conducted randomized controlled 
trials (RCTs)—have found PPV23 to be efficacious against pneumococcal pneumonia.  For 
example, one double-blind RCT in Japanese nursing home residents (a population expected 
to have a high incidence of pneumonia, and therefore better positioned to detect a vaccine 
effect) found a 62% relative risk reduction of pneumococcal pneumonia, and a 39% relative 
risk reduction of all-cause pneumonia with PPV23 (103).  When data from this study were 
pooled with others for the Cochrane meta-analysis, the effect was no longer significant; 
however, this does not exclude the possibility of a small protective effect against 
pneumococcal pneumonia from PPV23, which would be clinically significant in a high-risk 
population.  An important limitation of the Cochrane review is that the many of the studies 
it included were carried out in a general adult population, with limited data available for 
age-specific subgroup analyses.   
An important study of PPV23 in people aged ≥ 65 years has been published after the 
Cochrane review (104).  This study was observational in nature, but employed a test-
negative design: this reduces several biases and has been found to be similar to RCTs in 
providing estimates of vaccine effectiveness for seasonal influenza vaccines (105).  The 
study, carried out in Japan, found that the effectiveness of PPV23 was 27·4% against all 
pneumococcal CAP and 33·5% against CAP caused by the 23 vaccine serotypes (104).  
Effectiveness was not demonstrated against all-cause pneumonia or mortality.  
Furthermore, it was notable that this effect was only statistically significant for subjects 
who had been vaccinated within the previous two years.   
Conjugated vaccines, while covering fewer serotypes, protect against colonisation in 
children and young adults (106, 107).  In addition to efficacy against vaccine-type 
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bacteraemia and meningitis, PCV13 has been shown to reduce rates of vaccine-type CAP in 
a single large RCT in older adults (CAPiTA) (108).   However, with vaccine efficacy of 45.6%, 
this vaccine did not show complete protection against vaccine-type disease. PCV13 efficacy 
declined with increasing age: In a post-hoc analysis, overall vaccine efficacy against vaccine-
type CAP was 65% in 65-year-old subjects but only 40% in 75-year-olds (109). Furthermore, 
a concomitant increase in non-vaccine type disease was noted, resulting in no effect 
against pneumococcal pneumonia in general, and all-cause mortality was unaffected (108).  
A nested study within CAPiTA found that PCV13 reduced rates of vaccine-type 
pneumococcal colonisation in older adults compared with placebo, but that the effect was 
only detectable up to six months post-vaccine (110).   
1.4.2 Pneumococcal vaccines are variably immunogenic in older people 
The clinical findings reported in the previous section are discordant with immunological 
studies of pneumococcal vaccines in older adults.  In a study of 74 older adults, dialysis 
patients and transplant recipients (i.e. without young healthy controls), PPV23 was found 
to improve anti-CPS IgG levels against three selected vaccine serotypes (6, 14 and 23) and 
not only to improve opsonic activity, but to strengthen the correlation between IgG levels 
and opsonic activity, suggesting that vaccine-induced antibodies are more potent than 
naturally acquired antibodies (111).  A study of 219 adults aged ≥70 years found that PCV7 
was more immunogenic (as measured by concentration and function of post-vaccine anti-
CPS IgG) than PPV23 for all but one of the PCV7 serotypes (112). However, a larger study (n 
= 599) of adults aged 50—80 years found that PCV7 and PPV23 were equally immunogenic 
(as defined by IgG concentrations) at one month and one year following vaccination (84).  
No functional tests were performed.  The reasons for the discrepant results between these 
two studies remains unclear.  A randomized study of nursing home residents aged ≥80 
years found that both PPV23 and PCV7 were immunogenic in this population, with the 
conjugate vaccine resulting in higher IgG levels and opsonic activity for some serotypes, 
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and both vaccines equally immunogenic for others (113).  The effects of single-dose versus 
boosted vaccination, in various combinations, have been assessed in a number of studies 
but with conflicting results (reviewed in (114)).   
The differential effects of the two vaccines on B-cells have been studied extensively.  In a 
cohort of 348 subjects aged 50—70 years, the antibody responses were similar to previous 
studies: PCV7 lead to greater anti-CPS IgG concentrations than PPV23 for some but not all 
serotypes—four out of seven in this case (116).  However, serotype-specific memory B cell 
concentrations increased for all seven serotypes following PCV7 but decreased following 
PPV23 (117).  This is consistent with the T-dependent immunogenicity of PCV7.  
Importantly, repeated doses of unconjugated polysaccharide vaccines do not result in 
immune boosting—rather, the antibody response is inferior to that following primary 
vaccination (hyporesponsiveness) (118).  Memory B cell depletion has been implicated in 
this phenomenon (117), which can be avoided by spacing vaccine administrations by at 
least five years (119).  It is unclear whether repeated natural exposure to pneumococcal 
antigens is associated with hyporesponsiveness, but this intriguing hypothesis has been 
proposed as an additional mechanism of pneumococcal immunodeficiency in older people 
(117) and is an important topic for future research.   
The immune responses to PPV23 across an aged population are heterogeneous. One study 
has suggested that a four-fold increase in IgG concentration from baseline following 
vaccination is protective against recurrent pneumococcal CAP in older adults (115).  This 
study had a number of limitations (including low rates of confirmed pneumococcal 
aetiology in cases of CAP) and has not been replicated.   
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1.4.2.1 The duration of immunity following pneumococcal vaccination is the subject of 
ongoing research 
The above studies based all analyses on blood samples taken up to one month post-
vaccination.  Another study randomized 252 subjects aged 50—80 years to vaccination with 
either single-dose PPV23 or PCV7, or PCV boosted with either PPV23 or repeat PCV7, and 
followed them for two years (120).  Surprisingly, there was no significant difference in the 
quantity of circulating serotype-specific memory B-cells at two years between the four 
groups.  Two-year levels of serotype-specific memory and plasma cells were closely 
correlated with baseline serotype-specific IgG levels, and not with the IgG levels from 7 or 
28 days post-vaccination.  The authors concluded that pre-existing natural anti-
pneumococcal immunity was a more important driver of the post-vaccine immune 
response than the type or schedule of vaccine administered.  No functional assays were 
carried out, and there were no young adult control subjects, but this remains an important 
study.  It is unclear why these authors found no difference in memory B cell concentrations 
between PPV and PCV-vaccinated subjects while other authors found a dramatic difference 
(117), but different experimental methodologies and sampling timepoints between the 
various studies are possible explanations.     
Although some authors have found durable memory B cell responses following either PPV 
or PCV, clinical and antibody-based studies are less reassuring.  PPV-induced antibody 
levels decline in older people over five years (119); while they may not decline to the pre-
vaccination baseline, clinical data consistently show reduced protective efficacy over time, 
suggesting that this decline is relevant and clinically significant (104, 121).  Similar declines 
in opsonic function over time were seen in older adults who received PCV13 (110).  The 
immunological properties of PCV13 (T-cell-dependent immunity, leading to lasting 
immunological memory), suggest that any decline in efficacy would be of a lesser 
magnitude than that of PPV23; however, immunosenescence may well interfere with this.  
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In the CAPiTA trial of PCV13 in over-65s, conducted over four years, clinical efficacy did not 
appear to decline over time (108), although efficacy was lower in the oldest participants 
(109).  This suggests that there an age-related component to the clinical protective 
response following primary vaccination with PCV13. A longer period of follow-up would be 
required to determine the duration of protection in older people, but conjugate vaccines 
do appear to confer longer clinical protection than polysaccharide vaccines.  
1.4.3 Pneumococcal vaccines are more immunogenic in young than in older people 
While uncontrolled studies have shown an improved antipneumococcal immune response 
following vaccination in older people, this is far less impressive than the immune response 
generated by the same vaccine in healthy young people.  A study compared anti-CPS 
antibody levels in 58 volunteers aged >65 years and 44 controls aged <45 years, 28 days 
after they had received PPV23 (no pre-vaccination levels were taken) (122).  For the 
majority of serotypes, antibody levels did not differ significantly between the two groups.  
However, opsonic titres against all but one serotype (18C) were markedly higher in the 
younger subjects.  Antibody potency (opsonization titre divided by the antibody 
concentration) was at least two-fold higher for all serotypes in younger subjects than in 
older subjects, while the amount of antibody needed to achieve a 1:8 opsonization index (a 
putative protective level) in young subjects was less than half of that in the older subjects.   
We are unaware of any direct comparison studies of the immunogenicity of PCV in older 
and younger people.  Murine studies have explored this question, but the results were 
markedly different from with what would be expected in human subjects based on the 
state of current knowledge, and will therefore not be discussed here (123).   
1.4.4 Immunoglobulin subsets present a further area for study 
Immunoglobulin subsets—for example, IgM versus IgG, or even IgG1 versus IgG2—could 
differ between older and younger adults.  IgG responses can be divided into IgG1 
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(classically associated with T-cell independent responses to plain polysaccharide 
vaccination) and IgG2 (classically associated with T-cell dependent responses to PCV in 
children) (95).  However, it is notable that, at least for the meningococcal conjugate 
vaccine, a study found that vaccination of older children and adolescents generated a 
predominantly IgG2 response, with IgG1 responses restricted to the youngest children 
(124).  There is a dearth of research into these subsets specifically in older adults. One 
study of healthy adults of all ages found similar mean concentrations of total IgG1 and IgG2 
at all ages, but greater variability of IgG1 and IgG2 concentrations in individuals aged >70 
years (125).  (124)IgM responses in older adults have been studied in greater detail.   
1.4.5 Anti-CPS IgM responses are markedly deficient in older people 
A study compared sera from 45 healthy older subjects and 55 healthy young controls, all of 
whom had been vaccinated four weeks previously with PPV23, and tested the samples 
against three representative serotypes: 14, 18C and 23F (126).  In keeping with previous 
studies, absolute anti-CPS IgG levels were similar between both groups, but the younger 
adults had higher opsonic activity and potency than the older adults (albeit not achieving 
statistical significance for serotype 18C).  Young adults commonly demonstrated high levels 
of opsonic activity even with low levels of antibody (i.e. the correlation between antibody 
levels and opsonic activity was poor), whereas antibody levels and activity were tightly 
correlated in the older adults.  IgM made a disproportionately significant contribution to 
opsonic activity: when IgM was removed from the young subjects’ samples, their opsonic 
activity was decreased, with stronger correlation between their IgG levels and opsonic 
function.  When all serum samples were depleted of IgM and reanalyzed, the opsonic 
activity of the older adults’ sera did not decline and the differences in opsonic activity 
between old and young subjects were no longer statistically significant.  The authors 
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concluded that reduced functionality of IgM rather than IgG was responsible for the 
reduced opsonic capacity of older adults when compared with younger adults.   
The kinetics of IgM could partially explain the above findings: unlike IgG, post-vaccination 
IgM levels rise more slowly, and to a lower peak, in older adults compared with younger 
adults (127). All samples in the above study were taken quite soon after vaccination.   Little 
is known regarding the duration of IgM responses in older people beyond 28 days post-
vaccination, and thus the relevance of this laboratory-based study to long-term clinical 
protection is not certain.  However, additional research has shown that the underlying IgM 
B cell responses to vaccination, in addition to IgM activity itself, are also diminished in older 
people.   
A study comparing 14 older adults with young controls examined the immune response 
against two of the PPV23 serotypes (14 and 23F) and found that serotype 14-specific IgM 
did not rise significantly following vaccination in the older adults (though anti-23F IgM did) 
(128).  Opsonic activity improved following vaccination in older adults, and this was 
correlated with IgG levels but not with IgM levels, and was significantly lower than the 
opsonic activity of young vaccine recipients, consistent with previous studies.  Flow 
cytometric analysis showed differences between young and older subjects in their post-
vaccination B cell phenotypes: both absolute and relative numbers of CD27+IgM+ (IgM 
memory) B-cells were reduced in the older adults.  The serotype-specific immune response 
in the older adults was dominated by switched memory B-cells (CD27+IgM−).  This 
difference in B cell populations explained the poor IgM response in the older adults, and 
may provide a key insight into the underlying reasons for poor vaccine-induced clinical 
protection in this population, but the small numbers (of both subjects and serotypes 
examined) are an important limitation of this study.   
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Switched memory B-cells comprise part of a T-cell-dependent immune response while IgM 
memory B-cells are T-independent (69).  Regulatory T cell populations are reduced in older 
people (129); this has been implicated in altered inflammatory responses and susceptibility 
to pneumonia in the this population (reviewed in (64)).  Therefore, alterations in T-
dependent immunity coupled with a reduction in T-independent IgM memory B-cells leaves 
older people vulnerable on two fronts.   
IgM defects are unlikely to be the sole reason for the increased susceptibility of older 
people to pneumococcal disease.  However, by virtue of its pentameric structure, IgM 
would be expected to agglutinate and opsonize more efficiently than IgG, and thus even 
small defects in IgM levels or function would be expected to have a disproportionate 
impact.  IgM is also key to activating the complement cascade in response to 
pneumococcus (70).  While the IgM response to PCV has not been widely studied in older 
people, it is key to the immune response to conjugated vaccines in children (130).  
Furthermore, PCV-induced IgM antibodies appear to confer cross-protection against some 
non-vaccine serotypes in children (131)—this has not been demonstrated older people, but 
could represent another domain in which IgM is of key importance.  For now, the above 
data must be regarded as hypothesis-generating rather than conclusive, but they are 
intriguing nonetheless.   
1.5 Antibodies have mucosal as well as systemic activity 
It is generally reported that IgM and IgA are the principal antibodies present at mucosal 
surfaces (132, 133), although the relative contributions of different globulin fractions to 
total antibody levels varies markedly between different organ systems (134).  IgA-mediated 
defence against pneumococcus is limited, as all pneumococci synthesize an efficient IgA1 
protease, abrogating its protective effect (72).  In the final part of this review, we will 
explore the nature of mucosal anti-pneumococcal immunity and its relationship with age.   
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There is a degree of overlap between the mucosal and systemic humoral immune systems, 
and each is capable of influencing the other (133).  Antigens from the nasal mucosal surface 
are presented to nasopharyngeal-associated lymphoid tissue (NALT), leading to both local 
and systemic immune responses. Germinal centres in NALT are responsible for generating 
B-cells that secrete IgA and IgM at the mucosal surface. Furthermore, systemic antibodies 
can be transported from blood to mucosal surfaces.     
1.5.1 Systemic exposure to pneumococcal antigens via vaccination can lead to 
mucosal protection 
One study found that PPV leads to an increase in levels of all classes of anti-CPS in 
secretions (specifically saliva and tears; nasal secretions were not studied) (135). Notably, 
the fold increases in salivary IgG (4.5-fold) and IgM (4.0-fold) were more pronounced than 
that of IgA (2.0-fold).  However, the functional and clinical effects of these antibodies have 
not been explored.   
In young adults, systemic immunization with PCV13 leads to high serum concentrations of 
anti-pneumococcal IgG, which spills over into the nasal mucosal compartment and can, by 
virtue of its agglutinating properties, prevent the development of pneumococcal 
colonisation (73).  This is likely to be the mechanism for the reduction in pneumococcal 
colonisation following infant vaccination.   
1.5.2 Mucosal exposure to pneumococcal antigens can generate both systemic and 
local responses 
As outlined earlier, the upper respiratory mucosa represents humans’ first point of contact 
with the pneumococcus.  Transient pneumococcal exposure (in a human challenge model 
where subjects were inoculated but did not become colonised) resulted in the generation 
of mucosal anti-protein antibodies but not anti-CPS antibodies, and no change in systemic 
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antibody levels (136).  Prolonged exposure via colonisation leads to increases in functional 
local and systemic anti-CPS antibodies (60).   
Without vaccination, antipneumococcal antibody levels at respiratory mucosal surfaces are 
too low to prevent colonisation. However, “priming” by experimental pneumococcal 
colonisation is protective against subsequent colonisation up to one year later (60)—
whether this is due specifically to mucosal antibodies, serum antibodies (à la vaccination), 
T-cell immunity or a combination of these remains undetermined.   
In addition to inducing mucosal and systemic antipneumococcal antibodies, human 
pneumococcal colonisation leads to an increase in the number of pneumococcal-specific 
memory IL-17A+ CD4 T-cells (Th-17 cells) (137).  When stimulated by pneumococci in vitro, 
IL-17A secreted by these Th-17 cells enhanced the phagocytic killing of pneumococci by 
alveolar macrophages.  Importantly, this Th-17 increase is seen in both peripheral blood 
and in the lung itself, thus providing evidence of traffic of acquired immune memory from 
the upper to the lower respiratory tract.  However, an alternative hypothesis is that 
microaspiration of pneumococci during colonisation directly induces a local T cell 
infiltration and differentiation within the lungs.   
In summary, pneumococci are capable of stimulating a specific immune response at the 
mucosal surface in addition to generating systemic immunity.  The multifaceted mucosal 
immune response includes both specific antibodies and memory T-cells, and a response in 
the upper respiratory tract may be echoed in the lower respiratory tract.  High 
concentrations of anti-CPS antibodies at the nasopharyngeal surface can prevent 
pneumococcal acquisition.  A mucosal vaccine against pneumococcus could be a promising 
strategy to provide protection for the vulnerable older population.   
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1.5.3 Mucosal anti-pneumococcal immunity is affected by aging 
Detailed studies of mucosal immunosenescence in general have only been undertaken in 
mice: it appears that nasal immune function deteriorates with age, but at a similar rate to 
systemic immunity, whereas intestinal mucosal immunity “ages” at a faster rate (138).  A 
murine study demonstrated impaired innate antipneumococcal nasal mucosal immunity 
with increasing age: monocyte/macrophage influx in response to colonisation was delayed 
in old (18—23 month) mice compared with younger controls, and the older mice had 
impaired upregulation of innate immune response genes (including Toll-like receptors 1 
and 2, nucleotide-binding oligomerization domain-containing protein 2 and interleukin 1β) 
(139).  The effect of aging on nasal antibodies has not been studied in older humans, but 
salivary antipneumococcal antibodies have been shown to decrease in both concentration 
and rate of secretion with age (140).   
1.5.4 Murine studies of adjuvanted mucosal vaccines have shown promise 
Studies of mucosal vaccination strategies against pneumococcus have only been 
undertaken in murine models (reviewed in (141)) and examined both protein antigens and 
CPS.  The most intriguing findings from these studies have been the effect of novel 
adjuvants on restoring the immune response in aged mice to both protein and 
polysaccharide antigens.  Addition of CpG oligodeoxynucleotides (CpG-ODN) was found to 
improve the systemic and mucosal antibody response to conjugated pneumococcal 
serotype 9V CPS administered nasally to young mice (142).  CpG-ODN enhances antibody 
production through stimulation of type 1 helper T-cells; the underlying mechanism of this 
remains uncertain (143).  This same adjuvant restored the antibody response of aged mice 
to conjugated serotype 14 CPS administered systemically (144).  For nasally-administered 
pneumococcal surface protein A (PspA), a dual adjuvant strategy of CpG-ODN and plasmid-
expressing Flt3 ligand was required to induce similar antibody levels (serum and mucosal 
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IgG and IgA) in young and old mice (145).   This strategy also enhanced PspA-specific CD4 T-
cell responses in old mice and was protective against nasopharyngeal colonisation in these 
mice.   
It must be emphasized that mouse IgA, having a different configuration to human IgA, is 
less susceptible to cleavage by pneumococcal IgA protease.  Thus, if the above findings are 
to have applicability for human vaccination, it will be essential to demonstrate either that 
antibodies are a dispensable component of the mucosal immune response, or that other 
immunoglobulins—such as secretory IgM and IgG—are sufficient for protection in humans.  
If the relative dysfunction of anti-CPS IgM in older humans is indeed of clinical significance, 
then this may prove to be the Achilles’ heel of this vaccination strategy, unless an adjuvant 
can be identified that can restore the function of IgM in older adults.  With this caveat in 
mind, an appropriately-adjuvanted mucosal vaccine could still have enormous potential for 
reducing the burden of pneumococcal disease in older adults.   
1.6 Alternative antibody targets to polysaccharide 
Thus far, we have focused on anti-CPS antibodies.  These antibodies are induced by natural 
exposure to pneumococcus and are also the antigens employed in all currently-licensed 
pneumococcal vaccines.  Furthermore, there is a substantial body of literature comparing 
anti-CPS immunity in young and older adults.  However, the pneumococcus also expresses 
a variety of surface proteins which are conserved across different serotypes, many of which 
have been proposed as vaccine candidates (146) and indeed have been explored in 
mucosal vaccines  in animal models as outlined above.  Parenteral protein-based vaccines 
have shown a degree of promise during early-phase studies in young adults, but have yet to 
achieve their full potential (147).  Anti-protein immune responses have been demonstrated 
following colonisation (60) and may contribute to naturally-acquired protection against 
colonisation (58) although their mechanistic significance has not been definitively 
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established (148).  In children, studies are conflicting regarding whether anti-protein 
antibodies confer protection or serve as a marker of exposure and increased risk of disease 
(149, 150).    In a single study of young adults, antibodies against two out of 27 vaccine-
candidate proteins were found to be elevated following experimental colonisation with 
serotype 6B: PiuA and PspA-UAB055, while none were protective against colonisation (60).   
1.6.1 Anti-protein antibodies in older people 
Anti-protein antibody levels are reduced in older adults (65).  Anti-protein antibody levels 
rise following pneumococcal disease in older adults (151), and there is a suggestion that 
their functionality may not be adversely affected by aging, though these findings remain 
preliminary (German E et al, in press).  Apart from these, and the above-mentioned murine 
studies of mucosal anti-protein immunity, we are unaware of any substantial body of work 
exploring the nature of aging and anti-protein immunity, and this topic must be prioritized 
in future research.  
1.7 Summary of antibody-based pneumococcal immunity 
Impaired naturally-acquired CPS immunity leaves older people vulnerable to pneumococcal 
disease. This may or may not be related to reduced boosting due to infrequent 
pneumococcal colonisation.  The functional antibody responses to current pneumococcal 
vaccines are also suboptimal in older adults.  PCV13 has overcome some, but by no means 
all of the immunological limitations of PPV23.  Reduced antibody functionality combined 
with limited serotype coverage means that pneumococcal vaccination in older adults does 
not deliver as substantial a benefit as would be expected.   
If anti-CPS antibodies are to remain the mediator of protection, then improvements in the 
functionality of aged antibodies will need to be induced.  A mucosal vaccine, with an 
appropriate adjuvant, would be an attractive strategy.  Vaccination strategies seeking to 
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exploit non-capsular antigens or T cell-mediated immunity have shown a degree of promise 
in early-phase studies in young adults, but have yet to achieve their full potential (147).  
Careful studies of anti-protein immunity in older people would guide the exploration of 
such a vaccination strategy in older adults.  Future studies should investigate the dynamics 
of colonisation and mechanisms of naturally-acquired immunity in older people in greater 
detail, as well as exploring the nature of respiratory mucosal immunity in older people, in 
order to better inform vaccine development for this growing and vulnerable population.   
1.8 Controlled human infection models in research 
Studies of pneumococcal colonisation are limited by the sensitivity of diagnostic tests, 
variations in sampling methodology and low prevalence in certain settings, as outlined 
earlier.  Studies of pneumococcal disease have similar limitations.  In recent years, research 
into infectious diseases has been revolutionised by the development of controlled human 
infection models (CHIMs). CHIMs of a wide variety of pathogens have been carried out 
throughout history, particularly in the twentieth century, but many early studies were 
carried out in an ethical vacuum—in the most egregious cases, prisoners were infected 
without their consent (152).  In the decades following the second world war, an ethical 
framework for human challenge studies has been established (153).  CHIMs are now 
generally accepted as essential to study the pathogenesis and prevention of a number of 
infectious diseases (154), including cholera (155), malaria (156) and typhoid (157).  
1.8.1 Experimental Human Pneumococcal Colonisation 
Given that pneumococcal colonisation is key to the pathogenesis of pneumococcal disease 
as well as natural anti-pneumococcal immunity, a CHIM of pneumococcus can be 
established by inducing carriage rather than clinical disease (158).  The Liverpool School of 
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Tropical Medicine (LSTM) established an Experimental Human Pneumococcal Colonisation 
(EHPC) model in 2011.  Exclusion criteria typically comprised: 
• Allergy to penicillin  
• Smoking or ex-smoker with significant history 
• Chronic illness, particularly if expected to affect immunity (such as asthma, 
diabetes) 
• Taking steroids (including steroid nasal spray) or other immunosuppressants 
• Antibiotic therapy in the preceding four weeks 
• Caring responsibilities for children aged < 5 years, hospital patients or people with 
chronic illnesses  
• Pregnancy or lack of adequate contraception (women only) 
Initial studies of the model were carried out in volunteers aged between 18 and 50 years, 
and determined that experimental colonisation is feasible and safe in this population, and 
that it is reproducible (typically resulting in 45% of subjects becoming colonised), 
immunogenic and can be used as a vaccine testing platform (60, 107).    
1.9 Treatment of pneumococcal disease 
In this final section, we discuss the treatment of suspected or confirmed pneumococcal 
disease, with the former being a more common scenario in clinical practice.  Penicillin and 
other β-lactam drugs (such as cephalosporins) have historically been the mainstay of 
therapy for pneumococcal disease.  Other options include macrolides, tetracyclines and 
respiratory fluoroquinolones.   
1.9.1 Local treatment guidelines for pneumococcal disease 
In Table 1.2 and Table 1.3, we present a review of national guidelines and local formularies 
(primary and tertiary care) for the recommended treatment of any of: 
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• Lower respiratory tract infections in healthy adults 
• Suspected pneumococcal disease (pneumonia or meningitis) 
• Confirmed pneumococcal disease (pneumonia or meningitis)  
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Table 1.2: Local and national guidelines relevant to the treatment of suspected or confirmed pneumococcal respiratory infection 
Guideline Clinical scenario First-line antibiotic(s) Alternative antibiotic(s) 
Class(es) Specific agent(s) Class(es) Specific agent(s) 
BTS (7) Empiric treatment of 
mild CAP 
β-lactam 
 
Amoxicillin Macrolide OR 
tetracycline 
Clarithromycin OR Doxycycline 
BTS (7) Empiric treatment of 
severe CAP 
β-lactam 
PLUS 
macrolide 
 
Amoxicillin OR Benzylpenicillin 
OR Amoxicillin-Clavulanate (high 
severity) 
PLUS Clarithromycin 
Tetracycline OR 
fluoroquinolone 
(moderate); OR β-
lactam PLUS macrolide 
(severe) 
Doxycycline OR Levofloxacin 
OR Moxifloxacin (moderate); 
Cefuroxime OR Cefotaxime OR 
Ceftriaxone PLUS 
Clarithromycin (severe) 
BTS (7) Treatment of 
confirmed 
pneumococcal CAP 
β-lactam 
 
Amoxicillin OR Benzylpenicillin Macrolide OR β-lactam 
 
Clarithromycin OR Cefuroxine 
OR Cefotaxime OR Ceftriaxone 
Local hospital Empiric treatment of 
mild CAP 
β-lactam 
 
Amoxicillin Macrolide Clarithromycin 
Local hospital Empiric treatment of 
severe CAP 
β-lactam 
PLUS 
macrolide 
 
Amoxicillin (moderate) OR 
Benzylpenicillin (high severity) 
PLUS Clarithromycin 
Tetracycline OR 
glycopeptide PLUS 
macrolide 
Doxycycline (moderate 
severity); 
Teicoplanin PLUS 
Clarithromycin (high severity) 
Local primary 
care (159) 
Empiric treatment of 
mild CAP 
β-lactam 
 
Amoxicillin Macrolide OR 
tetracycline 
Clarithromycin OR Doxycycline 
Empiric treatment of 
moderately-severe 
CAP 
β-lactam 
PLUS 
macrolide 
Amoxicillin PLUS clarithromycin Tetracycline Doxycycline 
Local primary 
care (159) 
Empiric treatment of 
acute bronchitis 
β-lactam 
 
Amoxicillin Tetracycline Doxycycline 
CAP: Community-acquired pneumonia; Local hospital: Royal Liverpool University Hospital Antimicrobial Formulary (accessed October 2017); Local primary care: Pan-Mersey Area Prescribing 
Committee: Antimicrobial Guide and Management of Common Infections in Primary Care, 2017—2019 (159); National: British Thoracic Society Guidelines for the Management of Community 
Acquired Pneumonia in Adults: update 2009 (7).  All guidelines refer to treatment of adults.   
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Table 1.3: Local and national guidelines relevant to the treatment of suspected or confirmed pneumococcal meningitis. 
Guideline Clinical scenario First-line antibiotic(s) Alternative 
Class Specific agent(s) 
National (160) Treatment of suspected 
bacterial meningitis 
β-lactam (± glycopeptide 
or rifamycin) 
Ceftriaxone OR Cefotaxime; (Add Vancomycin OR 
Rifampicin if recent travel to a region with high 
rates of penicillin resistant pneumococci) 
Chloramphenicol 
National (160) Treatment of 
pneumococcal meningitis 
β-lactam (± glycopeptide 
or rifamycin) 
Ceftriaxone OR Cefotaxime (Benzylpenicillin 
acceptable if MIC ≤ 0.06 mg/L confirmed);  
(Add Vancomycin OR Rifampicin if cephalosporin 
resistance) 
Chloramphenicol 
Local hospital Treatment of suspected 
bacterial meningitis 
β-lactam Ceftriaxone Chloramphenicol 
Local hospital: Royal Liverpool University Hospital Formulary (accessed October 2017); National: The UK joint specialist societies guideline on the diagnosis and management of acute 
meningitis, 2016 (160).  All guidelines refer to treatment of adults.   
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1.9.2 Antimicrobial resistance in pneumococci 
Antimicrobial resistance (AMR) is a growing global threat.  Penicillin and macrolide 
resistance were identified in pneumococci in the 1960s (161) and today penicillin non-
susceptible pneumococci are listed on the WHO’s Global priority list of antibiotic-resistant 
bacteria (162).  Data on invasive pneumococcal isolates from the European Centre for 
Disease Prevention and Control show wide variation in pneumococcal susceptibility profiles 
between different countries, with (for example) >40% of Romanian isolates non-susceptible 
to penicillin versus 0.4% of Belgian isolates (163).  In recent years there has been a trend 
towards reduced rates of AMR in the UK; in 2016, 4.9% of invasive isolates were non-
susceptible to penicillin, 6.5% non-susceptible to macrolides and 2.6% non-susceptible to 
both.   
Microbiology laboratories define antimicrobial resistance based on the minimum inhibitory 
concentration (MIC): the lowest concentration of an antibiotic required to completely 
prevent growth of a given organism (164).  MICs are related to predicted concentrations of 
the given antibiotic (at standard doses) at the site of interest (e.g. in blood or in 
cerebrospinal fluid (CSF)) to predict whether the organism will be successfully treated by 
the antibiotic—this determines the “clinical breakpoint”.  Clinical breakpoints are generally 
determined by national or supranational bodies rather than individual hospitals; in Europe, 
they are set by the European Committee on Antimicrobial Susceptibility Testing (EUCAST) 
(165).   
1.9.2.1 Penicillin non-susceptibility 
Penicillin non-susceptibility in pneumococci derives from mutations in one or more of the 
six penicillin-binding proteins (166), and may have first been acquired via the “scavenging” 
of genes from commensal Streptococcus mitis (167, 168).  The term “penicillin resistance” 
is rarely employed when discussing pneumococci, as the significance of increased 
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pneumococcal MICs to β-lactam antibiotics remains controversial (169-171).  Low-level 
penicillin “resistance” (MIC ≤2 mg/L) can be overcome by high-dose intravenous penicillin 
therapy, as this achieves serum concentrations in excess of the MIC (172, 173).  Penicillin 
reaches lower concentrations in CSF, where its breakpoint is accordingly defined as 0.06 
mg/L.  Clinical and microbiological failure of penicillin monotherapy for bacteraemic 
pneumococcal pneumonia is encountered at higher levels of resistance, when penicillin 
MICs are >2 mg/L (174).  Lower-level penicillin resistance is typically associated with 
alteration of a single penicillin-binding protein, such as PBP-2B, while mutations in multiple 
genes (e.g. the combination of PBB-2A and PBB-2X in one series) confer higher-level 
resistance (175).  Penicillin non-susceptible isolates are usually sensitive to third-generation 
cephalosporins (172), which achieve therapeutic concentrations in CSF if administered at 
maximal doses (176).  Given this reliance on cephalosporins to overcome elevated penicillin 
MICs, it is not surprising that ceftriaxone resistance was associated with mortality from 
pneumococcal bacteraemia in a recent study (173).   
Although the EUCAST guidelines consider non-meningeal infections from pneumococci with 
an MIC up to 2 mg/L to be susceptible to high-dose benzylpenicillin (165), the doses in 
question (2.4g x 4—6/day) are in excess of those routinely recommended in the UK (7).  
Using EUCAST breakpoints, standard doses of benzylpenicillin (1.2g x 4/day) are only 
recommended for pneumonia caused by pneumococci with MICs up to 0.5 mg/L 
1.9.2.2 Macrolide resistance  
Resistance to macrolides typically results from either the acquisition of an efflux pump 
(low-level resistance, via the mef(A) gene) or a mutation in the macrolide binding site in the 
23S ribosomal subunit (high-level resistance, via the erm(B) gene) (168).  Macrolide 
resistance has been unequivocally associated with clinical and microbiological failure in 
cases of both pneumococcal pneumonia and bacteraemia (reviewed in (169)).  
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Nonetheless, larger-scale studies have suggested that the contribution of macrolide 
resistance to adverse clinical outcomes remains small (reviewed in (161)).   
1.9.2.3 Fluoroquinolone resistance 
Fluoroquinolone resistance has also been associated with clinical and microbiological 
failure in cases of pneumococcal pneumonia ((177), others reviewed in (178)).  Prior 
exposure to the non-respiratory fluoroquinolone ciprofloxacin has been hypothesised to 
select for low-level resistance mutations in DNA gyrase and topoisomerase IV in colonising 
pneumococci, with subsequent respiratory fluoroquinolone treatment having the potential 
to select for higher levels of resistance (177).  The lack of large prospective studies prevents 
us from accurately estimating the impact of fluoroquinolone resistance on treatment 
outcomes in pneumococcal disease.   
1.9.2.4 Resistance to other antimicrobials 
Trimethoprim-sulfamethoxazole (TMP-SMX) is not employed against respiratory tract 
infections in the UK.  However, it is widely employed globally as prophylactic therapy in 
HIV-infected patients, in whom it confers protection against invasive bacterial diseases in 
addition to its intended target, Pneumocystis jirovecii.  This has led to high rates (>90%) of 
pneumococcal resistance to TMP-SMX in regions with high HIV prevalence (179).  The 
clinical significance of TMP-SMX resistance remains undetermined.  Similarly, doxycycline is 
rarely administered to critically-ill patients with community-acquired pneumonia in the UK, 
which could result in clinical failures being under-noticed and under-reported.  One author 
estimated—based on rates of resistance, likely impact of resistance, and host factors—that 
there was an 82% likelihood of community-acquired non-meningeal pneumococcal disease 
responding to doxycycline, and a 65% chance for TMP-SMX, versus 97% for ceftriaxone 
(168).  There are no hard data to back up these assertions.  Vancomycin resistance is 
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exceedingly uncommon—thus, this agent remains the drug of “last resort” for 
pneumococci.  
1.9.3 The significance of colonisation with antibiotic-resistant pneumococci 
Given the strong links between pneumococcal colonisation and onward transmission, and 
between pneumococcal colonisation and disease, it is highly likely that resistance rates in 
colonising pneumococci will correlate with those of invasive pneumococci.  This is 
supported by epidemiologic studies in children (180).  Vaccine impact studies also support 
this hypothesis: when vaccine-serotype pneumococci are the most likely pneumococci to 
harbour resistance, pneumococcal vaccination programmes reduce the rates of infection 
with resistant pneumococci throughout the community (181).   
1.10 Summary 
1. It is unknown whether older adults are as susceptible to pneumococcal 
colonisation as younger adults, or even substantially susceptible at all.   
2. The niche of pneumococcal colonisation in older people may not be the same as 
that in young adults.   
3. Pneumococcal colonisation may not be an immunising event in older adults.  
4. There is a substantial unmet need for an improved pneumococcal vaccination in 
older adults.  
5. Currently, herd immunity from paediatric vaccination is key to protecting older 
adults from pneumococcal disease, but this is vulnerable to serotype replacement 
6. As pneumococcal colonisation is key determinant of pneumococcal transmission 
within communities, surveillance for antimicrobial resistance among colonising 
isolates is warranted.   
Items 1—4 could be answered by expanding Liverpool’s existing controlled human infection 
model of S pneumoniae into an older cohort than has previously been recruited.  This 
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would provide data to support, refute or generate hypotheses regarding susceptibility, site 
and immunogenicity of pneumococcal colonisation in this population, as well as providing a 
vaccine testing platform in a key risk population.  For items 5—6, the EHPC programme 
could also provide incidental surveillance data on colonisation, herd immunity and serotype 
replacement in adults the community, and be a valuable source of pneumococcal isolates 
for susceptibility testing.   
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2  Methodology 
This thesis reports results from two studies.  The “Aging and Immunity” study was the 
expansion of the Experimental Human Pneumococcal Carriage (EHPC) model into a cohort 
of older adults; in this chapter, we describe how the study was designed and executed, and 
the clinical and laboratory methods we employed.  The “Natural Carriage” study explored 
the rates and distribution of baseline pneumococcal carriage throughout the history of the 
EHPC programme; in this chapter, we report how these isolates were serotyped and tested 
for antimicrobial resistance.   
2.1 The NHS approval process 
Establishing an EHPC study requires careful coordination between the clinical team and 
numerous approval bodies, including the local NHS Research Ethics Committee (REC) and 
the relevant National Health Service (NHS) trust Research Development and Innovation 
(RD&I) department, as outlined in the flowcharts below (Figure 2.1, Figure 2.2).  All 
previous EHPC studies had undergone a similar approval process, and the flowcharts 
include specific dates and identifiers for the “Aging and Immunity” study.  Following ethical 
approval, protocol amendments required provisional approval by the sponsor(s) before 
review by the REC.   
REC applications were made using the online Integrated Research Application System 
(IRAS) form, supported by other documents including a participant information sheet, 
protocol, questionnaires, provisional intention to sponsor letter, advertisements and 
General Practitioner (GP) letters (see APPENDIX 5).  
The NHS REC defines a sponsor as an individual, organisation or group taking on 
responsibility for securing the arrangements to initiate, manage and finance a study. The 
sponsor’s role is to ensure that the research safeguards the rights, safety, dignity and 
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wellbeing of participants.  In addition, the sponsor ensures the research is registered on a 
public database and reviews all REC amendments prior to submission, while confirming 
that research complies with legislation and Good Clinical Practice (GCP) requirements.  
The decision regarding single sponsorship versus co-sponsorship was taken on a study-by-
study basis.  For the “Aging and Immunity” study, both LSTM and the local NHS trust 
requested that, as the study would take place on NHS premises (the clinical research unit 
(CRU) of the Royal Liverpool University Hospital (RLUH)) and involved a degree of risk, the 
study should be co-sponsored by the Royal Liverpool and Broadgreen University Hospitals 
Trust (RLBUHT) in addition to LSTM.  A contract was drawn up between the two 
institutions, including designated oversight and liability roles for each party and a material 
transfer agreement between the two sites.  In addition, specific approval was obtained 
from the CRU.   
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Develop all documentation for ethics: 
including patient information leaflet (PIL), 
consent form, protocol, GP letter, hospital 
advert.  
Develop study design and initial version of 
protocol  
Complete Integrated Research Application 
System (IRAS) form – complete REC, R&D and 
Clinical Research Network (CRN) portfolio 
sections and submit 
Arrange date for Research Ethics Committee 
(REC) 
Attend REC meeting 
 
Address all REC amendments and submit 
 
REC approval 
General outline of ethical approval process  Specific to “Aging and Immunity” study 
Additional amendments during the study, as 
required 
Submitted 16 December 2015 
Attended 21 January 2016 
 
15 February 2016 
Favourable opinion 4 February 2016, full 
approval 15 February 2016 
Ref 16/NW/0031 
ISRCTN (International Standard Randomised 
Controlled Trials No.) registration  
ISRCTN ID 10948363 
As part of good research practice, even 
though this study was not a randomised trial, 
it was prospectively registered with ISRCTN 
Amendment 1 (Technical modifications requested 
by local RD&I, alterations to sampling schedule) 
Submitted 18 March 2016 
Amendment 2 14 April 2016 (Adding the Royal 
Liverpool Hospital as co-sponsor) 14 April 2016 
Amendment 3 (Adding text of a study website) 10 
May 2016  
Amendment 4 (Expanding inclusion criteria and 
adding extra samples) 7 February 2017 
Amendment 5 (Specific approval to use the 
DocMail® service to send letters from primary 
care practices within the Merseyside Clinical 
Commissioning Group) 19 July 2017 
Amendment 6 (Amending the protocol to remove 
certain criteria of restricted medications and the 
placebo group) 18 October 2017 
Figure 2.1: Overview of ethical approval process 
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Trust agree to sponsor 
 
Already in place from previous studies 
Discussed at operational group meeting 
on 10 February 2016 
 
Finance and insurance agreements 
 
Material Transfer Agreements (MTAs) 
Other approvals – Directorate manager, 
pharmacy 
Advertising and recruitment 
1.  
Site Specific Information Form (SSIF) 
submission on IRAS – only to be submitted 
when ready to start (commences 70-day 
countdown for recruitment) 
Clinical Research Unit (CRU) approval: risk 
management plan, discussion at 
operational group meeting, testing of 
emergency phone number 
 
Set up Data Monitoring and Safety 
Committee (DMSC) 
Research Development and Innovation 
department (RD&I) - Study number and 
title established 
Review at local RD&I meeting (with 
independent peer review) – provisional 
intent to sponsor letter granted 
Complete Governance Registration 
Information Document (GRID) and 
Declaration of Interest (DoI) form from 
RD&I; Engage with finance and pharmacy 
 
JRO (Joint Research Office) application 
 
Number 5174 
Title Experimental Human Pneumococcal Carriage  
Working towards a nasal vaccine for pneumonia: 
The effect of age on immune function 
Short title EHPC: Aging and Immunity 
29 February 2016  
From this point, we were permitted to 
advertise and hold information sessions, 
but not to consent participants for the 
study 
11 February 2016 
11 February 2016 
 
General outline of NHS approval process  Specific to “Aging and Immunity” study 
31 May 2016 
24 March 2016 
First consent 1 June 2016 
31 May 2016 
Figure 2.2: Overview of NHS approval process 
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2.2 Recruitment and advertising 
All advertisement materials required approval by the REC before use (See APPENDIX 3 for an 
example), and only locations listed in the ethically-approved study protocol could be used 
for advertising.  Advertisements inviting volunteers to participate were placed on: 
• Physical notice boards in public and private areas, including libraries, bingo halls, 
gymnasia and GP waiting rooms; 
• The intranet/internet of local universities, colleges, LSTM and Royal Liverpool 
University Hospital (RLUH); 
• Social media including Facebook and Twitter; 
Participants were also approached based on their prior consent to receive generic research 
communications (the Consent4Consent database, established by the RLUH).   For studies of 
particular population groups, we conducted targeted outreach and public engagement 
events at (among others) adult education centres, bowling clubs, food fairs, libraries, 
retirement associations and Women’s Institute meetings.  Finally, a collaboration between 
the Clinical Research Network (CRN) and local primary care centres could request practices 
to screen their patient lists against the study inclusion/exclusion criteria and send letters of 
invitation to potentially eligible participants.  
Interested persons were asked to contact the research team by phone, text message or 
email for further information. Potential participants were sent a copy of the participant 
information sheet and invited to contact a member of the research team if still interested 
in participating.  
Potential participants were invited to discuss the study during a 45-minute appointment 
(including a 30-minute group presentation); family members were welcome to attend 
these appointments as well. They were asked to demonstrate that they understand the 
study’s objectives, associated risks and potential benefits. At this point, they had an 
opportunity to discuss the study with a study clinician and ask questions privately; they 
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were given an unrestricted amount of time to decide whether to participate or not.  If 
individuals agreed to participate in the study and met the inclusion criteria, they were 
invited to provide written informed consent. Once consent was obtained, the participant’s 
GP was permitted to share their medical records (either by sending an electronic summary 
or filling out a questionnaire (see APPENDIX 5)), and this also contributed to the eligibility 
assessment.   
2.3 Safety considerations  
The natural history of pneumococcal colonisation suggests that the risk to adults of 
developing pneumococcal infection during EHPC very low: < 5% of adults are colonised at 
any time, while the incidence of invasive disease is 20/100 000 patient years. In addition, 
the following factors further supported our confidence in our ability to safely run the study: 
• Specific inclusion/exclusion criteria were in place, to minimise the risk of 
pneumococcal disease; 
• Serotype selection meant that bacteria of lower pathogenicity were used, rather 
than those typically associated with severe disease; 
• Dose ranging studies were performed and published at the start of the EHPC 
programme, to lay a foundation for future studies (60); 
• Specific safety measures were in place, including 24-hour access to the study team 
and standby antibiotics; 
• At the time of ethics application for the “Aging and Immunity” study, the study 
team had six years of experience in human challenge studies involving over 400 
participants, following very similar protocols, and facing the same safety issues.  No 
episodes of pneumococcal infection or severe adverse events (SAEs) had occurred 
in any of our participants. 
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The risk for pneumococcal disease increases with both age and comorbidity (182, 183) and 
so the inclusion/exclusion criteria for the “Aging and Immunity” study were designed to 
minimise any risk of pneumococcal disease, balanced with a desire to recruit as 
representative a sample as possible.    
2.3.1 Inclusion criteria for the “Aging and Immunity” study, with rationales 
• Adults aged 50-84 years—previous EHPC studies had used 50 as their upper age 
limit;  
• Fluent spoken English—to ensure a comprehensive understanding of the research 
project and their proposed involvement; 
• WHO performance status 0 (able to carry out all normal activity without restriction) 
or 1 (restricted in strenuous activity but ambulatory and able to carry out light 
work)—because attendance at multiple visits were required, and as a surrogate for 
control of comorbidities 
• Access to telephone—to allow safety and timely communication; 
• Capacity to give informed consent. 
2.3.2 Exclusion criteria for the “Aging and Immunity” study, with rationales 
Clinical judgement was used in interpreting these exclusion criteria, with any concerns 
discussed with the chief investigator before enrolment.   
• Caring responsibilities for children aged < 5 years, hospital patients or people with 
chronic illnesses—to minimise the exposure to potentially pathogenic bacteria in 
those at high risk; 
• History of drug or alcohol abuse—to minimise risk of pneumococcal disease; 
• Smoking any cigarettes currently or within the last six months—minimise risk of 
pneumococcal disease; 
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• Ex-smoker with a significant smoking history (>20 pack-year history of smoking OR 
up to 20 pack-year history of smoking but quit less than five years ago OR up to 10 
pack-year history of smoking but quit less than six months ago*)—to minimise the 
risk of pneumococcal disease, plus ensure that carriage rates were not affected by 
epithelial changes caused by smoking; 
• Any current treatment for asthma—to avoid excess risk of infection and minimise 
confounding effect of medications such as corticosteroids (an EHPC study 
exclusively enrolling participants with asthma was carried out at the same time as 
this study); 
• Taking daily medications that may affect the immune system e.g. steroids, steroid 
nasal spray, disease-modifying anti-rheumatoid drugs—to ensure homogeneity of 
the cohort and minimise risk of pneumococcal disease; 
• Taking medication that affects blood clotting e.g. aspirin, clopidogrel, warfarin or 
other oral or injectable anticoagulants—to reduce risk of bleeding associated with 
study procedures, also likely a surrogate marker of underlying systemic illness; 
• Significant cardiorespiratory disease (excluding stable hypertension)—to minimise 
risk of pneumococcal disease or severe complications should pneumococcal 
disease occur; 
• Disease associated with altered immunity, including diabetes, active malignancy, 
rheumatological conditions—to minimise risk of pneumococcal disease; 
• Other uncontrolled comorbidities, as determined by the clinical investigator, which 
would be expected to increase the risk of pneumococcal disease; 
• Any acute illness (new symptoms within preceding 14 days which are unexplained 
by the known past medical history)—to avoid confounding symptoms and minimise 
                                                          
* One pack-year is defined as smoking 20 cigarettes per day for one year. 
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risk of pneumococcal disease (e.g. due to impaired mucosal immunity from 
concomitant viral infection); 
• Having received any antibiotics in the preceding 28 days—to improve chance of 
carriage acquisition; 
• History of culture-proven pneumococcal disease—to reduce confounding of 
carriage rates and other laboratory measurements by immunological memory of 
prior pneumococcal exposure; 
• Allergy to penicillin— beta-lactam antibiotics are used for termination of carriage in 
the study protocol; 
• Involved in another clinical trial unless observational or in follow-up (non-
interventional) phase—investigational medicinal products could have 
unanticipated effects on immunity, and multiple blood tests for multiple studies 
could be risky for participants; 
• Prior participation in a clinical trial involving EHPC and bacterial inoculation in the 
past three years—to improve chance of carriage acquisition.  
Of note, prior PPV23 receipt was not an exclusion criterion, as it is recommended for all 
adults aged ≥ 65 years (100) and therefore it was expected that the majority of participants 
above this age would have received this vaccine.  PPV23 is not believed to affect the 
acquisition of nasopharyngeal colonisation (102), and so a pragmatic decision was made to 
accept volunteers who had received the vaccine.   
Specific “stop criteria” based on findings on pre-screening physical examination and 
investigations were also defined for this study.   
2.3.3 Pre-screening and “stop criteria” 
In EHPC studies of younger volunteers, baseline clinical screening (medical history, clinical 
exam and full blood count) were performed on the same day as their baseline samples (e.g. 
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pre-inoculation nasal wash, baseline serum etc).  For older volunteers, a more 
comprehensive clinical assessment was required to determine that a participant was safe 
to enrol, and there was greater potential for participants to be excluded pre-inoculation on 
clinical grounds.  Therefore, all clinical/safety assessments were bundled together as a 
“pre-screening” visit (which could take place some weeks before inoculation), and scientific 
baseline samples performed at a screening visit the week before inoculation.   
In addition to clinical history, medication review and clinical cardiac and respiratory 
examination (standard for all EHPC studies), all participants underwent electrocardiography 
(ECG) and spirometry.  Two blood samples were sent at pre-screen: a full blood count 
(including haemoglobin, platelet count, white blood cell count and differential) and a renal 
profile (including sodium, potassium, urea and creatinine).  If any of these assessments 
breached the protocol-defined “stop criteria” (Table 2.1), the participant would be 
excluded.   
Table 2.1: Stopping criteria for use during participant assessment prior to commencing the “Aging and 
Immunity” study.   
Stop criteria 
Clinical history and examination STOP if unexplained or concerning findings 
on history or examination 
Engagement with research team STOP if the research team have concerns 
about volunteer’s ability to commit to 
frequent communication and safety checks 
Full blood count STOP if haemoglobin <10g/L 
STOP if total white cell count <1.5 x109/L 
STOP if total white cell count >10 x109/L 
STOP if platelets <75 x109/L 
Renal profile STOP if sodium is outside reference range 
STOP if potassium is outside reference range 
STOP if urea is above reference ULN 
STOP if creatinine is above reference ULN 
ECG STOP if any evidence of significant 
conductive or ischaemic defect 
Resting oxygen saturation STOP if < 95% 
Spirometry STOP if FEV1 <LLN 
FEV1 Forced Expiratory Volume in one second; LLN Lower Limit of Normal; ULN Upper Limit of Normal 
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2.3.4 Risk stratification 
Participants were stratified in age-defined risk categories (Table 2.2).  The rationale for the 
age groups related to published pneumococcal disease rates (Centres for Disease Control 
and Prevention (183)) and clinical guidance for general use of PPV23 (age ≥ 65).   
Table 2.2: Age-defined risk categories for participants.   
Risk categories 
0 1 2 3 
Young healthy 
volunteers – not 
included in this 
study 
Age 50-64 Age 65-74 Age 75 - 84 
 
The study protocol required safety to be demonstrated in Category 1 before moving onto 
Category 2, and in Category 2 before moving onto Category 3.   Safety was defined as per 
practice in previous EHPC studies: at least six uneventful inoculations per group and no 
reservations among the clinical team and Data Monitoring and Safety Committee (DMSC) 
before proceeding.   
 
2.3.5 The Data Monitoring and Safety Committee 
A DMSC reviews accumulating data during a clinical trial and advises the sponsor on the 
future management of the trial.  A DMSC for the EHPC studies (consisting of two 
experienced trialists—one clinician and one statistician) has been in place for 6 years.  The 
DMSC’s role was to discuss the safety report containing information on all participants, 
either at the request of the study’s chief investigator, at the end of the study and/or in the 
event of any serious adverse events (SAEs).  The study team would provide the DSMC with 
general safety reports at key points during the study and update them regarding 
progression to higher risk groups.   
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2.3.5.1 Serious Adverse Events 
An SAE is an adverse event or adverse reaction that:  
• Results in death, or 
• Is life-threatening, or 
• Requires hospitalisation or prolongation of existing hospitalisation, or  
• Results in persistent or significant disability or incapacity, or  
• Consists of a congenital anomaly or birth defect. 
According to the EHPC study protocols, any unexpected (i.e. not listed in the protocol as an 
expected occurrence) related (i.e. resulting from administration of any of the research 
procedures) SAEs would be recorded and reported to the sponsors and DMSC (within 24 
hours of the principal investigator becoming aware). In the event of any unexpected 
related SAE, the study would be stopped temporarily for investigation and any further work 
referred back to the REC for consideration within 7 days. 
2.4 Study design 
The study schedule and procedures are outlined in Figure 2.3.  Following inoculation, 
participants were seen for a follow-up nasal wash on days 2, 7, 9, 14, 22 and 29.  If 
experimental colonisation was not identified on or by day 14, the participant could omit 
the day 22 visit, as they were deemed to be at lower risk of pneumococcal diseases and 
thus required less intensive follow-up.  Serum samples were taken at baseline and on day 
29.  All follow-up visits included a clinical assessment, and participants were asked to 
record their temperature daily for the first seven days, sending their temperature to the 
research team via text message.   
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Visit 2 (d-5): Screening 
Baseline Samples: Nasal wash and serum 
collection 
Visit 6 (d9) 
Nasal wash 
Visit 7 (d14) 
Nasal wash 
*Only carriage positive participants attend 
 
Take amoxicillin 
500mg three times a 
day for 3 days 
 No Yes 
Experimental carrier? 
(At least one culture-positive nasal 
wash and <2 negative nasal washes 
by day 29) 
 
Visit 8 (d22)* 
Nasal wash  
Visit 5 (d7) 
Nasal wash 
Visit 4 (d2)  
Nasal wash 
 
Visit 3 (d0) 
Pneumococcal inoculation 
 
Informed consent 
GP questionnaire to confirm eligibility  
 
Visit 1: Pre-screening appointment   
Medical history, clinical examination, ECG, 
spirometry, full blood count, renal profile  
Visit 9 (d29)  
Nasal wash and serum collection 
 
Figure 2.3: Study flowchart 
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2.5 Sample size calculation 
In order to compare this group with previous healthy volunteers, a total sample of 64 
inoculated subjects was required. A cohort of this size would permit the detection of a 
difference of 0.78 at α = 0.05 with a power of 0.80, allowing for study non-completion. 
The underlying assumptions were: 
• Experimental colonisation rate is 45% in healthy volunteers (previous published 
data) (60); 
• Experimental colonisation rate falls to 10% in older people (i.e. relative risk is 0.22, 
expected from published cross-sectional studies of carriage prevalence suggesting 
very low carriage rates amongst older people) (39); 
• Participant drop-out would lead to 10% non-completion rate.  
Of note, we did not allow for natural colonisation with pneumococcus at baseline when 
calculating our sample size, as our literature review suggested that this would occur at 
negligible rates in an older population.  In fact we did identify three “natural carriers” 
during this study.  Therefore we performed post-hoc sensitivity analyses which excluded 
these participants.   
2.6 Clinical procedures 
2.6.1 Pneumococcal challenge 
On inoculation days, each participant was seen by a study clinician to assess for any acute 
symptoms, to ensure that inoculation was safe to go ahead.  The participant was then 
placed in a semi-recumbent position on a reclining chair. A P200 micropipette was used to 
draw up 80,000 colony-forming units (CFU) of pneumococcus suspended in 100µL 0.9% 
sodium chloride solution (normal saline) The plunger was depressed slowly and the pipette 
tip arced to and fro along the apex of the nostril.  Direct visualisation of the tip was 
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maintained at all times.  The participant was advised to breathe through their mouth, and 
then requested to remain in the reclining chair for 15 minutes.  
2.6.2 Safety briefing 
Participants were given a post-inoculation advice sheet, including emergency contact 
details and “red flag” symptoms (see APPENDIX 6: Post-inoculation safety leaflet). They were 
given a thermometer and requested to send their temperature to the research team by 
text message daily for the first week post-inoculation.  They were also given a three-day 
course of amoxicillin 500mg tablets.  If they became unwell they were advised to check 
their temperature and contact the research team, who would advise them to seek 
healthcare, take amoxicillin and/or attend the research facility the next day for a review.   
2.6.3 Nasal wash 
Nasal wash was essential to determine colonisation.  Nasal washes were performed at 
baseline screening pre-inoculation and at pre-determined study-specific timepoints 
thereafter.   
A modified Naclerio method was used for nasal wash in all EHPC studies (184). This has 
been validated by our team as being at least as sensitive as, and better tolerated than the 
WHO gold standard nasopharyngeal swab for the detection of pneumococci in adults (36, 
37).    
In the Naclerio method, 5mL of normal saline is introduced using a syringe and held for a 
few seconds in the nose before being expelled in to a sterile container.  The participant is 
advised to occlude their pharynx, either by pressing their tongue against their hard palate, 
or by “holding a swallow mid-way through”.  The procedure is repeated twice in each 
nostril, thus using 20mL saline in total. In the event of nasal wash loss (e.g. through 
inadvertent swallowing) the procedure may then be repeated to obtain an adequate 
specimen (defined as ≥10mL saline recaptured) using up to an additional 10mL of saline.  
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Nasal wash samples were kept at ambient temperature and transported to the laboratory 
within one hour of collection.   
2.6.4 Oropharyngeal swab 
The participant’s tongue was depressed using a tongue depressor, exposing the 
palatopharyngeal arch. Flocked swabs (Copan diagnostics, obtained from ThermoFisher, 
Basingstoke, UK) were used to make five small circular motions in contact with the mucosa 
of the palatopharyngeal arch in contact whilst avoiding the tongue. Swabs were placed in 
sterile containers with 1mL skim milk, tryptone, glucose, and glycerin (STGG) media 
(produced in-house) and transported to the laboratory at ambient temperature.  Throat 
swabs were always taken prior to nasal sampling to ensure that the oropharynx was not 
inadvertently contaminated with nasal pathogens.   
2.6.5 Saliva samples 
Saliva collection was performed using the Salivette® system (Sarstedt AG & Co, Nümbrecht, 
Germany), comprising a small absorbent sponge with a sterile plastic container that can be 
directly transferred to a centrifuge. The participant was asked to hold the sponge in their 
mouth until they perceived it as being saturated with saliva. The sponge was transported to 
the laboratory in the container () on wet ice.   
2.6.6 Blood sampling 
Up to 50mL of venous blood was collected at protocol-defined timepoints using standard 
phlebotomy techniques.   
2.7 Laboratory procedures 
2.7.1 Experimental bacterial inoculum preparation 
An isolate of serotype 6B pneumococcus (strain BHN418, GenBank accession number 
ASHP00000000.1) was provided by Prof PW Hermans (Radboud University, Nijmegen, The 
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Netherlands).  The reference laboratory at Public Health England tested the isolate and 
found it to be fully sensitive to all standard antibiotics, including penicillin.  Genome 
sequencing for purity of each inoculum batch was performed by the Wellcome Sanger 
Institute (Hinxton, UK).  A mid-log culture was frozen at -80°C in aliquots of 20% glycerol-
enriched Vegitone broth (Sigma-Aldrich, Dorset, UK).  On experimental inoculation days, an 
aliquot was thawed, washed twice, and re-suspended in 500µL normal saline before being 
diluted to achieve the target dose of 80,000 CFU/100µL.  The actual inoculated dose 
achieved on the day was calculated by plating the thawed isolate prior to transport to the 
clinical research facility, and again upon return.  Three 10µL dots were plated in parallel 
lines on blood agar, and colonies counted using the Miles and Misra method (185).  The 
mean of the colony counts on the pre- and post-dose plates was accepted as the true 
inoculated dose.  A variation of half or double of the target dose was considered 
acceptable, as it had previously been demonstrated in dose-ranging studies that this range 
is safe and leads to similar colonisation outcomes (60). 
2.7.2 Bacterial culture 
Nasal wash samples were centrifuged for ten minutes at 3,345g, and the supernatant 
separated from the residual pellet.  The pellet was resuspended in 100µL STGG, 20µL of 
which was streaked on a gentamicin/blood agar plate and incubated overnight at 37°C in 
5% carbon dioxide.  (The gentamicin suppresses competing respiratory pathogens, thus 
maximising the chance of pneumococcal detection.)  Experimental colonisation was 
defined as the identification of serogroup 6 pneumococcus on the plate the following day.  
Pneumococci were defined using classical microbiological criteria:  
1. Typical draughtsman-like colony morphology on agar;  
2. The presence of α-haemolysis;  
3. Optochin sensitivity;  
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4. Solubility in bile salts;  
5. Gram-positive diplococci on microscopy.   
Serogroup was confirmed by a commercially available latex agglutination test 
(PneumoLatex, Statens Serum Institut, Copenhagen, Denmark); more detailed serotyping 
was not deemed necessary for experimental colonisation, as pneumococci from serogroup 
6 in general are rare in the UK (34).  Therefore, the detection of serogroup 6 pneumococci 
in a volunteer recently exposed to serotype 6B could reasonably be assumed to represent 
experimental colonisation.  Natural colonisation was defined as identification of 
pneumococci that belonged to any other serogroup from a nasal wash at any timepoint.   
2.7.2.1 Pneumococcal colonisation density determination 
The STGG nasal wash pellet suspension was serially diluted on blood agar and incubated 
overnight as described above.  The following day, colonies were counted and multiplied by 
the dilution factor and pellet volume to determine the density in CFU/µL.  This was divided 
by the volume of nasal wash returned by the participant, leading to a result reported in in 
CFU/mL of nasal wash.  The remaining pellet suspension was stored at -80°C pending 
molecular testing.   
2.7.3 Oropharyngeal swab post-collection processing 
Upon receipt in the lab, the STGG samples were stored at -80°C pending molecular testing.   
2.7.4 Saliva post-collection processing 
Upon receipt in the lab, saliva was extracted from the cotton wool by centrifuging the 
salivette at 3700g for 3mins at 4°C.  The saliva was resuspended in an equal volume of 
STGG with 50% glycerol and stored at -80°C pending molecular testing.   
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2.7.5 Pneumococcal detection using qPCR 
We compared the performance of culture and qPCR on nasal wash specimens, and also 
used qPCR to analyse oropharyngeal swabs and saliva samples.  The choice of target gene is 
key in pneumococcal qPCR, given the high number of shared genes between pneumococci 
and other commensal streptococci (186, 187).  The autolysin gene (lytA) is generally 
considered to be the most specific for pneumococcus.  Specificity can be further improved 
by targeting two genes, and only classifying samples that detect both genes as positive (44).  
Our analysis was simplified because we knew that our participants had been exposed to 
serotype 6B. Therefore, we defined a positive pneumococcal qPCR as detection of both lytA 
and the 6A/B capsular polysaccharide gene (cpsA).   
2.7.5.1 Bacterial DNA extraction for qPCR 
DNA was extracted using the Agowa Mag Mini DNA isolation kit (LGC Genomics GmbH, 
Berlin, Germany) from 200µL of oropharyngeal swab and 300µL of nasal wash pellet and 
saliva.  Thawed samples were centrifuged at 20,200g for seven minutes. The pellet was re-
suspended in protease mix with lysis buffer (300µL; one part protease to six parts buffer), 
100µL of zirconium beads and 300µL of phenol.  The suspension was disrupted twice using 
a tissue homogeniser (Precellys Evolution, Bertin Instruments, Montigny-le-Bretonneux, 
France) at maximum speed for three minutes, with cooling on ice in between, and then 
centrifuged at 9,391g for 10 minutes at 20°C for separation of phases. The aqueous phase 
was mixed with binding buffer (600µL) and magnetic beads (10µL), then vortexed and 
incubated for 30-120 minutes in an orbital shaker (Fisher Scientific, Loughborough, UK) at 
room temperature. The sample and magnetic beads were washed twice with 200µL wash 
buffer, after which the beads were dried at 55°C for 10 minutes. The bacterial DNA was 
eluted with 63µL of elution buffer, whereupon the beads were removed using a magnet 
separator and the eluent stored at -20°C.   
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2.7.5.2 Multiplex amplification of lytA and cpsA genes 
The master mix included 9.375µL of diethylpyrocarbonate-treated water and 12.5µL of 
TaqMan® Universal PCR Master Mix (from ThermoFisher, Basingstoke, UK) and primers and 
probes for the two genes of interest (all from EuroGenTec, Southampton, UK). For lytA, we 
added 0.15µL of forward primer (5’-ACGCAATCTAGCAGATGAAGCA-3’), 0.15µL of reverse 
primer (5’-TCGTGCGTTTTAATTCCAGCT-3’) and 0.075µL of probe (5’-(FAM)-
GCCGAAAACGCTTGATACAGGGAG-(BHQ1)-3’) (186).  For cpsA, we added 0.1µL of forward 
primer (5’-AAGTTTGCACTAGAGTATGGGAAGGT-3’), 0.1µL of backward primer (5’-
ACATTATGTCCATGTCTTCGATACAAG-3’) and 0.05µL of probe (5’-(HEX)- 
TGTTCTGCCCTGAGCAACTGG–(BHQ1)-3’) (188). All volumes were multiplied by the planned 
number of wells when preparing the master mix. We added 2.5µL of extracted DNA to 
22.5µL of the master mix in each well. On each plate, two negative controls used 25µL 
master mix only, and each plate contained a standard curve of 10-fold dilutions of 
pneumococcal genomic DNA (106-101 copies/mL). Samples were assayed as duplicates, 
using thermal cycling conditions: 10 minutes at 95°C for DNA denaturation followed by 40 
cycles of 15 seconds at 95°C and one minute at 60°C. All qPCR thermal cycling was 
performed in the same MX3005P Real-Time qPCR system (Agilent Technologies, Stockport, 
UK), with the detection threshold set at 3900 for lytA and 650 for cpsA.  
The lower limit of detection was set at 40 cycles (48). The qPCR plate was repeated if:  
1. There was DNA detected in either of the negative control wells;  
2. Any of the standards between 106-102 were not detected; 
3. Neither of the 101 standards was detected; 
4. The cycle threshold difference between any duplicates of 103—106 standards was 
>1 
5. R2 of the two standard curves <0.98  
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6. The slope of standard was not between -3.1 and -3.6; 
7. Efficiency was not between 90% and 110%. 
2.7.6 Anti-capsular polysaccharide IgG ELISA  
We measured anti-6B CPS IgG titres using a modification of the WHO enzyme-linked 
immunosorbent assay (ELISA) protocol.  Serum samples were depleted of cell wall 
polysaccharide (CWPS) antibodies by incubating for 30 minutes in phosphate-buffered 
saline (PBS) blocked with heat-inactivated foetal bovine serum (ThermoFisher, Basingstoke 
UK) and 10µg/mL solution of CWPS (Statens Serum Institut, Copenhagen, Denmark).  These 
pre-absorbed serum samples were then transferred to a 96-well plate (Maxisorp microtiter, 
Nunc, Roskilde, Denmark) that had been coated overnight at 4°C with 5µg/mL purified 
pneumococcal 6B CPS (Statens Serum Institut).  The samples were serially diluted from 
1:400 to 1:3,200 in the microtiter plates, then incubated for two hours at room 
temperature.  Reference serum 98SF (US Food and Drug Administration (FDA)) was pre-
absorbed in a similar fashion and serially diluted from 1:500 to 1:32,000, with one row left 
blank, as a standard curve.  The samples were washed three times with PBS containing 
0.05% Tween, and then the secondary antibody (goat anti-human IgG conjugated to 
alkaline phosphatase; Sigma-Aldrich Corporation, Dorset, UK) was added and incubated for 
90 minutes.  The wells were washed three times again prior to incubation with p-
nitrophenylphosphate (Sigma-Aldrich Corporation) for 15-20 minutes at room temperature 
for colour development.  Antibody detection was performed using a FLUOstar Omega plate 
reader (BMG Labtech GmbH, Ortenberg, Germany), with optical densities read at 405nm.  
The antibody concentrations were determined by comparing the fluorescence in each 
sample well against the standard curve generated from the serially diluted 98SF reference 
serum, and are reported in ng/mL. All samples were analysed in duplicate.   
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2.7.7 Serotyping of natural carriage isolates 
All isolates were initially tested using a commercially available latex agglutination kit 
(PneumoLatex, Statens Serum Institut, Copenhagen, Denmark).  This kit comprises a series 
of reagents and an identification key. When pneumococci were identified on a plate, a 
single colony would be added to a drop of each reagent. Depending on which reagent or 
reagents were agglutinated, the identification key would identify which serogroup the 
isolate belonged to.  Some serogroups (e.g. 3 or 8) cannot be subdivided into serotypes, 
and therefore no further identification procedures were needed for these.  The remainder 
(e.g. serogroup 9 or 19) were sent to the Bacterial Microarray Group at St. George's 
University of London (BμG@S Biosciences) for molecular serotyping.  This methodology 
(serotyping from genomic DNA on a molecular microarray) has been published previously 
and has been validated in a multicentre study (189-191).   
2.7.7.1 Bacterial DNA extraction for molecular serotyping 
The DNA was extracted using the QIAamp minikit (Qiagen, Hilden, Germany) according to 
the manufacturer’s instructions.  Briefly: following centrifugation, the bacterial pellet was 
resuspended in 180 μL of an enzyme lysis solution comprising 20 mg/mL lysozyme, 20 mM 
Tris-HCl, 2 mM EDTA and 1.2% Triton.   After 30 minutes incubation at 37°C, 200 μL Qiagen 
buffer AL and 20 μL proteinase K were added, and the mixture was incubated for 30 
minutes at 56°C followed by 15 minutes at 95°C. The standard manufacturer's extraction 
protocol was followed, and DNA was eluted into 200 μL Qiagen buffer AE.  
2.7.7.2 Molecular serotyping 
The BμG@S microarray contains thousands of oligonucleotide probes corresponding to the 
genes that (in combination) determine the pneumococcal capsular serotype.  
Fluorescently-labelled genomic DNA is hybridised to these probes, and the fluorescent 
intensity is used to determine the serotype.  Approximately 300 ng of the extracted DNA 
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(quantified using a NanoDrop spectrophotometer; ThermoFisher, Basingstoke UK) was 
fluorescently labelled with either ULS-Cy3 (green) or ULS-Cy5 (red) using the Agilent 
Technologies Genomic DNA ULS Labeling Kit (Agilent Technologies, Stockport, UK). (The red 
and green channels are analysed independently, meaning that one array can measure two 
samples.) The fluorescently labelled samples were hybridised overnight to the Senti-SP 
v1.6.0 microarray, according to the Agilent Array CGH protocol. The microarrays were 
washed and scanned using an Agilent microarray scanner and feature extraction software. 
The BμG@S Biosciences methodology applies a Bayesian algorithm to the results to 
determine which serotype is present in each sample (190).   
2.7.8 Antimicrobial susceptibility testing 
• Antimicrobial susceptibility testing of natural carriage isolates was performed 
according to methodology recommended by the European Committee on 
Antimicrobial Susceptibility Testing (EUCAST) (165), screening using disc diffusion 
and confirming minimum inhibitory concentrations (MICs) using gradient diffusion.  
The agents chosen, concentrations within each disc and susceptibility cutoff 
diameters are shown in Table 2.3.  The agents were selected because of their 
prominence in national and local treatment guidelines (see Table 1.2 and Table 1.3 
in the INTRODUCTION), with the addition of trimethoprim-sulfamethoxazole given its 
global importance.  Antibiotics with rare/restricted indications that were unlikely to 
be encountered in a community setting (and therefore unlikely to exert selective 
pressure for resistance in healthy, community-dwelling adults, e.g. rifampicin, 
chloramphenicol) were excluded, but vancomycin was included because of its role 
as “antibiotic of last resort” against pneumococcus.   
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Table 2.3 Antimicrobial agents selected for susceptibility testing.   
Class of 
antimicrobial agent 
Specific agent used for 
AMR screening 
Concentration of 
agent within disc 
EUCAST zone 
diameter 
breakpoint 
(mm) (165) 
S ≥ R < 
β-lactam Oxacillin 1µg 20 * 
Macrolide Erythromycin 15µg 22 19* 
Fluoroquinolone Norfloxacin 10µg 11 * 
Tetracycline Tetracycline 30µg 25 22* 
Folate antagonist Trimethoprim-
sulfamethoxazole 
1.25/23.75µg 18 15 
Glycopeptide Vancomycin 5µg 16 16 
*Isolates whose zone diameters were less than the EUCAST breakpoint were subjected to additional MIC 
determination, as outlined in the text.  
2.7.8.1 Inoculum preparation 
An inoculum was prepared by growing bacteria overnight on blood agar and suspending a 
selection of colonies from the plate in saline. The density was confirmed to be equivalent of 
0.5 McFarland standard using a multiplate spectrometer (FluoStar Omega, BMG Labtech, 
Ortenberg, Germany).  100µL of suspension was pipetted into microplate wells, with 100µL 
saline as a blank, and optical densities (OD) were measured at 625nm.  An OD of 0.08—
0.13 at 625nm equates to a 0.5 McFarland standard (192).  For internal consistency, both 
between samples and within replicates of samples, we aimed for a blank-corrected OD of 
0.1±0.01—inocula were diluted with additional saline if their OD was too high, or 
supplemented with bacterial colonies if too low.  If an acceptable OD was not achieved 
within 60 minutes of commencing inoculum preparation, a fresh inoculum would be 
prepared from the original plate.   
2.7.8.2 Inoculation 
Plates were inoculated within 60 minutes (ideally within 15 minutes) of inoculum 
preparation, using MH-F media: Mueller-Hinton agar supplemented with 5% defibrinated 
66 
 
horse blood and 20 mg/L β-nicotinamide adenine dinucleotide (ThermoFisher, Basingstoke, 
UK).  A sterile cotton swab was dipped in the inoculum and streaked over the agar plate 
three times, rotating the plate by 60° between each pass, thus achieving a confluent lawn 
of growth.   
2.7.8.3 Antimicrobial disc application 
Within 15 minutes of inoculation, six discs (one containing each antibiotic of interest; 
ThermoFisher, Basingstoke, UK) were firmly applied to the surface of the agar, evenly-
spaced apart, using a disc dispenser.  The plates were inverted and incubated face down in 
stacks of no more than 5 for 16–20 hours at 35°C (± 1°C) with 5% CO2.   
2.7.8.4 Disc diameter assessment 
Following incubation, inhibition zones were read from the front with the naked eye, using 
reflected light, and disc diameters measured using a ruler.  The published EUCAST disc 
diameters (Table 2.3) were used to classify isolates as sensitive or resistant, with additional 
MIC measurement if indicated.  Isolates identified as intermediate susceptibility on disc 
diffusion were classified as resistant.   
2.7.8.5 Minimum inhibitory concentration determination 
MICs for isolates identified as potentially resistant on disc diffusion were determined using 
Etest strips (BioMérieux, Basingstoke, UK), following the manufacturers’ instructions.  
Briefly, an inoculum of 0.5 MacFarland units was prepared—in brain heart infusion broth 
(ThermoFisher, Basingstoke UK) rather than saline—and plated on MH-F agar following the 
same procedures used for disc diffusion. An Etest strip was applied using sterile forceps so 
that the entire strip was in complete contact with the agar surface. Plates were incubated 
face down in stacks of no more than 5 for 20—24 hours at 35°C with 5% CO2.  MICs were 
defined as the point showing no growth viewed from the front of the plate, using reflected 
light with the lid removed.  EUCAST breakpoints are given in Table 2.4: 
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Table 2.4: EUCAST antibiotic breakpoints 
Class of antimicrobial agent Specific agent tested MIC breakpoint 
(mg/L) (165) 
S ≤ R > 
β-lactam Benzylpenicillin 
(infections other than 
meningitis) 
0.06 2 
Benzylpenicillin 
(meningitis) 
0.06 0.06 
Ampicillin 0.5 2 
Ceftriaxone 0.5 0.5 
Fluoroquinolone Levofloxacin 2 2 
Macrolide Clarithromycin 0.25 0.5 
Tetracycline Doxycycline 1 2 
 
2.7.8.6 Quality control 
When preparing the inocula for disc diffusion, colony counts were performed on serial 
dilutions from each inoculum to retrospectively validate the OD results from the 
spectrometer. In the case of Escherichia coli, 0.5 McFarland is accepted as equating to 1 to 
2 × 108 CFU/mL; our pneumococcal colony counts were all between 0.5 and 3 × 108 
CFU/mL.   
Following EUCAST recommendations, the AST methodology was optimised using a known 
resistant strain, and one plate of this strain was included with each batch of test samples.  
Streptococcus pneumoniae NCTC 12977 (also known as ATCC 49619 and obtained from 
Public Health England), is a serotype 19F pneumococcus originally isolated from a sputum 
sample in Arizona and has low-level, chromosomally-mediated penicillin resistance.  
EUCAST has published the antimicrobial disc diameter ranges that should be observed 
when testing this strain (193), and readings by two independent readers were consistently 
within these limits, with the exception of co-trimoxazole (1—2mm wider than predicted on 
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two occasions).  No cause for this could be identified (other antibiotic discs on the same 
plate had diameters within the predicted range).  This may bias the study towards 
underestimating the rates of co-trimoxazole resistance.   
Two independent readers measured each inhibition zone.  For sensitivity, both the 
individual readings and the average of the two readings were checked against the EUCAST 
breakpoints. While inter-reader variability of 1—2mm was common, all readings (separate 
or averaged) were in agreement when classifying isolates as sensitive or resistant.  The full 
procedure was replicated using a freshly-prepared inoculum for resistant isolates and in 
cases of discrepancies or suspected cross-contamination.  Measurement by two 
independent reviewers was not mandated for MIC measurements, as the Etest results are 
simpler to interpret.   
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3 Establishing Experimental Human Pneumococcal Carriage in 
Older Adults 
3.1 Background 
As outlined in the INTRODUCTION, anti-pneumococcal polysaccharide immunity is diminished 
in older adults.  This immunodeficiency affects both natural and vaccine-induced 
antibodies.  It remains unclear whether pneumococcal colonisation occurs at high rates in 
older adults or, if it does, whether it is an immunising event.   
If EHPC could be established in older volunteers, it would answer the questions of how 
susceptible this population is to nasopharyngeal colonisation.  It would also open the 
possibility of vaccine trials (with an endpoint of colonisation acquisition) in an older 
population, particularly if the rate of experimental colonisation is high.  Finally, EHPC in 
older people would provide a platform for experimental studies of mucosal immunity and 
the systemic response to colonisation in this population, including serum anti-capsular 
polysaccharide (CPS) antibody levels.   
3.1.1 Aims 
1. To establish EHPC in a cohort of adults aged ≥50 years; 
2. To determine the rate of experimental colonisation in older adults; 
3. To describe the dynamics of experimental colonisation (density and duration) in 
older adults; 
4. To assess demographic and medical factors associated with experimental 
colonisation in older adults; 
5. To assess the safety of EHPC in older adults. 
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3.2 Methods 
3.2.1 Clinical procedures 
Ethical approval, inclusion/exclusion criteria, participant recruitment and clinical 
procedures are summarised in sections 2.1, 2.2, 2.3, 2.4 and 2.6.  Pneumococcal 
vaccination (PPV23) status was determined by review of each participant’s primary care 
medical record.   
3.2.2 Laboratory procedures 
Nasal washes were tested for the presence and density of S pneumoniae as outlined in 
section 2.7.2.   
3.2.3 Study objectives 
The primary endpoint was the rate of colonisation, as determined by the detection of S. 
pneumoniae serogroup 6 by classical bacterial culture methods from one or more nasal 
wash samples in the first 14 days following initial pneumococcal challenge.  Secondary 
endpoints included colonisation density, colonisation rates by age and by pneumococcal 
vaccination status, and the safety and tolerability of EHPC in older participants.   
3.2.4 Statistical analysis 
Descriptive statistics were used for reporting participant characteristics and microbiology 
results, with χ2 or Fisher’s exact test used to compare colonisation rates between different 
groups, where appropriate.  We did not recruit a dedicated cohort of younger controls to 
directly compare carriage rates.  Instead, for comparative purposes, we use aggregate 
results from colonisation studies of serotype 6B in young volunteers conducted between 
January 2015 and April 2017 (n = 225).   
Participants who became colonised did not necessarily have colonisation detected at every 
single time point—this is generally assumed to represent low-density colonisation rather 
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than true clearance and re-acquisition of experimental colonisation.  When calculating 
average colonisation densities at each timepoint, temporarily non-colonised participants 
(as opposed to “never-colonised” participants) were assigned a colonisation density of 0 
CFU/mL.  Total bacterial density over the time of the study was defined as the area under 
the density curve (AUC).  The AUC was calculated according to the trapezoid rule using 
values of [log10 (bacterial density+1)] for each interval, with all participants assigned a 
density of 0 CFU/mL on inoculation day.   
We used binary logistic regression to look for associations between demographic variables 
and colonisation outcomes.  In particular, we hypothesised that older age would be 
associated with reduced odds of developing experimental colonisation.  We also explored 
whether male sex, PPV23 status, smoking history and/or receipt of statin therapy would be 
associated with developing experimental colonisation.  We used the p value of the Wald 
statistic to establish whether each predictor was significantly associated with colonisation 
in univariate analysis, and pre-specified that we would include any variables with a p value 
≤ 0.2 in an adjusted multivariate model, eliminating any that became non-significant using 
backward stepwise regression.  
All analyses were performed using SPSS version 24 (IBM, New York).   
3.3 Results 
3.3.1 Participant characteristics 
The first participant was inoculated on 13 June 2016, and the last was inoculated on 19 
February 2018.  The recruitment process and screening outcomes are outlined in Figure 
3.1.  The oldest participant was 80 and the median age was 64 years.  The baseline 
characteristics are outlined in Table 3.1, with a more detailed age breakdown in Figure 3.2. 
Ten participants were excluded on the basis of abnormal clinical findings at their pre-
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screening visit, all of whom were referred for appropriate follow-up investigations and 
care.   
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Table 3.1: Baseline characteristics of all volunteers in the study 
 
 Age-defined risk category Total 
50-64 65-74 75 – 84 
Number of participants inoculated 34 25 5 64 
Number of females 18 (52.9%) 15 (60%) 3 (60%) 36 (56.3%) 
Age at inoculation, median (range) 59 (52—62) 69 (66—70) 78 (78—79) 64 (59—69) 
Inoculation dose, CFU/mL, median (range) 83,833 (76,000—
90,167) 
84,333 (69,333—
92,833) 
84,750 (73,833—
89,167) 
84,333 (69,333—
92,833) 
Number of ex-smokers 10 (29.4%) 11 (44%) 2 (40%) 22 (34.4%) 
Pack years smoked, median (IQR) 10 (4.5—10) 5 (2—10) 8 (1—8) 6.5 (3.3—10) 
Number with any reported comorbidity* 14 (41.2%) 15 (60%) 3 (60%) 32 (50.0%) 
Number prescribed any regular medication 11 (32.4%) 18 (72%) 3 (60%) 32 (50.0%) 
Number prescribed statin therapy 2 (5.9%) 5 (20%) 2 (40%) 9 (14.1%) 
Prior pneumococcal polysaccharide vaccine 0 17 (68%) 5 (100%) 22 (34.4%) 
Naturally colonised at baseline, n (serogroups) 3 (23, 3, 15) 0 0 3 (23, 3, 15) 
*Comorbidities reported in more than one participant included the following: 
• Benign prostatic hyperplasia: 5 
• Depression: 5 
• Hiatus hernia: 4 
• Hypothyroidism: 4 
• Osteoporosis: 3 
•  
• Bicuspid aortic valve: 2 
• Glaucoma: 2 
• Migraines: 2 
• Previous malignancy: 2 (1 melanoma, 1 testicular) 
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64 completed 29 days of follow-up 
64 inoculated with pneumococcus 
75 attended pre-screening visit 
83 provided informed consent to 
take part in the study and for their 
90 healthy volunteers aged ≥50yrs 
attended information session after 
receiving initial approach by email 
7 ineligible/not interested 
5 withdrew consent 
3 ineligible based on primary care 
records: 
• 1 history of alcohol excess 
• 1 diabetes mellitus 
• 1 undergoing investigations 
for possible prostatic cancer 
 
1 withdrew consent 
10 failed pre-screen 
• 4 failed spirometry 
• 2 turned out to have history 
of alcohol excess and 
abnormal blood results 
• 2 newly-identified cardiac 
murmurs 
• 1 newly-identified atrial 
fibrillation 
• 1 revealed history of 
splenectomy that wasn’t on 
their GP record 
 
Figure 3.1: Outcomes from recruitment, consent and pre-screening processes  
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Figure 3.2: Cumulative proportion graph showing the age distribution of inoculated participants 
 
3.3.2 Microbiological results 
The median inoculation dose was 84,333 CFU/mL (range 69,333—92,833 CFU/mL). We 
detected experimental colonisation by day 14 in 25 participants (39.1%) (Table 3.2, Figure 
3.3).  When baseline natural carriers were excluded, the rate was 37.7% (23/61).  Three 
participants missed visits—two non-carriers missed day 14 (attending day 22 instead) and 
one carrier attended their day 29 visit on day 22.   
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Table 3.2: Microbiological results 
Total number of participants 64 
Developed experimental colonisation 
Colonised having been negative at baseline 
Colonised on top of prior natural carriage 
25 
23 
2 
Maintained natural colonisation without developing experimental 
colonisation 
1 
Developed natural colonisation during the study 3 
Experimental colonisation density, mean (SD) (CFU/mL of nasal 
wash) 
Day 2 
Day 7 
Day 9 
Day 14 
Day 22 
Day 29 
 
6,396 (20,544) 
42,558 (213,895) 
141,649 (762,178) 
5,251 (19,187) 
15,012 (63,566) 
1,732 (14,699) 
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Figure 3.3: Microbiological status of participants pre- and post-inoculation 
(NVT GpG: Non-vaccine type, Group G)  
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As shown in Figure 3.3, three participants developed incident natural carriage during the 
study.  Two carried for only one day, while the third had detectable colonisation over three 
weeks.  Incident natural carriage is relatively infrequent in EHPC studies—as a comparison, 
in a study of 194 young adults carried out between 2015—2016, it occurred in four 
participants (study awaiting publication, data from EHPC internal safety records).   
3.3.2.1 Colonisation rates in different age groups 
The overall colonisation rate of 39.1% did not differ significantly from the 46.7% achieved 
in 225 young adults inoculated using exactly the same methods and during a similar time 
period (p = 0.281).  A breakdown of carriage rates by age decile is shown in Table 3.3 and 
Figure 3.4.  Carriage rates within the over-50 cohort did not differ by age decile (χ2 for trend 
p = 0.146).  In a sensitivity analysis excluding those with baseline natural colonisation, the 
differences still did not achieve statistical significance for the overall comparison (p = 0.212) 
or the age deciles (bearing in mind that all three natural carriers were aged <60 years).   
Table 3.3: Experimental colonisation rates in different age categories 
Age category Number of 
participants 
Number 
of carriers 
Percentage 
colonisation 
P value 
(versus young 
adults) 
Under 50* 225 105 46.7% - 
50—80 64 25 39.1% 0.281 
Age deciles:  50—59 19 9 47.4% 0.953 
 60—69 31 13 41.9% 0.620 
 70—80 14 3 21.4% 0.095 
*The results for “under 50s” were obtained in other studies by the same team between 2015—2017, using the 
same methodology 
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Figure 3.4: Experimental colonisation rates compared with a young adult cohort, and broken down by age decile 
within the older cohort. 
Error bars represent 95% CI 
3.3.2.2 Experimental colonisation density and duration 
The average colonisation densities at each timepoint are given in Table 3.2.  As shown in 
Figure 3.5, densities varied substantially within and between participants; the average AUC 
of density was 34.4 CFU.days/mL (95% CI 19.9—48.9).  While the majority of carriers were 
identified as such on their first post-inoculation nasal wash, four were first identified on 
day 7, two on day 9 and one on day 14.  The median duration of colonisation was 22 days, 
with 8/25 participants still having detectable colonisation at day 29, but four participants 
never carried beyond day 2.   These ranges and fluctuations in density and variable 
durations of colonisation are similar to those seen in young volunteers following both 
experimental and natural colonisation (J Rylance et al, manuscript under review, pre-print 
deposited at https://www.biorxiv.org/content/early/2018/06/14/343319; (48)).  The mean 
AUC of density did not differ between age deciles (p = 0.843 using ANOVA).  Using 
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Pearson’s correlation coefficient, we found no significant association between participant 
age and AUC of colonisation density (r = -0.099, p = 0.636; Figure 3.6).   
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Figure 3.5: Colonisation density over time in experimental carriers 
Each dashed line represents an individual participant; the heavy line represents the average density at each timepoint. The lines for participants identified as carriage-negative at certain time points 
are shown intersecting with the lower limit of detection for colonisation by culture-based methods.  
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Figure 3.6: Correlation between participant age and colonisation density 
(Dashed lines represent 95% CI) 
 
3.3.2.3 Experimental colonisation in PPV23 recipients 
Experimental colonisation was not affected by prior receipt of PPV23: 36.4% colonisation (n 
= 8/22) in PPV23 recipients versus 40.5% (n = 17/42) in non-recipients.  This remained true 
if the analysis was restricted to over-65s—36.4% (n = 8/22) in vaccine recipients versus 
37.5% (n = 3/8).  It also remained true when restricting analysis to over-65s who had 
received PPV23 within the preceding five years—46.2% (n = 6/13) in recent vaccine 
recipients versus 29.4% (n = 5/17) in the remainder.  These results were similar when 
excluding baseline natural carriers—the overall comparison was 36.4% colonisation (n = 
8/22) in PPV23 recipients versus 38.5% (n = 15/39) in non-recipients.    
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3.3.2.4 Experimental colonisation and statin therapy 
Statins have anti-inflammatory properties, but their utility in infectious disease prevention 
or mitigation remains unclear (194-196).  In our study, the rate of colonisation in 
participants taking statins was 33.3% (n = 3/9) versus 40% (n = 22/55) in the remainder (p = 
0.5 by Fisher’s exact test).   
3.3.2.5 Logistic regression model 
The results of univariate logistic regression exploring predictor variables for experimental 
colonisation are shown in Table 3.4.  Since none of our predictor variables approached a 
statistically significant association with the outcome, we did not progress to multivariate 
regression.  
Table 3.4: Predictors of experimental colonisation, using univariate logistic regression 
 Odds ratio 95% CI p value (Wald) of 
predictor 
Age (years) 0.97 0.90—1.03 0.313 
Male sex 0.59 0.21—1.66 0.319 
PPV23 receipt 0.84 0.29—2.43 0.749 
Ex-smoker 0.56 0.19—1.65 0.292 
Statin therapy 0.75 0.17—3.32 0.705 
 
3.3.3 Safety of EHPC in older adults 
There were no incidences of confirmed or suspected pneumococcal disease following 
inoculation, and no serious adverse events.  No temperatures ≥38°C were detected while 
the participants were monitoring their temperatures daily for the first seven days post-
inoculation.  Six participants developed symptoms that required clinical review by the 
research team: 
• One non-colonised participant (age 62) developed sciatica 10 days after inoculation 
and was advised to take over-the-counter analgesia. 
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• One non-colonised participant (age 58) developed upper respiratory symptoms 20 
days after inoculation; clinical examination was normal and a pharyngeal swab was 
negative for respiratory viruses; the symptoms resolved spontaneously. 
• One colonised participant (age 64) complained of chest discomfort on day 7; ECG 
and clinical assessment were normal, and a working diagnosis of muscular pain was 
made; the symptoms resolved spontaneously. 
• One colonised participant (age 64) developed an earache on day 14; otoscopy was 
normal, and the symptoms gradually resolved spontaneously. 
• One non-colonised participant (aged 65) developed a pruritic abdominal rash on 
day 7.  The rash responded to empirical treatment for tinea corporis with topical 
miconazole/hydrocortisone. 
• One colonised participant (aged 71) complained of myalgia on day 7 and of an itchy 
eye on day 22; on both occasions, nothing was identified on clinical examination 
and the symptoms resolved spontaneously.   
In addition, one participant (non-colonised, age 71) attended his GP with a sore throat 20 
days after inoculation, and was given an analgesic spray which improved his symptoms.  
None of the above symptoms required extra appointments or reporting to the DMSC.   
 
3.4 Discussion 
EHPC is safe and feasible in older adults.  The rates of colonisation in the oldest participants 
in this cohort were lower than those seen in younger adults, but these differences are not 
statistically significant.  If there was a true difference in the rates of colonisation seen in the 
over-50s versus the under-50s (i.e. a relative risk reduction of 0.14) then the sample size 
required to demonstrate this would have been >300 subjects.  The patterns of density and 
duration of experimental colonisation are similar to those in younger adults.  This cohort 
was notable for a higher-than-expected rate of natural colonisation at baseline, as well as 
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three incidences of natural colonisation arising during the study.  We include those 
participants who were natural carriers at baseline in our calculations, but sensitivity 
analyses without these participants produced similar results. We also found that PPV23 had 
no discernible effect on experimental colonisation, even when restricting the analysis to 
over-65s (the target population) who had been vaccinated within five years (the putative 
duration of protection).  Furthermore, PPV23 had no effect on colonisation in a model that 
was adjusted for age, sex, smoking status and statin therapy.  This is consistent with a 
previous meta-analysis of the effects of PPV23 (102).  In the next chapter, we will present 
the results of anti-capsular antibody measurement in all participants, and assess if these 
titres are a stronger predictor of experimental colonisation than PPV23 status.    
New vaccine strategies are needed to protect older people against pneumococcal disease.  
The safety, tolerability and high rates of experimental colonisation seen in this study are 
supportive of the use of EHPC for vaccine testing in this key vulnerable population.   
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4 Experimental Human Pneumococcal Carriage in Older 
Adults—Immunological Findings 
4.1 Background 
As outlined in section 1.3.1 of the INTRODUCTION, all adults have circulating antibodies 
against pneumococcal capsular polysaccharide (CPS).  While population studies have 
demonstrated diminished antibody concentrations with increasing age (65), the antibody 
kinetics following pneumococcal exposure have not been studied in older people.  
Therefore, we do not know if the fall in antibody levels with age reflects reduced exposure 
to pneumococcal antigens (i.e. colonisation) in older people or a true decline in immune 
function with age.  In this chapter, we will explore the early antibody response to 
pneumococcal exposure.   
The ideal timepoint to measure post-exposure anti-CPS antibodies has not been defined.  
One clinical study obtained “convalescent serum” any time between ten days and 12 weeks 
after pneumococcal infection (88), while a colonisation study had a ten-month interval 
between serum samples (29).  However, vaccine studies have found that anti-CPS IgG levels 
reach their peak at four weeks post-PPV23 administration in both young and old adults 
(126, 127), and therefore we chose this timepoint for our study.  This timeframe is also 
similar to that of previous EHPC studies in young adults, facilitating future analyses directly 
comparing immune responses in different age groups (60).   
Pre-existing anti-CPS antibodies are hypothesised to be protective against pneumococcal 
colonisation.  A previous EHPC study of young adults did not confirm this hypothesis (60)—
baseline anti-CPS IgG levels were no different in volunteers who did and did not become 
colonised. We can explore whether this remains the case in older adults by measuring 
antibody levels prior to pneumococcal challenge in our cohort.   
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Antibody-mediated protection against colonisation is a key principle underpinning the 
childhood PCV13 programme.  However, PPV23 has not been shown to prevent 
colonisation (102), and did not protect against EHPC in our cohort aged 50—80 (section 
3.3.2.3).  Comparing baseline antibody levels and colonisation outcomes in vaccinated and 
unvaccinated participants will allow us to delve deeper into this conundrum.   
In addition, as outlined in section 1.3, anti-CPS antibody boosting has been demonstrated 
following pneumococcal colonisation (29), including EHPC (60).  The role of pneumococcal 
colonisation in the maintenance of natural immunity has not been explored in older adults.  
Comparing pre- and post-challenge antibody levels in our cohort will allow us to examine 
this phenomenon.  Multiple doses of pneumococcal polysaccharide do not necessarily 
result in proportionate cumulative increases in antibodies, particularly in older people 
(hyporesponsiveness, (117, 197)).  The antibody responses to experimental colonisation in 
vaccinated participants will therefore be of particular interest.   
4.1.1 Hypotheses 
We test seven hypotheses in this chapter, informed by previous literature on the subject: 
1. Higher baseline anti-CPS IgG levels are found in PPV23-vaccinated participants—if 
confirmed, this would justify subgroup analysis based on vaccine status for other 
hypotheses; 
2. Post-PPV23 antibody levels are not different in participants for whom a long time 
had passed since vaccination, compared with more recent vaccinees.  Opinions 
differ on the durability of the immune response to PPV23, and some authorities 
recommend revaccination after five years (99).  However, well-powered studies 
have found that, while antibodies do decline in the years after vaccination, they 
remain elevated well above pre-vaccination titres at five years (119).  Classifying all 
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participants who had ever received PPV23 as vaccine recipients would simplify our 
analysis.   
3. High baseline antibody levels are not associated with colonisation outcomes (i.e. 
baseline antibody levels would not be different in carriers and non-carriers, similar 
to young adults in previous EHPC studies (60)); 
4. Experimental colonisation results in boosting of anti-CPS antibody levels (similar to 
young adults in EHPC (60)); 
5. Pneumococcal challenge without subsequent culture-positive colonisation does not 
have any effect on systemic anti-CPS antibody levels (similar to young adults in 
EHPC (60, 137)); 
6. Higher baseline antibody levels are associated with reduced bacterial density (as 
measured by AUC) in colonised participants (PCV13 vaccination of children and 
young adults is associated with lower colonisation density, suggesting that control 
of density is antibody-driven (107, 198)); 
7. Antibody levels and responses are diminished in the oldest age decile (65).  
4.2 Methods 
4.2.1 Clinical procedures 
Participant enrolment, inoculation and colonisation determination was carried out as 
outlined in sections 2.2, 2.4 and 2.6.  Pneumococcal vaccination (PPV23) status was 
determined by review of each participant’s primary care medical record.  Serum samples 
were taken at baseline and at 29 days (± 7 days) post-inoculation.   
4.2.2 Laboratory procedures 
Pneumococci were cultured as outlined in section 2.7, and colonisation density was 
determined as outlined in section 2.7.2.1.  Anti-6B CPS IgG levels were measured in 
baseline and day 29 serum samples using ELISA, as described in section 2.7.6.  We defined 
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experimental carriers as participants who had S. pneumoniae serogroup 6 isolated from 
nasal wash at any timepoint following inoculation.   
4.2.3 Statistical analysis 
The antibody titres (in ng/mL) were log-transformed to achieve a normal distribution prior 
to statistical analysis, and the transformed results are reported in this chapter.  Fold change 
in antibodies was defined as the difference between the log-transformed day 29 and 
baseline levels.  Baseline levels were compared between groups (e.g. carriers and non-
carriers) using the unpaired t test, with the paired t test used for before-and-after 
comparisons.  Correlations between continuous variables were assessed using Pearson’s 
correlation.  We pre-specified that, if we identified higher baseline anti-CPS IgG levels in 
PPV23 recipients, we would perform analyses on the whole cohort and also on subgroups 
defined by PPV23 status.   
When reporting changes in antibody levels over time, we had a choice between presenting 
the mean values pre- and post-challenge within each group (e.g. carriers and non-carriers) 
or comparing the two groups based on the fold change in antibodies.  Previous literature 
suggests that either approach is acceptable (60, 199), and both absolute levels and fold-
changes are used in clinical practice (200, 201).  As our analysis is largely exploratory, we 
present many of our between-group comparisons using both approaches where 
appropriate.   
We used binary logistic regression to assess the effect of baseline antibody levels on the 
development of experimental colonisation and used linear regression to assess the effect 
of baseline antibodies on colonisation density (as defined by AUC).  We pre-specified that 
we would adjust the antibody levels for age and sex, given their well-documented effects 
on anti-pneumococcal immunity (65), regardless of findings on univariate analysis (i.e. 
forced-entry method of multivariate regression).  We excluded PPV23 status because its 
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effects would be largely accounted for by the antibody levels—this was supported by our 
initial finding that baseline antibody levels were indeed higher in PPV23 recipients.  We 
used the p value of the Wald statistic (in logistic regression) or ANOVA (in linear regression) 
to establish whether each predictor was significantly associated with colonisation.   
All tests were two-tailed, and a p value of < 0.05 was considered significant.  All analyses 
were performed using SPSS version 24 (IBM, New York). 
 
4.3 Results 
For each serum sample, we selected the dilution that gave a blank-corrected optical density 
(OD) closest to 0.1 (or at least between 0.7 and 2.0) in both replicates, as these fell along 
the linear part of the standard dilution curve.  We excluded replicates whose coefficient of 
variation (i.e. 
Standard deviation
Mean
) was ≤25%.  Fifteen sample pairs required repeat testing, 
either for poor agreement between replicates or insufficient dilution.    Four participants’ 
results were excluded for poor agreement between replicates despite multiple repeated 
rounds of testing, and an additional participant did not have a post-inoculation serum 
sample available; therefore results are reported for 59 participants.   
4.3.1 Baseline antibody levels and PPV23 
History of PPV23 receipt was associated with higher baseline anti-CPS IgG levels (Table 4.1).  
Table 4.1: Baseline anti-CPS IgG levels, by vaccine status 
 Prior PPV23 (n = 
20) 
No PPV23 (n = 
39) 
p 
value 
Anti-6B CPS IgG at baseline, log 
ng/mL, mean (SD) 
3.58 (0.28) 3.33 (0.37) 0.01 
Anti-6B CPS Ig denotes immunoglobulin directed against serotype-specific capsular polysaccharides, as 
measured by ELISA.    
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There was no association between baseline antibody levels and time since PPV receipt, as 
shown in Figure 4.1.   
 
Figure 4.1: Correlation between baseline anti-CPS IgG levels and time since PPV23 receipt 
(N = 20; dashed lines represent 95% CI) 
 
4.3.2 Antibody responses to experimental colonisation 
Baseline and post-challenge antibody titres in colonised and non-colonised subjects are 
shown in Table 4.2 and Figure 4.2.  The baseline levels—3.37 log ng/mL in non-carriers, 
3.48 log ng/mL in carriers—did not differ between the two groups (p = 0.25).   
We did not identify an increase in antibody levels following colonisation: The mean titre in 
colonised volunteers was essentially the same at baseline (3.48 log ng/mL) and on day 29 
(3.47 log ng/mL).  The mean titre in subjects who did not develop experimental 
colonisation fell to 3.27 log ng/mL at day 29 from 3.37 log ng/mL at baseline (p = 0.039).    
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Table 4.2: Immunological outcomes following pneumococcal challenge.  
 Anti-6B CPS IgG log ng/mL, mean (SD) p 
value Baseline Day 29 
Colonised (n = 24) 3.48 (0.35) 3.47 (0.43) 0.958 
Non-colonised (n = 35) 3.37 (0.36) 3.27 (0.41) 0.039 
 
 
Figure 4.2: Anti-6B CPS IgG levels at baseline and day 29 following inoculation 
Each symbol represents a single participant. The lines and error bars in the first panel represent mean (SD); the 
lines in the second panel connect the baseline and day 29 values for each participant. N = 24 carriers, 35 non-
carriers. * p < 0.05 
An alternative approach would be to analyse according to the fold-change in antibody 
levels following pneumococcal challenge.  The differences between log-transformed 
baseline and day 29 values were normally distributed.  The mean fold change in colonised 
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volunteers was -0.003 (standard deviation 0.29), while in non-colonised volunteers it was -
0.09 (SD 0.25).  This difference was not statistically significant (p = 0.217 by the unpaired t 
test).   
After finding increased baseline IgG levels in PPV23 recipients, we repeated the analysis 
separately on PPV23 recipients and non-recipients, for the reasons outlined in the 
introduction to this chapter.  The results excluding all PPV23 recipients are shown in Table 
4.3 and Figure 4.3.   
Table 4.3: Immunological outcomes following pneumococcal challenge, excluding PPV23 recipients 
 Anti-6B CPS IgG log ng/mL, mean (SD) p 
value Baseline Day 29 
Colonised (n = 16) 3.43 (0.39) 3.47 (0.50) 0.581 
Non-colonised (n = 23) 3.26 (0.34) 3.17 (0.37) 0.133 
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Figure 4.3: Anti-6B CPS IgG levels at baseline and day 29 following inoculation, excluding PPV23 recipients 
Each symbol represents a single participant. The lines and error bars in the first panel represent mean (SD); the 
lines in the second panel connect the baseline and day 29 values for each participant. N = 16 carriers, 23 non-
carriers. There were no statistically significant differences within or between groups.   
When PPV23 recipients were excluded, baseline anti-CPS IgG levels remained similar 
between carriers and non-carriers (3.43 vs 3.26 log ng/mL, p = 0.16).  There were no 
changes in antibody levels in either colonised or non-colonised participants.  The mean fold 
change in colonised participants was +0.05 (SD 0.34), versus -0.09 (0.28) in non-colonised 
participants (p = 0.17 using the unpaired t test).   
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Results for the remaining participants (i.e. only those that had received PPV23) are shown 
in Table 4.4 and Figure 4.4.  There was a fall in antibody levels post-colonisation (from 3.58 
to 3.47 log ng/mL) but this missed the threshold for statistical significance (p = 0.055).  
Non-colonised participants’ antibody levels also dropped.  The mean fold change was -0.2 
(SD 0.13) in colonised participants versus -0.09 (0.21) in non-colonised participants (p = 
0.91 using the unpaired t test).   
Table 4.4: Immunological outcomes following pneumococcal challenge, PPV23 recipients only 
 Anti-6B CPS IgG log ng/mL, mean (SD) p 
value Baseline Day 29 
Colonised (n = 8) 3.58 (0.27) 3.47 (0.26) 0.055 
Non-colonised (n = 12) 3.58 (0.31) 3.5 (0.4) 0.143 
 
92 
 
 
Figure 4.4: Anti-6B CPS IgG levels at baseline and day 29 following inoculation, among PPV23 recipients only 
Each symbol represents a single participant. The lines and error bars in the first panel represent mean (SD); the 
lines in the second panel connect the baseline and day 29 values for each participant.  N = 8 carriers, 12 non-
carriers. There were no statistically significant differences within or between groups. 
The mean fold change in vaccinated colonised participants (-0.1) was in the opposite 
direction to that of unvaccinated colonised participants (+0.05) but this was not statistically 
significant (p = 0.235).   
4.3.3 Antibody responses and colonisation density 
We used Pearson’s correlation to assess the relationship between AUC of colonisation 
density and antibody levels within the colonised cohort.  AUC did not correlate significantly 
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with day 29 antibody levels (r = -0.115, p = 0.59) or with fold change in antibody levels (r = 
0.319, p = 0.128).  There was a moderate correlation between higher baseline anti-CPS IgG 
levels and lower colonisation densities, the statistical significance of which was borderline 
(r = -0.401, p = 0.052; Figure 4.5).   The correlations were weaker in participants who had 
never received PPV23.  By contrast, correlation coefficients between antibody levels and 
reduced colonisation density were stronger in participants who had received PPV23, 
although they did not reach statistical significance. There were non-significant negative 
correlations between baseline antibodies and colonisation density (r = -0.57, p = 0.204) and 
between Day 29 antibodies and colonisation density (r = -0.53, p = 0.181), but not between 
fold change and density (r = 0.122, p =0.773).   
 
 
Figure 4.5: Correlation of baseline anti-6B IgG with area-under-the-curve of density in pneumococcal carriers 
(N = 24; dashed lines represent 95% CI) 
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4.3.4 Antibody responses and age 
The mean baseline antibody concentrations in each age decile are shown in Table 4.5. 
There was no difference in baseline concentrations between the three groups (p = 0.23 
using ANOVA, p = 0.366 when excluding PPV23 recipients).  There was also no correlation 
between baseline antibody levels and age (r = -0.038, p = 0.817; PPV23 recipients 
excluded).   
Table 4.5: Baseline anti-6B IgG levels and responses in different age deciles 
 Age deciles P value 
50—59 (n = 
19) 
60—69 (n 
=26) 
70—80 (n 
=14) 
Baseline anti-CPS IgG titre, log 
ng/mL, mean (SD) 
3.38 (0.37) 3.36 (0.37) 3.55 (0.29) 0.23 
Fold change in 
antibody levels 
(log-transformed) 
post-challenge, 
mean (SD) 
Colonised +0.08 (0.35) -0.05 (0.27) -0.05 (0.17) 0.606 
Non-
colonised 
-0.17 (0.31) -0.05 (0.25) -0.08 (0.21) 0.510 
 
Using the paired t test, we compared changes in antibody levels between baseline and day 
29 in carriers and non-carriers in each decile, and found no significant differences (data not 
shown).  As shown in Table 4.5, there were no differences in the fold change in antibody 
levels between the different age deciles in either carriers or non-carriers.  Of note, the 
average fold change was positive in carriers aged <60 years while it was negative in older 
carriers, although this was not statistically significant.  Using Pearson’s correlation we 
found that fold change in antibody levels in response to colonisation did not correlate with 
age in either carriers (r = -0.221, p = 0.229, shown in Figure 4.6) or non-carriers (r = 0.085, p 
= 0.626).  Further subdividing by PPV23 status resulted in no correlations between fold-
change of antibodies and age, in either carriers or non-carriers (data not shown).   
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Of note, reduced antibody levels have been associated with male sex in previous 
population studies (65).  There were no differences in mean baseline antibody titres 
between males (3.44 log ng/mL, SD 0.42) and females (3.39 log ng/mL, SD 0.30; p = 0.585).   
 
Figure 4.6: Fold change in anti-CPS IgG levels after pneumococcal challenge plotted against age (colonised 
participants only) 
(N = 24; dashed lines represent 95% CI) 
 
4.3.5 Regression analysis—experimental colonisation 
The results of univariate logistic regression exploring predictor variables for experimental 
colonisation are shown in Table 4.6, with the results of multivariate regression in Table 4.7.  
Baseline antibody levels did not have a significant effect on the odds of developing 
experimental colonisation, and this was not affected by adjusting for age and sex.   
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Table 4.6: Predictors of experimental colonisation, using univariate logistic regression 
 Odds ratio 95% CI p value (Wald) 
Age (years) 0.97 0.9—1.03 0.313 
Male sex 0.59 0.21—1.66 0.319 
Baseline antibody levels (log ng/mL) 2.46 0.54—11.14 0.242 
 
Table 4.7: Predictors of experimental colonisation, using multivariate logistic regression 
 Odds ratio 95% CI p value (Wald) 
Age (years) 0.96 0.89—1.03 0.264 
Male sex 0.48 0.16—1.44 0.188 
Baseline antibody levels (log ng/mL) 3.54 0.69—18.26 0.132 
(Constant) 0.173 - 0.582 
 
4.3.6 Regression analysis—experimental colonisation density 
The results of univariate linear regression exploring predictor variables for experimental 
colonisation density are shown in Table 4.8.  Baseline antibody levels were associated with 
lower colonisation density, with borderline statistical significance—these results are (by 
definition) identical to those found when using Pearson’s correlation (Section 4.3.3).  Age 
and sex alone were not associated with colonisation density.   
Table 4.8: Predictors of experimental colonisation density (as defined by AUC), using univariate linear regression 
 Unstandardised Standardised 
β 
p value  
B Standard 
error 
95% CI 
Age (years) -0.44 0.92 -2.33 — 1.45 -0.1 0.64 
Male sex 14.82 14.66 -16.0 — 44.64 0.2 0.34 
Baseline antibody 
levels (log ng/mL) 
-40.4 19.7 -81.27 — 0.43 -0.4 0.052 
 B denotes the unstandardised regression coefficient, and β the standardised coefficient.   
As pre-specified, we went on to perform multivariate analysis, adjusting antibody levels for 
age and sex (forced entry method).  The results are shown in Table 4.9.  Baseline antibody 
levels, adjusted for age and sex, were significantly associated with reduced colonisation 
density in experimental pneumococcal carriers. 
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Table 4.9: Predictors of experimental colonisation density (as defined by AUC), using multivariate linear 
regression 
 Unstandardised Standardised 
β 
p value  
B Standard 
error 
95% CI 
Age (years) -0.33 0.87 -2.14 — 1.47 -0.08 0.7 
Male sex 22.05 14.25 -7.67 — 51.77 0.31 0.14 
Baseline antibody 
levels (log ng/mL) 
-44.43 20.0 -86.15 — -2.71 -0.44 0.038 
(Constant) 200.72 81.1 31.56 — 369.88 - 0.022 
B denotes the unstandardised regression coefficient, and β the standardised coefficient.   
 
This model shows that, although higher baseline antibody levels do not affect the 
acquisition of experimental colonisation, a 1 log increase in pre-challenge antibody levels 
corresponds with a reduction in experimental colonisation AUC density of 44.4 
CFU.days/mL for those who do become carriers.  The model R2 was 0.25—i.e. the adjusted 
baseline antibody levels could only explain 25% of the variation in colonisation density in 
our sample.   
4.4 Discussion 
We investigated seven hypotheses in this chapter, and the findings are summarised in 
Table 4.10.    
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Table 4.10: Summary of immunological results 
 Hypothesis Finding 
1 Higher baseline anti-CPS IgG levels are 
found in PPV23-vaccinated participants 
Retained. 
2 Post-PPV23 antibody levels are not 
significantly lower in participants for 
whom a long time had passed since 
vaccination 
Retained. 
3 High baseline antibody levels are not 
associated with colonisation outcomes 
Retained—similar baseline antibody 
levels in participants who did and 
didn’t develop experimental 
colonisation. 
4 Experimental colonisation results in 
boosting of anti-CPS antibody levels 
Refuted—no change in antibodies 
following experimental colonisation.  
5  Pneumococcal challenge without 
colonisation does not have any effect 
on systemic antibody levels 
Refuted—fall in antibody levels in 
the cohort as a whole. However, this 
was only barely statistically 
significant. 
6 Higher baseline antibody levels are 
associated with reduced bacterial 
density in colonised participants 
 Retained—following adjustment for 
age and sex, higher baseline 
antibodies were associated with 
lower colonisation density, albeit 
with a p value of only 0.038, i.e. only 
just clearing the threshold for 
significance.   
7 Antibody levels and responses are 
diminished in the oldest age decile 
Not identified.   
The implications of these findings can be explored under two broad headings, as outlined in 
the introduction to this chapter: 
1. Antibody-mediated protection against colonisation 
2. Antibody boosting following colonisation 
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4.4.1 Antibody-mediated protection against colonisation 
Baseline anti-CPS antibody levels were not different between participants who did and did 
not go on to develop experimental colonisation.  This remained true when the cohort was 
subdivided based on PPV23 status.  This finding is consistent with EHPC studies in younger 
adults which drew the same conclusion (60) and our finding that PPV23 was not protective 
against colonisation in our previous chapter.  This does not explain why PCV13—which also 
induces anti-CPS antibodies—is protective against colonisation in younger participants 
(107).   
Indeed, a study of the effect of PCV13 on colonisation in older adults was published after 
our study was completed, based on a nested cohort within the CAPiTA study (108, 110).  
This study found that PCV13 did reduce the rate of vaccine-type colonisation compared 
with placebo at six months post-vaccine, but not at later timepoints.  It may be that PCV13 
results in improved antibody delivery to mucosal compartments (73) compared with 
natural or PPV23-induced immunity.  Equally, as outlined in Chapter 1, other facets of 
immunity must be involved in preventing colonisation.   
Higher baseline antibody levels, adjusted for age and sex, were significantly associated with 
lower colonisation density.  Although the model fit was poor, this finding is biologically 
plausible.  It is also consistent with the mechanism of action of vaccine-induced antibodies: 
in a previous EHPC study in young adults, PCV13 reduced the risk of pneumococcal 
acquisition (compared with placebo) but was also associated with reduced density in 
participants who did acquire colonisation (107).  
The implications of antibody-mediated control of density will require further study.  Higher 
colonisation density was associated with an increased risk of transmission in a murine 
model (202).  This association is widely held to be true for human children (203), but has 
yet to be demonstrated.  As adults are less likely than children to transmit in any case, the 
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public health relevance of higher densities in colonised adults is uncertain.  However, it is 
also plausible that higher colonisation density would be associated with higher risk of 
disease.  Adults with pneumococcal pneumonia have been found to have higher 
colonisation density than controls (24, 204), but in the absence of prospective studies a 
causal relationship remains to be determined.   
Older adults’ antibodies have been associated with reduced opsonophagocytic capacity in 
other studies (80).  However, reduction in colonisation density may be mediated by 
agglutination rather than opsonophagocytic killing (73), and future studies should explore 
the agglutination capacity of antibodies in older adults.   
The reduction in colonisation density by antibodies was small, and the majority of variation 
in density was unexplained by the multivariable model.  Similarly, pneumococcal vaccines 
are immunogenic but only confer partial protection against vaccine-type pneumococcal 
colonisation or disease (104, 110).  It remains clear that serotype-specific, antibody-
mediated immunity alone is not sufficient to control pneumococcal colonisation in older 
adults.   
4.4.2 Antibody boosting following colonisation 
In our primary analysis of the entire cohort, we did not identify antibody boosting in 
colonised recipients. This contrasts markedly with results seen in younger adults (60), and 
is supportive of a hypothesis that anti-pneumococcal immune responsiveness is diminished 
in older people.   
We demonstrated a small but statistically significant drop in anti-6B IgG levels following 
pneumococcal challenge without colonisation.  This may represent hyporesponsiveness.  In 
previous studies, hyporesponsiveness has not manifested itself as a fall in antibody levels 
following antigen challenge. Rather, it has manifested as a lower-than-expected rise in 
antibody titre after a PPV23 booster vaccination compared with the response to the 
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primary vaccine or to a PCV13 booster (116, 118, 197).  Serotype-specific memory B cell 
levels have been shown to fall following revaccination with PPV23 in older adults (117).  
These memory B-cells may undergo similar terminal differentiation in response to live 
pneumococcus.  However, these terminally-differentiated B-cells are still capable of 
secreting antibodies, and therefore a fall in antibody titres after four weeks remains 
unexpected.   
Another possible explanation is that peripheral antibodies were sequestered in the nose 
following pneumococcal challenge, leading to a drop in circulating levels.  This 
phenomenon has previously been noted for mucosal antibodies in PCV13-vaccinated young 
adults (preventing colonisation via agglutination), but did not affect peripheral antibody 
levels (73).  Therefore, it may be that some individuals have the capacity to recruit 
circulating antibodies (or antibody-secreting cells) to the nasopharyngeal mucosal surface 
and it is this capacity, rather than the absolute antibody concentration in blood, that 
determines whether the individual is protected against colonisation.  Further work 
specifically exploring the dynamics of mucosal rather than systemic immunity during EHPC 
in older people could investigate this hypothesis.  During the “Aging and Immunity” study 
we collected a number of mucosal samples, including nasal wash, nasal matrix absorption 
and nasal microbiopsy (205), and these will allow us to measure mucosal antibody, 
cytokine levels and immune cell populations over the duration of a challenge/colonisation 
episode in this older population.   
An EHPC study in young adults demonstrated a functional immune boost following 
colonisation—participants were protected against reacquisition of the same serotype for 
up to one year (60).  Our group plans to re-challenge carriers from the “Aging and 
Immunity” study with serotype 6B to provide further insight into the true impact of 
pneumococcal colonisation on immunity.   
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Recently there has been growing interest in the use of “seroincidence” to estimate 
pneumococcal colonisation incidence in populations.  If our EHPC results are similar to the 
antibody responses to naturally-acquired colonisation, this suggests that seroincidence 
would have poor sensitivity for identifying pneumococcal acquisition in older adults.  
Applying the same definition as a recent paediatric study to our cohort —any increase in 
serotype-specific antibodies between two timepoints (79)— gives seroincidence a 
sensitivity of 37.5% and specificity of 70.1% for identifying pneumococcal colonisation.   
4.4.2.1 Antibody boosting and vaccine status 
When we divided the participants by PPV23 status, we did not identify any statistically-
significant changes in antibody levels post-challenge.  These subgroups were under-
powered.  In addition, dividing the cohort by PPV23 status results in obvious age 
imbalances.     
4.4.2.2 Age-related trends 
While we did not identify an age-related trend within our cohort, clearly the responses to 
EHPC in this cohort of older adults are different to those previously reported in younger 
adults (60), and direct comparisons with serum from young controls would be a valuable 
future project.  The antibody response to colonisation may also be serotype dependent.  
Previous population studies have shown a decline in antibodies against certain serotypes 
(e.g. serotype 3) with age, but not in other serotypes including 6B (65).  By contrast, an 
observational study of colonisation in young adults found that 6B did not provoke as strong 
an antibody response as other serotypes (29).  It is unlikely that we will be able to study the 
serological response to experimental challenge with different serotypes in older adults, as 
EHPC studies with serotypes other than 6B have failed to establish high, reproducible rates 
of carriage thus far (Victoria Connor et al, unpublished data, and (60)).   
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While we did not measure functional activity in this study, IgG levels and serum 
opsonophagocytic activity are reasonably well correlated in older adults (126).  As 
mentioned above, a study of agglutinative as well as opsonophagocytic function in this 
cohort would provide valuable mechanistic insight.   
4.4.3 Conclusions 
While this cohort of older adults proved susceptible to experimental colonisation with 
pneumococcus, their anti-capsular antibody responses to pneumococcal challenge were 
markedly different to those previously reported in young adults.  In particular, 
pneumococcal challenge with colonisation did not boost antibody levels, and challenge 
without colonisation was associated with a fall in antibody levels.  We found no evidence of 
superior antibody responses to colonisation in PPV23 recipients.  Although pre-existing 
serotype-specific antibodies were not protective against colonisation acquisition, they may 
have a role in controlling colonisation density.   
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5 Defining the Pneumococcal Colonisation Niche using 
Different Sampling Methods 
5.1 Background 
As outlined in Table 1.1 and Section 1.2 of the INTRODUCTION, the ideal method to detect 
pneumococcal colonisation remains a matter of dispute, particularly in older adults.  
Published rates of colonisation differ substantially, and some of this may depend on the 
site of sampling—e.g. nasopharynx versus oropharynx—with some authors suggesting that 
the niche of colonisation changes with age (43).  Each site can be sampled using different 
methodologies—e.g. nasopharyngeal swab versus nasal wash; oropharyngeal swab versus 
saliva.  Finally, the sensitivity and specificity of different laboratory assays—e.g. culture vs 
qPCR—are quite different, and assay performance can vary between different types of 
samples from different niches.   
Defining both the niche of colonisation and the ideal sampling method is vital to maximise 
the yield of epidemiological colonisation studies and establish the true underlying rate of 
colonisation.  In addition, colonisation can be an endpoint for vaccine studies, and the 
definition of colonisation can affect the estimation of vaccine efficacy.   
A report from a WHO working group in 2013 recommended that  
For adults, both [nasopharyngeal] and [oropharyngeal] samples should be collected. 
However, if only one sample is possible, collecting from the nasopharynx is more sensitive 
than from the oropharynx (36).   
The report also recommended  
The [nasopharyngeal] swab approach for collection of the sample. [Nasopharyngeal] 
aspirates or washes are also acceptable methods of specimen collection as they have 
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sensitivity for pneumococcal detection equal to, or greater than, that of [nasopharyngeal] 
swabs, but may be less tolerated by participants (36).    
In our local context, nasal washes have been tolerated better than swabs in adults (37).  
The WHO working group recommended culture rather than molecular methods for 
pneumococcal detection, but acknowledged that  
Molecular testing of paired [nasopharyngeal and oropharyngeal] samples is needed to 
establish if the recommendations for anatomic site of sampling apply also to studies using 
molecular detection of pneumococci (36). 
Studies that compared the performance of culture and molecular methods for detecting 
community-acquired pneumococcal colonisation are summarised in Table 1.1 of the 
INTRODUCTION. The comparative performances of nasal wash, oropharyngeal swab and saliva 
have not been assessed in EHPC before.  A post-hoc study of EHPC in young adults 
compared the sensitivity of nasal wash culture and lytA qPCR, and found that 42.6% of 
samples were positive by qPCR versus 27.5% by nasal wash (48). The sensitivity of qPCR 
was 93.2% while the specificity was 75.9%.  The authors concluded that qPCR’s advantage 
was in detecting low-density colonisation.  The authors also speculated that continuous 
qPCR detection when culture results are negative may represent prolonged low-density 
carriage, living cells that are in a culture-unfavourable metabolic state, or remaining 
pneumococcal debris (48).  However, lytA qPCR may generate false-positive results by 
detecting other commensal streptococci; many experts now advocate targeting two genes 
in pneumococcal qPCR to maximise specificity (47).  This approach has not yet been applied 
to older participants or to oral samples in EHPC subjects.   
Along with their respective sensitivities and specificities, numerous other factors affect the 
choice of test and analysis method, such as patient acceptability, labour intensity, cost, 
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logistic and infrastructure requirements and ability to harmonise methodology across a 
variety of settings.   
When designing the “Aging and Immunity” study, we pre-specified that colonisation would 
be defined using nasal wash culture.  This facilitated direct comparisons with previous EHPC 
studies, and was the most logical definition given that participants underwent nasal 
inoculation.  For this reason, nasal wash culture would be the “gold standard” against 
which other diagnostic methods for experimental pneumococcal colonisation would be 
compared.  Alongside each nasal wash, we also took paired oropharyngeal swabs and saliva 
samples.  In this chapter, we compare the performance of molecular analysis of these 
samples with nasal wash culture in this cohort.   
5.1.1 Hypotheses 
We test the following hypotheses in this chapter:  
1. Nasal wash qPCR will identify pneumococcus in more samples than nasal wash 
culture (48); 
2. Oropharyngeal swab qPCR will identify pneumococcus in more samples than than 
nasal wash (see Table 1.1 for literature review); 
3. Saliva qPCR will identify the highest number of positive samples (Table 1.1); 
4. qPCR targeting lytA alone is more sensitive but less specific than qPCR targeting 
both lytA and cpsA genes (186); 
5. EHPC studies take samples at multiple timepoints, thus maximising the likelihood of 
detecting colonisation by culture—therefore, at the participant level (rather than 
the individual sample level) culture and molecular methods have similar sensitivity 
and specificity for classifying participants as colonised or non-colonised;  
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5.2 Methods 
We obtained nasal wash, oropharyngeal swab (OPS) and saliva samples at each timepoint 
in the “Aging and Immunity” study (see the timeline in Figure 2.3).  We tested the samples 
from baseline and days 2, 7 and 14 post-inoculation using qPCR.  (These timepoints are 
common to all EHPC studies, and future work will involve molecular tests on archived 
samples from young volunteers at these same timepoints.)  
5.2.1 Clinical procedures 
Nasal wash was performed as outlined in Section 2.6.3, OPS as in Section 2.6.4 and saliva 
collection as in Section 2.6.5.   
5.2.2 Laboratory procedures 
Nasal wash culture and pneumococcal identification were performed as outlined in Section 
2.7.2.  OPS and saliva samples were not cultured prior to DNA extraction and qPCR; future 
work will explore the effect of culture enrichment on test performance.   
Nasal wash pellets, OPS and saliva were stored in STGG at -80°C, and for the current 
analysis they underwent multiplex qPCR targeting both the lytA and the 6A/B capsular 
polysaccharide (cpsA) genes, as outlined in Section 2.7.5—two targets were chosen to 
maximise the specificity, with a positive qPCR requiring detection of both targets within 40 
cycles.  A schematic outlining the sample timing, samples taken and analytic methods is 
given in Figure 5.1.   
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Timepoints 
Baseline pre-inoculation 
Day 2 post-inoculation 
Day 7 post-inoculation 
Day 14 post-inoculation 
Nasal wash  
Oropharyngeal swab 
Saliva  
Culture 
qPCR 
qPCR 
qPCR 
Figure 5.1: Sampling schedule and testing methods employed in this chapter 
qPCR: quantitative polymerase chain reaction 
Comparisons 
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5.2.3 Statistical analysis 
Nasal wash culture was used as the “reference standard” against which the other tests 
would be measured.  We assessed the relative performance of each sample strategy at 
each timepoint for our primary analysis.  We included participants who were colonised with 
non-6B serotypes at any timepoint, as our diagnostic methods were intended to be 
serotype-specific.  As a secondary analysis, we re-ran each comparison with qPCR targeting 
lytA alone, to see if qPCR specificity was reduced by only targeting one gene.  Another 
secondary analysis assessed sensitivity and specificity at the participant level, defining a 
positive result as detection of pneumococci by a given method at any post-inoculation 
timepoint for each participant. We defined sensitivity and specificity as follows: 
• Sensitivity = 
Test positives
All culture positives
 
• Specificity = 
Test negatives
All culture negatives
 
Sensitivities and specificities are presented with 95% CIs which were calculated based on 
Newcombe’s efficient score method (206), using an online calculator 
(http://vassarstats.net/clin1.html, accessed 08 July 2018).  
5.3 Results 
Sixty-four adults aged 50—84 years provided 254 sample pairs for nasal wash culture/qPCR 
and nasal wash culture/OPS qPCR (two subjects had missed their day 14 visit), and 251 
sample pairs for nasal wash culture/saliva qPCR (two subjects missed their day 14 visit and 
a further three samples had insufficient saliva volume for testing).   
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5.3.1 Performance of qPCR versus nasal wash culture 
5.3.1.1 Nasal wash qPCR 
Using nasal wash culture, 20.1% of samples were positive for S pneumoniae serotype 6B, 
while 18.1% were positive using nasal wash qPCR (Table 5.1).   
Table 5.1: Performance of nasal wash lytA/6AB qPCR versus culture 
 Nasal wash culture Totals 
Positive Negative 
Nasal wash 
lytA/6AB qPCR 
Positive 41 5 46 
Negative 10 198 208 
Totals 51 203 254 
 
Sensitivity of qPCR versus the reference standard of culture = 
41
51
 = 80.4% (95% CI 66.5—
89.7%). 
Specificity of qPCR versus culture = 
198
203
 = 97.5% (94—99.1%). 
At the participant level, two participants were newly identified as carriers using nasal wash 
qPCR—one was qPCR positive at all three timepoints, while the other was only positive at 
one timepoint.  However, four culture-positive participants were missed by qPCR.   
5.3.1.2 Oropharyngeal swab qPCR 
As shown in Table 5.2, 7.9% of samples were positive by OPS qPCR.  
Table 5.2: Performance of oropharyngeal lytA/6AB qPCR versus nasal wash culture 
 Nasal wash culture Totals 
Positive Negative 
Oropharyngeal swab 
lytA/6AB qPCR 
Positive 16 4 20 
Negative 35 199 234 
Totals 51 203 254 
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Sensitivity of OPS qPCR versus NW culture = 
16
51
 = 31.4% (19.5—46%). 
Specificity of OPS qPCR versus NW culture =  
199
203
 = 98% (94.7—99.4%). 
Two culture-negative participants were newly identified as carriers using OPS qPCR; one of 
these was also positive by nasal wash qPCR.  However, 11 culture-positive participants 
were missed by OPS qPCR.   
5.3.1.3 Saliva qPCR 
As shown in Table 5.3, only 1.6% of samples tested positive by saliva qPCR. 
Table 5.3: Performance of saliva lytA/6AB qPCR versus nasal wash culture 
 Nasal wash culture Totals 
Positive Negative 
Saliva lytA/6AB 
qPCR 
Positive 3 1 4 
Negative 48 199 247 
Totals 51 200 251 
 
Sensitivity of saliva qPCR versus NW culture = 
3
51
  = 5.9% (1.5—17.2%). 
Specificity of saliva qPCR versus NW culture = 
199
200
 = 99.5% (96.8—99.9%). 
One participant was newly identified as colonised using saliva qPCR (the participant was 
also qPCR positive in both NW and OPS), while 21 carriers were missed entirely.   
5.3.2 Performance of lytA qPCR alone 
We performed two-target qPCR to maximise test specificity.  However, lytA is generally 
accepted to be the most specific single gene for pneumococcus (186), and there is a 
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substantial body of literature in which qPCR for lytA alone was used to diagnose 
pneumococcal colonisation (24, 48).  Therefore we did a secondary analysis of the 
performance of single-target qPCR.  Since lytA qPCR is serotype-independent, nasal wash 
culture positivity for any pneumococcal serotype (i.e. including “natural carriers”) was 
considered the reference standard in this analysis.   
5.3.2.1 Nasal wash lytA qPCR 
As shown in Table 5.4, 23.6% of samples were positive for S pneumoniae using nasal wash 
culture, compared with 24.4% using nasal wash lytA qPCR.   
Table 5.4: Performance of nasal wash lytA qPCR versus culture 
 Nasal wash culture Totals 
Positive Negative 
Nasal wash lytA 
qPCR 
Positive 52 10 62 
Negative 8 184 192 
Totals 60 194 254 
 
Sensitivity of lytA qPCR versus culture = 
52
60
 = 86.7% (74.9—93.7%). 
Specificity of lytA qPCR versus culture = 
184
194
 = 94.8% (90.5—97.4%). 
 
5.3.2.2 Oropharyngeal lytA qPCR 
Table 5.5: Performance of oropharyngeal lytA qPCR versus nasal wash culture 
 Nasal wash culture Totals 
Positive Negative 
Oropharyngeal swab 
lytA qPCR 
Positive 22 14 36 
Negative 38 180 218 
Totals 60 194 254 
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Sensitivity of OPS lytA qPCR versus NW culture = 
22
60
 = 36.6% (24.9—50.2%). 
Specificity of OPS lytA qPCR versus NW culture =  
180
194
 = 92.8% (87.9—95.8%). 
5.3.2.3 Saliva lytA qPCR 
Table 5.6: Performance of saliva lytA qPCR versus nasal wash culture 
 Nasal wash culture Totals 
Positive Negative 
Saliva lytA qPCR Positive 8 6 14 
Negative 52 185 237 
Totals 60 191 251 
 
Sensitivity of saliva lytA qPCR versus NW culture = 
8
60
  = 13.3% (6.3—25.1%). 
Specificity of saliva lytA qPCR versus NW culture = 
185
191
 = 96.8% (92.9—98.7%). 
5.3.3 Molecular methods in natural carriers 
Our use of serotype-specific methods (latex agglutination of culture samples and 6A/B 
qPCR) meant that we did not exclude participants who were “naturally” colonised with 
pneumococcus from our primary analysis.   Colonisation with non-6B serotypes was 
detected at 11 timepoints by culture, including two episodes of dual colonisation with 6B 
and a natural strain.  NW lytA qPCR was positive at 10/11 timepoints.  OPS and saliva lytA 
qPCR were jointly positive at one timepoint, and separately positive at one further 
timepoint each.  In the two instances where there was dual colonisation, NW qPCR was 
positive by both lytA and 6AB; in one of these cases saliva lytA qPCR was positive but 6A/B 
was negative.   
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5.3.4 Classification of volunteers as carriers 
When reporting the results of the primary analysis in this chapter, we noted how many 
participants were “newly identified as colonised” or “missed” by each molecular diagnostic 
method.  In this secondary analysis, we formally assess the performance of molecular 
methods versus nasal wash culture for classifying volunteers as experimental carriers.  If a 
volunteer tested positive by a given method at any of the three post-inoculation 
timepoints, they were classified as positive. Nasal wash culture for serotype 6B 
pneumococcus was again considered the reference standard (carriers of non-6B serotypes 
were classified as culture negative).  Missing samples were disregarded, and two volunteers 
who only tested positive for colonisation by culture on day 9 (i.e. did not have paired 
samples for molecular diagnostic) are classified as culture negative in this analysis.   
5.3.4.1 Nasal wash lytA/6AB qPCR 
Table 5.7: Performance of nasal wash lytA/6AB qPCR versus culture at participant level 
 Nasal wash culture Totals 
Positive Negative 
Nasal wash 
lytA/6AB qPCR 
Positive 19 2 21 
Negative 4 39 43 
Totals 23 41 64 
 
 
Sensitivity of qPCR versus culture = 
19
23
 = 82.6% (60.5—94.3%). 
Specificity of qPCR versus culture = 
39
41
 = 95% (82.2—99.2%). 
115 
 
5.3.4.2 Oropharyngeal lytA/6AB qPCR 
Table 5.8: Performance of oropharyngeal lytA/6AB qPCR versus nasal wash culture at participant level 
 Nasal wash culture Totals 
Positive Negative 
Oropharyngeal swab 
lytA/6AB qPCR 
Positive 12 2 14 
Negative 11 39 50 
Totals 23 41 64 
 
Sensitivity of OPS qPCR versus NW culture = 
12
23
 = 52.2% (31.3—72.6%) 
Specificity of OPS qPCR versus NW culture =  
39
41
 = 95% (82.2—99.2%) 
5.3.4.3 Saliva lytA/6AB qPCR 
Table 5.9: Performance of saliva lytA/6AB qPCR versus nasal wash culture at participant level 
 Nasal wash culture Totals 
Positive Negative 
Saliva lytA/6AB 
qPCR 
Positive 2 1 3 
Negative 21 40 61 
Totals 23 41 64 
 
Sensitivity of saliva qPCR versus NW culture = 
2
23
  = 8.7% (1.5—29.5%) 
Specificity of saliva qPCR versus NW culture = 
40
41
 = 97.6% (85.6—99.9%) 
5.4 Discussion 
We investigated five hypotheses in this chapter, and the outcomes are summarised in Table 
5.10.  A summary of the main results, juxtaposed with the results for lytA qPCR alone, is 
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given in Table 5.11.  A heatmap (Figure 5.2) summarises the findings of the primary analysis 
graphically.  
Table 5.10: Outcomes of hypotheses tested in this chapter 
 Hypothesis Outcome 
1 Nasal wash qPCR will identify 
pneumococcus in more samples than 
nasal wash culture 
Rejected—similar numbers of samples 
identified using either method, qPCR 
80.4% sensitive versus culture 
2 Oropharyngeal swab qPCR will identify 
pneumococcus in more samples than 
nasal wash culture 
Rejected—oropharyngeal swab 31.4% 
sensitive 
3 Saliva qPCR will identify the highest 
number of positive samples 
Rejected—5.9% sensitivity 
4 qPCR targeting lytA alone is more 
sensitive but less specific than qPCR 
targeting both lytA and cpsA genes 
Retained, but differences in sensitivity 
and specificity very small between the 
two methods (See Table 5.11) 
5 At the participant level, culture and 
molecular methods have similar 
sensitivity and specificity 
Rejected—culture was already superior 
to molecular methods at the individual 
sample level, and this did not change 
when a participant-level definition was 
used; similar sensitivity and specificity 
within each method at the sample and 
participant level, although OPS qPCR 
more sensitive at participant level than 
at sample level 
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Table 5.11: Summary of dual-target and single-target qPCR results 
 Sensitivity Specificity 
(Nasal wash culture) (100%) (100%) 
Nasal wash lytA/6AB qPCR 80.4% (66.5—89.7%) 97.5% (94—99.1%) 
lytA qPCR 86.7% (74.9—93.7%) 94.8% (90.5—97.4%) 
Oropharyngeal lytA/6AB qPCR 31.4% (19.5—46%) 98% (94.7—99.4%) 
lytA qPCR 36.6% (24.9—50.2%) 92.8% (87.9—95.8%) 
Saliva lytA/6AB qPCR 5.9% (1.5—17.2%) 99.5% (96.8—99.9%) 
lytA qPCR 13.3% (6.3—25.1%) 96.8% (92.9—98.7%) 
95% confidence intervals are given in parentheses.  
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Figure 5.2: Heatmap summarising the results of different pneumococcal tests 
Each row represents an individual participant’s sampling timepoint, each column a diagnostic method. Shaded 
squares indicate a positive result, with increasing darkness of shading indicating that a participant was positive by 
one, two, three or four diagnostic methods at that timepoint.  As shown in the pie chart, 77% of samples (n = 196) 
were negative for pneumococci by all four methods.    
NW, nasal wash; OPS, oropharyngeal swab; qPCR, quantitative polymerase chain reaction 
 
Negative by all detection methods 
(n = 196 samples) 
Positive by any method 
(n = 58) 
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None of the molecular sampling techniques demonstrated a sufficiently high sensitivity to 
replace nasal wash culture as the reference standard for pneumococcal detection in older 
adults.   If we had used only molecular methods, we would have detected fewer 
experimental carriers than we did using culture, even if we had analysed samples from 
multiple anatomical sites.   Combining culture with molecular methods for routine analysis 
in the “Aging and Immunity” study would have detected three new experimental carriers if 
both nasopharyngeal and oropharyngeal samples were tested, while adding a significant 
workload to the laboratory.   
The oral samples showed particularly poor sensitivity for pneumococcal detection by qPCR.  
This is in marked contrast with the results of community-based colonisation screening 
studies (44).  Unidentified issues with sample collection, processing or storage may have 
contributed to the high false negative rate.  In addition, oropharyngeal pneumococcal 
detection rates may indeed be low following experimental nasal inoculation, but this may 
not hold true for community-acquired colonisation.   
All molecular methods demonstrated high specificity.  Recent studies have reported 
capsular polysaccharide production by commensal streptococci (such as Streptococcus 
mitis) and the detection of the cps gene in these species (207), raising a concern that our 
lytA/cpsA qPCR could be vulnerable to false positives.  There were no lytA-positive, cpsA-
positive samples at baseline from any site in any of our participants. Therefore we remain 
confident that lytA/cpsA-positive samples obtained after serotype-6B pneumococcal 
exposure are more likely to represent genuine detection of experimental colonisation.   
5.4.1 Non-serotype-specific molecular testing 
Molecular methods are generally considered more sensitive but less specific than culture; 
hence, refinements to pneumococcal qPCR tend to focus on increasing specificity, e.g. by 
mandating two gene targets.  Our study found that lytA/6AB qPCR from any site had low 
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sensitivity but high specificity.  Therefore we looked at the performance of lytA qPCR alone.  
We found that omitting the cpsA qPCR came with a modest drop in specificity, and a 
similarly modest rise in sensitivity (Table 5.11). Nasal wash lytA qPCR had a sensitivity of 
86.7%, 95% CI 74.9—93.7%; the 93.2% sensitivity of nasal wash lytA qPCR in young adults 
falls (just) within this confidence interval (48).   
We cannot state with confidence how many lytA qPCR-positive, culture-negative samples 
represented true pneumococcal colonisation, perhaps in low densities, rather than a false 
positive assay due to (for example) commensal streptococcal detection.  40% of such 
samples (12/30) were from participants who were culture-positive at other timepoints, 
suggesting that the qPCR was detecting either true low-density colonisation or residual 
pneumococcal debris.   
In participants colonised with non-6B serotypes, nasal wash lytA qPCR performance did not 
differ substantially from that of culture.  The two “natural carriers” who were positive by 
nasal wash lytA/6AB qPCR also had dual colonisation including serogroup 6 identified on 
nasal wash culture—this reassures us that no experimental carriers were missed by culture 
due to overgrowth by non-6B serotypes.   
5.4.2 Reliability of saliva sampling 
The pneumococcal yield from saliva was surprisingly low—given the high rate of salivary 
colonisation identified in other studies, it is possible that methodological issues related to 
saliva collection or processing led to a high false-negative rate in our sample.  For example, 
a Dutch study identified colonisation in 28% of older adults using culture-enriched qPCR of 
saliva (44). This study used a similar absorbent sponge methodology to ours, but 
immediately placed the sample in glycerol and transported it to the laboratory on dry ice, 
whereas we transported our samples without preservative on wet ice, with a 1—2-hour 
interval between collection and processing.  However, other Dutch studies have detected 
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high salivary colonisation rates using much simpler methods—e.g. a paediatric study (88% 
colonisation) asked subjects to spit into a sterile container which was transported to the 
laboratory on wet ice within 4 hours (46).  Another study found that pneumococci could be 
reliably detected in dried saliva that had been stored for up to a month at ambient 
temperature (208).  Of note, these saliva samples were spiked with pneumococci, and thus 
may have been less representative of epidemiological participant samples.  These studies 
suggest that the salivary pneumococcal yield is not profoundly affected by the collection 
method.  Nonetheless, the discordance between our results and the sizeable body of 
evidence from the Netherlands remains unexplained. In addition, other studies in EHPC 
participants have required participants to spit directly into an STGG-filled tube, and these 
studies detected pneumococcal DNA in saliva up to 48 hours post-inoculation (E Nikolaou, 
unpublished data).  Future EHPC studies in older adults should adopt this methodology.  
Overall, our findings suggest that, if salivary PCR is employed, it should be used in parallel 
with other sampling strategies rather than on its own.   
Some authors have suggested that culture-enrichment pre-qPCR improves the sample yield 
(209).  Preliminary work with spiked samples in our lab found that qPCR of both culture-
enriched and raw samples were complementary, with a combination of the two methods 
yielding the highest number of positive samples (E Nikolaou, unpublished data).  Future 
work will explore the performance of culture enrichment in samples from the over-50 
cohort.   
5.4.2.1 Oral fluids other than saliva 
A variety of secretions are produced in the oral cavity, including saliva but also gingival-
crevicular fluid (210).  Gingival crevicular fluid has been found to contain numerous 
inflammatory mediators and antibodies, which can be reflective of an individual’s systemic 
inflammatory and immune status (210)(211).   Did our collection methods truly obtain 
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samples of participants’ saliva, or did we in fact collect an alternative oral secretion, or a 
mixture of saliva and other secretions?  
During saliva collection, we observed that a number of participants found it uncomfortable 
to hold the sponge in their mouth for the requisite duration; some found it easier to move 
the sponge around using their tongue, while others preferred to let it rest in a single 
location.  To minimise participant discomfort, we did not mandate a standardised 
anatomical niche in which to place the sponge.  Our collection and analytical methods were 
based on a modification of a protocol shared by a Dutch team (M-L Chu, personal 
communication), in which absorbant sponges were placed between gum and cheek.  
Therefore, we feel that our collection method retains validity, although it would have been 
ideal to completely standardise the saliva collection manoeuvre between participants. 
Gingival crevicular fluid is secreted in particularly small volumes, typically being collected 
using a filter paper strip rather than sponges (211).  Therefore, the fact that our 
participants were able to saturate a sponge suggests that saliva formed a significant 
fraction of the fluid we obtained.   
Gingival crevicular fluid does differ in composition from saliva, although it has been argued 
that differences in component concentrations are unlikely to translate to different 
conclusions in research should one fluid be substituted for the other (210). If 
pneumococcus colonises the oral cavity, there is no reason to suppose that the relative 
compositions of different oral secretions are more or less inhabitable to this encapsulated 
pathogen, which has adapted to tolerate inhospitable mucosal surfaces and evade mucosal 
host defences (212)(72).   
5.4.3 Limitations of nasal wash culture as an EHPC reference standard 
We chose nasal wash culture as our reference standard based on its use in prior EHPC 
studies.  However, comparison between a culture-based reference standard and a 
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(potentially more sensitive) molecular diagnostic method poses challenges.  Had we been 
able to culture the samples taken from the oropharyngeal niche, this would have facilitated 
direct comparisons between culture of oral and nasal samples, and then between qPCR of 
oral and nasal samples.  Overgrowth of oral samples by commensal flora is a major 
limitation of this approach, but including a culture-enrichment step in future studies could 
overcome this limitation (209)(47).   
Numerous methods exist to establish the performance of a diagnostic test in the setting of 
an imperfect reference standard, ranging from construction of composite reference 
standards (sometimes by panel consensus) to correction via statistical modelling (reviewed 
in (213)).  For example, a study assessing a new highly-sensitive PCR methodology (Xpert 
Ultra, versus the standard Xpert) for the diagnosis of tuberculous meningitis compared 
each diagnostic method (culture, Xpert and Xpert Ultra) against a reference standard of 
“positive by any of the three methodologies” (214).  
A future EHPC study could adopt a similar methodology—for example, assessing each qPCR 
from individual niches against a reference standard comprising qPCR positivity from any 
sample.  However, given the low positivity rates of oropharyngeal and salivary qPCR in this 
chapter, such a study would require methodological refinement—e.g. incorporating a 
culture-enrichment step and/or a different saliva collection methodology.   
5.4.4 The role of nasal wash culture outside the context of EHPC 
Nasal wash culture has a number of disadvantages. It can be uncomfortable and technically 
challenging for participants, although better tolerated than nasopharyngeal swab (37).  In 
addition, saline impairs pneumococcal viability, meaning that the sample must reach the 
laboratory within an hour of collection.  If nasal wash were used for field studies without 
near-patient laboratory facilities, then the sample would require freezing upon collection 
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or a preservative like glycerol or STGG to be added immediately afterwards.  The 
reasonable sensitivity of nasal wash qPCR could help overcome this limitation.   
In epidemiologic studies, simply detecting pneumococcal colonisation is not always 
enough—ideally, serotypes should also be identified.  Currently, serotype identification can 
only be performed with confidence on culture-based samples.  When performing qPCR in 
EHPC, we could be confident that a positive 6AB qPCR coupled with a positive lytA qPCR, in 
a participant recently inoculated with serotype 6B, represented serotype 6B colonisation.  
Serotyping of qPCR-positive samples from a general population is more logistically 
challenging, as potentially every lytA-positive sample must undergo repeat qPCR with 
separate probes for every serotype.  The majority of currently available probes only identify 
pneumococci at the serogroup level (47).  Current vaccines may not target every member 
of a serogroup: for example, of serotypes 9N, 9L and 9V, only 9V is in PCV13, and thus the 
detection of serogroup 9 by qPCR is of limited epidemiologic utility.  Novel methods, such 
as microarray analysis of genomic DNA, can classify pneumococci at serotype level (191) 
and could potentially be adapted for use with qPCR-positive samples.   
Culture also allows the phenotypic measurement of antimicrobial susceptibility, another 
important metric in epidemiologic studies.  Potentially, PCR probes directed against specific 
genes known to encode resistance could be employed—however, the issue of potential 
contamination with commensal flora cannot be overcome.  In addition, there have been no 
prospective studies correlating the detection of antimicrobial resistance genes with 
phenotypic susceptibility in pneumococci (215).   
5.4.5 Conclusions 
Nasal wash culture was superior to qPCR of nasal wash, oropharyngeal swab or saliva for 
detecting experimental pneumococcal colonisation in older adults.  We did not identify any 
potential benefit to integrating molecular diagnostics and/or alternative niches of 
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colonisation into routine EHPC practice.  We cannot rule out methodological limitations or 
qualitative differences between natural and experimental colonisation, and our results 
from qPCR of oral samples are discordant with the majority of community-acquired 
colonisation studies in older adults (Table 1.1).  Hence we cannot state with certainty that 
nasal wash culture is the optimum pneumococcal detection methodology in all 
circumstances.  Nonetheless, our findings underscore the validity of nasal wash culture in 
the EHPC model and reinforce the advantages of this strategy.  In the next chapter, we will 
employ culture, serotyping and antimicrobial resistance testing on nasal wash samples 
collected since the inception of the EHPC programme, demonstrating the utility of this 
approach in a “real world” context.   
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6 Community-Acquired Pneumococcal Colonisation in 
Healthy, Low-Risk Adults in Liverpool 
6.1 Background 
Previous chapters have discussed how older adults are highly susceptible to colonisation 
with serotype 6B pneumococcus, and that this appears to be independent of natural or 
PPV-induced anti-CPS immunity.  Serotype 6B is included in the 13-valent pneumococcal 
conjugate vaccine (PCV13), which is routinely administered to children in the UK.  
Childhood pneumococcal vaccination has been shown to induce “herd immunity”, reducing 
vaccine-type colonisation in vaccinated children but also in unvaccinated adults (33) and 
reducing rates of invasive pneumococcal disease at regional and national population levels 
(216).   
A study published after ours was completed suggested that PCV13 could reduce rates of 
vaccine-type colonisation in older adults, but that the effect did not persist beyond six 
months (110). PPV23 (which also covers serotype 6B) has not been shown to protect 
against colonisation, including in our study of EHPC in older adults.  There are no plans to 
introduce PCV13 for older adults in the UK (100), and therefore childhood vaccination 
programmes will remain the cornerstone of community protection against pneumococcal 
colonisation, transmission and disease.   
6.1.1 The outlook for PCV13 in the UK 
When PCV13 was introduced into the UK childhood vaccine programme, it was 
administered at two and four months of age, with a booster dose at 13 months—this is 
denoted as a “2 + 1” schedule.  Recently the UK Joint Committee on Vaccines and 
Immunisation announced that the schedule would be changed to “1 + 1” (priming at 3 
months, boosting at 13 months), based on new immunological data (217, 218).  This was 
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predicated on the demonstration that vaccine-type pneumococci were circulating at 
negligible levels, and therefore that vaccine effectiveness on carriage rates could be 
maintained despite the new schedule’s more limited immunogenicity. However, the 
assertion that carriage was “controlled in all age groups” was based on studies of families 
rather than the general adult population (34).  Adults without regular contact with children 
may be less susceptible to the ecological effects of childhood PCV13 programmes, and 
could represent a “reservoir” of vaccine-type pneumococci with important implications for 
public health (35).  This reservoir could reintroduce vaccine-type pneumococci into the 
paediatric population, reversing the gains made by the PCV13 programme.   
Since the most virulent serotypes tend to be included in vaccine formulations, these will 
have higher disease-causing potential if they continue to circulate.  Following the rollout of 
PCV7 in 2006, serotype 19A (a non-PCV7 serotype) emerged as one of the leading causes of 
invasive pneumococcal disease (219, 220).  This supported a switch to PCV13, which covers 
serotype 19A. However, despite substantial declines in invasive serotype 19A disease in 
children since the introduction of PCV13 in the UK, it continues to cause disease in over-65s 
(5).  Rates of disease due to serotype 3 have not fallen in the UK adult or paediatric 
population since PCV13 was introduced (5), consistent with laboratory studies showing that 
vaccination against this serotype is relatively less effective (221).   
6.1.2 Serotype replacement 
Even if vaccine-type pneumococci are eliminated in the young adult population through 
herd immunity, overall rates of pneumococcal colonisation may still not decrease if non-
vaccine serotype (NVT) pneumococci move into the newly-vacant niche.  Serotype 
replacement has been demonstrated for pneumococcal disease of all age-groups in the UK 
(5).  This is highly likely to reflect serotype replacement in colonisation as well, which has 
been demonstrated in UK children and families (77, 222).  Serotype replacement in 
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colonisation has not been explored in the general UK adult population with the same rigour 
that has been applied to household and family surveys.   
6.1.3 Related research on this topic 
A study in the Netherlands specifically compared a cohort of parents to a cohort of adults 
who had no regular contact with children aged <6 years (47).  Nasopharyngeal swab culture 
detected colonisation in 9% (n = 26/298) of parents compared with 1% (n = 4/323) in 
“childless” adults (p<0.001).  The yield was substantially improved by culture-enriched 
qPCR targeting two pneumococcal surface proteins in saliva samples, resulting in 30% (n = 
89/298) colonisation in parents versus 6% (n = 18/323) in “childless” adults (p<0.001).   The 
reliance on molecular methods meant that the investigators could not precisely assign 
serotypes to all isolates: 43% of isolates were unserotyped, and many others could only be 
identified at the serogroup level.  The low rates of colonisation in “childless” adults limited 
the investigators’ ability to discern trends in serotype replacement compared with parents, 
although they still concluded that there was no evidence of a reservoir of NVTs in adults 
vis-à-vis children.  However, a study with a more precise method of serotyping would have 
greater potential to unmask any such trends.   
The most recent UK colonisation survey was carried out in 2015/2016 and enrolled children 
and their parents from two regions in southern England (223).  Colonisation was detected 
by nasopharyngeal swab culture in only 2.8% of parents (n = 8/284)—all were NVTs.  The 
proportion of colonised parents fell between the first survey in 2001/2002 (7.6%) and the 
most recent survey, while the proportion of under-5s colonised remained stable at around 
50%.   
6.1.4 Antimicrobial resistance and colonisation 
Since neither population immunity, natural immunity nor vaccine-induced immunity 
provide complete protection against pneumococcus in older adults, pneumococcal disease 
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will inevitably continue occurring in this population.  Antimicrobial therapy will remain 
necessary to reduce mortality in these cases.  Childhood PCV13 programmes can have 
complex effects on antimicrobial resistance rates (33, 181, 224).  Surveillance of invasive 
pneumococcal isolates in the UK has found rates of penicillin non-susceptibility as high as 
10% and macrolide resistance in 5—7% (225).  A recent colonisation study in UK adults 
attending primary care found penicillin and macrolide resistance in 13.9% (each) of isolates 
(based on 36 carriers out of 3,211 adults screened), but did not have matching serotype 
data (30).  The Dutch study comparing parents with “childless” adults relied on molecular 
detection of pneumococci and did not assess antimicrobial susceptibility (47). There are no 
longitudinal data of colonisation with resistant pneumococci in healthy UK adults, but this 
would provide further insight into the intersection of serotype replacement and 
antimicrobial resistance.   
Healthy volunteers participating in the EHPC programme at LSTM undergo screening for 
pneumococcal colonisation prior to experimental inoculation.  In this chapter we use these 
volunteers as a surrogate for the general healthy adult population to conduct a pilot study 
of the rates of colonisation, serotype distributions and antimicrobial susceptibility profiles 
over time.    
6.1.5 Hypotheses 
We test four hypotheses in this chapter, informed by previous literature on the subject: 
1. The prevalence of pneumococcal colonisation is <3% (recent studies in UK adults 
have found rates of colonisation between 1.2—3.4% (30, 34, 223)); 
2. The serotype composition changes over time in favour of non-vaccine-type 
colonisation (i.e. serotype replacement (222)); 
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3. Pneumococcal colonisation rates in young adults remain stable over time, with 
increases in non-vaccine-type colonisation balancing out any reduction in vaccine-
type colonisation (222); 
4. Antimicrobial resistance rates are low (<10% of isolates) and remain unchanged 
during the study period, reflecting the low exposure to healthcare 
settings/antibiotics anticipated among our cohort.   
6.2 Methods 
We reviewed all nasal washes from screening visits of EHPC volunteers between October 
2010 and March 2017 to identify natural carriers at baseline.  These isolates were 
subjected to serotyping and antimicrobial susceptibility testing.   
6.2.1 Inclusion and exclusion criteria 
No nasal washes were excluded from this analysis.  While the inclusion/exclusion criteria 
for EHPC varied to a small degree between studies, in general they remained similar to the 
criteria outlined in section 1.8.1.  In particular, smoking, recent antibiotics and close 
contact with the chronically ill or children under 5 were always exclusion criteria.  
(However, contact with these “at-risk” groups prior to participation was not recorded, 
because researchers were only concerned about the risks of post-inoculation contact.) Age 
>50 years was an exclusion criterion until the “Aging and Immunity” study commenced in 
2016, therefore the age distribution of participants is heavily weighted towards younger 
adults.  
Two trials of pneumococcal vaccines were performed during the period of analysis—one of 
the licensed PCV13 (n = 100 (107)), one of the experimental serotype-independent GEN004 
vaccine (n = 96; NCT02116998).  Pre-vaccine nasal washes were available for the PCV13 
study, but the baseline nasal washes in the GEN004 study were taken 64 days post-vaccine.  
Interim results suggest that this vaccine does not have a statistically significant effect on 
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colonisation (147).  It may still cause a small reduction in rates of colonisation, in which 
case our results would be biased towards underestimating true natural carriage rates.  The 
vaccine was designed with the aim of affecting all serotypes equally, therefore we worked 
under the assumption that serotype distributions were not biased by including participants 
from this trial (226).  It is unknown (but unlikely) whether rates of antimicrobial resistance 
were biased by including these participants.   
For studies with multiple inoculations (“re-challenges”), only the first screening nasal wash 
was included for each participant.  Similarly, participants who were screened twice within 
the same study (e.g. due to rescheduling their inoculation) were only counted once (their 
first screen).  However, volunteers who participated in more than one EPHC study were 
included on each occasion.  If a participant was recorded on our internal database as 
having been colonised at baseline but did not have a stored sample of their isolate, they 
were classified as “carriage negative” for this analysis.   
6.2.2 Clinical procedures 
Nasal washes were performed as outlined in section 2.6.3.   
6.2.3 Laboratory procedures 
Pneumococcal identification was performed as outlined in section 2.7.2, molecular 
serotyping as in section 2.7.7 and antimicrobial susceptibility testing as in section 2.7.8.  
Pneumococci were classified as vaccine or non-vaccine serotypes based on their presence 
or absence in PCV13, whose serotypes are shown in Table 6.1 alongside the additional 
serotypes included in PPV23.   
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Table 6.1: Serotypes in the two licensed pneumococcal vaccines 
Serotype PCV13 PPV23 Serotype PCV13 PPV23 
1   11A   
2   12F   
3   14   
4   15B   
5   17F   
6A   18C   
6B   19F   
7F   19A   
8   20   
9N   22F   
9V   23F   
10A   33F   
Shaded boxes indicate that the serotype is included in the indicated vaccine 
 
We determined antimicrobial susceptibility using EUCAST clinical breakpoints (Table 2.3, 
Table 2.4).  Meningitis breakpoints were used when determining penicillin susceptibility, 
and intermediately-susceptible isolates were classified as resistant.  We defined multiple 
drug-resistant (MDR) pneumococci as those that were resistant to at least three classes of 
antibiotic (224, 227).   
6.2.4 Statistical analysis 
For purposes of comparison, we made the assumption that maximal vaccine coverage of 
under-5s with the primary series of PCV13 was first achieved on 1 April 2015 (i.e. five years 
after its introduction) and divided our period of analysis into before and after this 
timepoint.  The timing and magnitude of serotype replacement following vaccination have 
varied substantially between different studies, regions and age groups (97); our assumption 
is supported by UK IPD data, showing an inflection in the rate of NVT IPD in young adults 
around 2014-2015 (5).  We compared the proportion colonised, the proportion colonised 
with PCV13 serotypes and the proportion of isolates displaying antibiotic resistant 
phenotypes before and after 1 April 2015 using χ2 or Fisher’s exact test where appropriate.   
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We compared serotype diversity during the two time periods using the Simpson index. The 
Simpson concentration, λ, sums the squares of the proportion of each serotype relative to 
the total number of isolates, and its inverse (1/ λ) is commonly used as a measure of 
species diversity (228, 229).  The closer the value of 1/ λ is to the total number of 
serotypes, the more evenly dispersed the serotypes are in the population.  All analyses 
were performed using SPSS version 24 (IBM, New York).   
6.3 Results 
Between September 2011 and March 2017, 795 healthy volunteers met the inclusion 
criteria for EHPC studies, signed informed consent and underwent at least one nasal wash.  
A demographic breakdown is given in Table 6.2. The median age was 21 years (IQR 20—23 
years) and 452 (56.9%) were female.  We detected natural colonisation in 52 subjects 
(6.5%, 95% CI 5.0—8.5%).  Another three participants were recorded as colonised but had 
no samples for analysis—we classified these three as non-colonised.  Two of the natural 
carriers reported in the “Aging and Immunity” study (Section 3.3.2) are included in this 
analysis, with the third being detected after the dataset for this study was finalised.   
We identified PCV13 serotypes in 17/52 (32.7%); the numbers of each serotype are given in  
Table 6.3 with numbers of vaccine versus non-vaccine serotypes over time shown in Figure 
6.1.  The microarray detected dual colonisation in one subject—99% of the signal was 
attributed to serotype 37 and 1% to 19F; we classified the participant as colonised with 
serotype 37. 
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Table 6.2: Demographic characteristics of participants 
 Non-carrier (n = 
743) 
Carrier (n = 52) Total (n = 795) 
Age, median (IQR) 21 (20—23) 21 (19—23) 21 (20—23) 
Female sex, n (%) 428 (57.6%) 24 (46.2%) 452 (56.9%) 
Year of screen,  
n (% of annual total):  
 
2010 
 
8 (100%) 
 
0 
 
8 
 2011 65 (97%) 2 (3%) 67 
 2012 129 (89.6%) 15 (10.4%) 144 
 2013 31 (96.9%) 1 (3.1%) 32 
 2014 66 (93%) 5 (7%) 71 
 2015 154 (94.5%) 9 (5.5%) 163 
 2016 178 (93.2%) 13 (6.8%) 191 
 2017 112 (94.1%) 7 (5.9%) 119 
 
 
  
135 
 
 
Figure 6.1: Percentage of volunteers colonised with pneumococcus each year 
NVT, non-vaccine type; VT, vaccine-type. Error bars represent 95% CI.  Note the scale on the y axis.  
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Prior to 01 April 2015, 24/368 subjects (6.5%) were colonised, with 28/427 colonised after 
01 April 2015 (6.6%; p = 0.98 by χ2).  Among colonised participants, 8/24 (33.3%) were 
carrying PCV13 serotypes before 01 April 2015 versus 9/28 (32.1%, p = 0.93) afterwards 
(Table 6.3, Figure 6.2).  The Simpson diversity index of the pre-01/04/2015 sample was 10.3 
while post-01/04/2015 it was 11.2.   
Table 6.3: Number of volunteers colonised with each serotype 
Serotype Pre 01/04/2015 Post 01/04/2015 Total 
3*† 5 5 10 
23B 2 3 5 
8† 2 2 4 
11A† 2 2 4 
35F 2 2 4 
37 2 2 4 
15A 1 2 3 
19F*† 1 2 3 
19A*† 1 2 3 
9N† 1 1 2 
31 0 2 2 
33F† 2 0 2 
35B 1 1 2 
6A* 1 0 1 
10A† 0 1 1 
15C 1 0 1 
24F 0 1 1 
Total 24 28 52 
Total numbers are provided in addition to numbers before and after the five-year anniversary of PCV13 
introduction 
* included in PVC13; † included in PPV23 
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Figure 6.2: Serotype distribution during the two time periods 
This bar chart shows the numbers of volunteers colonised with vaccine (left) and non-vaccine (right) serotypes, before (white bars) and after (grey bars) the five-year anniversary of PCV13 
introduction. (This figure has been included in a published paper (230), included in this thesis as Appendix 11) 
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6.3.1 Antimicrobial resistance 
We identified resistance to at least one antibiotic in 8/52 isolates (15.4%), and the 
susceptibility profiles are summarised in Table 6.4.  Two of the eight resistant isolates were 
PCV13 serotypes.  Therefore, 2/17 (11.8%) PCV13 serotypes harboured antimicrobial 
resistance versus 6/35 (17.1%) of NVTs (p = 0.99 by Fisher’s exact test; Figure 6.3).   
There was one case of discordance between disc diffusion screening and Etest MIC 
measurements. Norfloxacin disc screening suggested that an isolate was quinolone 
resistant, but it was determined to be sensitive when the levofloxacin MIC was measured 
(MIC 1.5 mg/mL, with 2 mg/mL being the cutoff for resistance).  
The highest rate of resistance was against penicillin (5/8 isolates), followed by 
clarithromycin and doxycycline (4/8 each).  We did not detect any levofloxacin or 
vancomycin resistance.  Two isolates displayed MDR phenotypes.  Using EUCAST non-
meningitis breakpoints, all penicillin non-susceptible isolates would have been deemed 
“intermediate susceptibility”, and all were fully-susceptible to amoxicillin and ceftriaxone.   
All antimicrobial resistant isolates were detected after 01 April 2015—i.e. 0/24 natural 
carriers harboured resistance before 01 April 2015, versus 8/28 (28.6%) after. This 
difference was statistically significant, with a p value of 0.005 by Fisher’s exact test.   
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Table 6.4: Antimicrobial susceptibility profiles among the eight isolates with any resistance detected 
 
 
*Included in PCV13 
F: Female; M: Male; R: Resistant; S: Sensitive; TMP-SMX: Trimethoprim-sulfamethoxazole 
 
 
 
Subject ID Date isolated Age 
(yrs) 
Sex Serotype Susceptibility to antimicrobial agents 
Penicillin G Clarithromycin Doxycycline TMP-SMX 
402/109 07/04/2015 27 F 24F S S S R 
402/057 21/04/2015 23 M 15A R R R S 
016/040 29/10/2015 18 M 15A R R S S 
016/174 18/02/2016 21 F 23B R S S R 
018/010 06/07/2016 57 M 23B R S S R 
019/020 13/10/2016 20 M 3* S S R S 
019/099 16/11/2016 19 F 8 S R R S 
019/165 08/02/2017 20 M 19F* R R R S 
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Figure 6.3: Numbers of isolates from each serotype in whom resistance was identified to any antimicrobials 
Solid components represent pan-sensitive isolates, while cross-hatched components denote numbers resistant to any antimicrobial.  
(This figure has been included in the supplementary appendix of a published paper (230), included in this thesis as Appendix 11) 
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6.4 Discussion 
In this pilot study, conducted over 7.5 years of screening healthy adult volunteers for 
participation in clinical research, we incidentally detected pneumococcal colonisation in 
6.4%.  The prevalence of PCV13 serotypes was low, dominated by serotype 3 and did not 
change over time.  Antimicrobial resistance was identified in 15.4% of isolates, all of whom 
were screened in 2015 or later.  The outcomes for each of our hypotheses are outlined in 
Table 6.5.   
Table 6.5: Outcomes of each hypothesis investigated in this chapter 
 Hypothesis Finding 
1 The prevalence of pneumococcal 
colonisation is <3% 
Refuted—colonisation identified in 6.4% 
(95% CI 5—8.5%). 
2 The serotype composition changes 
over time in favour of non-vaccine-
type colonisation 
Refuted—low prevalence of PCV13 
serotypes throughout, and grossly similar 
serotype distributions/diversity over time. 
3 Pneumococcal colonisation rates in 
young adults do not decline during 
the study period 
Retained. 
4 Antimicrobial resistance rates are 
low (<10% of isolates) and remain 
unchanged during the study period 
Refuted—antimicrobial resistance rates low 
but >10%, and all detected after 01 April 
2015. However, resistance rates against 
individual agents all <10%.  
 
6.4.1 Serotype findings 
We found low rates of PCV13-serotype compared with NVT colonisation in young adults, 
with the exception of serotype 3, and did not identify any change in the proportion of 
PCV13 versus non-vaccine type colonisation over time.   
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6.4.1.1 Vaccine type colonisation 
Three PCV13 serotypes continued to circulate during our period of analysis—3, 19F and 
19A.  One explanation is that these serotypes are less susceptible than others to herd 
protection from childhood PCV programmes.   
 PCV7 (covering serotypes 4, 6B, 9V, 14, 19F and 23F) had been included in the childhood 
vaccine programme since 2006, while PCV13 was introduced in 2010, i.e. the same year 
that screening for EHPC commenced. Therefore, it appears that circulation of PCV7 
serotypes was already controlled within the adult population, except serotype 19F.  A 
similar persistence of serotype 19F in IPD has recently been reported in the Alaskan native 
population (231).   
It is concerning that carriage of serotypes 3 and 19A has continued in adults throughout the 
PCV13 era.  Both serotypes are generally associated with above-average virulence and case 
fatality rates (220, 232).  PCV13 is known to have poor efficacy against serotype 3 (221), 
which continues to cause invasive disease among all ages in the UK (5).  Invasive disease 
due to serotype 19A is declining in children in the UK, but it remains an important cause of 
pneumococcal disease in over-65s (5).  
A reservoir of colonisation among adults could explain these findings.  The immune 
threshold for protection against pneumococcal colonisation is higher than that for disease 
(79), and therefore these serotypes may also continue to circulate in children.  However, 
the most recent UK childhood colonisation survey found only one serotype 3 and two 19A 
isolates in 150 colonised children aged <5 years (223).   
6.4.1.2 Non-vaccine type colonisation 
We did not identify any major patterns, dominant serotypes or changes over time among 
the NVTs isolated from healthy adults.  Serotype 23B was the most common NVT (five 
isolates), followed by 8, 11A, 35F and 37 (four each).  Serotype 8 has emerged as the 
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commonest cause of invasive disease in the UK population (particularly over-65s) in recent 
years, responsible for one in five of all cases (5).   
Of the ten commonest serotypes identified in colonisation in our study, half (serotypes 3, 8, 
15A, 19A and 23B) were also among the top ten serotypes causing invasive disease in 
England and Wales in 2016—2017 (5). Thus, our pilot data are somewhat reflective of 
current national trends in IPD.  The most recent UK childhood colonisation survey did not 
identify any children colonised with serotype 8, and serotypes 3 and 19A were among the 
least frequently isolated (223).   However, this survey did identify high rates of childhood 
colonisation with (for example) serotypes 10A and 22F, which are important in disease and 
were under-represented in our adult cohort.  A colonisation study including all age groups 
and covering a wider geographical area would be the ideal. If such a survey could 
successfully identify a range and ranking of serotypes that reflect disease incidence, then 
colonisation surveys could have the potential to predict serotype replacement in disease 
following the introduction of higher-valency conjugate vaccines.   
6.4.1.3 Serotype diversity 
We used the Simpson index to quantify serotype diversity. The closer the Simpson index is 
to the total number of serotypes in the sample, the more diverse the sample is.  We 
identified 14 distinct serotypes both before and after 01/04/2015, as shown in Table 6.3. 
With respective Simpson indices of 10.3 and 11.2, it appears that both time periods were 
similar in terms of serotype richness.  Visual inspection of Figure 6.2 gives a similar 
impression.   
6.4.2 Antimicrobial resistance 
Overall 15.4% of isolates were resistant to at least one antibiotic. We identified penicillin 
non-susceptibility in 10% of young adult pneumococcal carriers, and macrolide resistance 
in 8%, both of which mirror the resistance rates in invasive isolates (225).  Among those 
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colonised with resistant pneumococci, co-resistance to two or three agents was common, 
again reflecting emerging patterns in invasive disease (224).   In the penicillin non-
susceptible subjects, the penicillin MICs were generally low, meaning that all would be 
classified as “intermediate susceptibility” using non-meningitis breakpoints.  However, one 
subject (#019/165) had a penicillin MIC of 0.75 mg/L, which would be less likely to respond 
to intravenous benzylpenicillin at routine UK doses (1.2g QDS) even in non-meningeal 
infections (165).   
Most of the resistant isolates were from non-vaccine serotypes.  We identified dual 
resistance to penicillin and clarithromycin in two out of three carriers of serotype 15A.  
Serotype 15A has been among the top ten serotypes causing IPD in the UK since 2011, with 
a recent study finding that over 30% of these invasive isolates were resistant to three 
antibiotic classes (224).  Further analysis found that the majority of these multi-resistant 
15A isolates belonged to multilocus sequence type 63, suggestive of clonal spread within 
the population.  In our results, clonal expansion of resistance is also likely for serotype 23B, 
where we identified two carriers with resistance to both penicillin and TMP-SMX.  
Multilocus sequence typing or indeed whole genome sequencing would be required to 
confirm this hypothesis.   
However, not all resistance is due to clonal expansion—we also found co-existent 
clarithromycin and doxycycline resistance in 3/8 resistant isolates, all with different 
serotypes.  This suggests the spread of AMR via mobile genetic elements.  The Tn916 family 
of conjugative transposons commonly carries genes for both macrolide (e.g. Mef(E) or 
Erm(B)) and tetracycline (e.g. Tet(M)) resistance in pneumococci (233, 234).  Mobile genetic 
elements allow the spread of AMR between populations of pneumococci but also to other 
unrelated bacteria in the nasopharyngeal niche.  Again, genetic analysis would be needed 
to investigate this hypothesis further.   
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6.4.3 Limitations 
Our study has some important limitations.  We lack detailed medical history for the 
participants, as we did not have consent to retain these after the participants’ original trial 
participation had concluded.  However, the strict inclusion criteria mandated by EHPC 
studies mean that the study population is quite homogeneous, defined as it is by the 
absence of significant risk factors for pneumococcal colonisation.  Most recruitment events 
for EHPC studies were carried out in local universities, and it is reasonable to assume that 
the majority of recruits were themselves students or university employees, but we lack 
precise data on the source of each individual participant.  Prior antimicrobial exposure is 
unknown, beyond a requirement that all participants must not have received antibiotics in 
the month prior to enrolment.  Contact with children or healthcare settings pre-enrolment 
was not an exclusion criterion; it is unlikely that people would give up childcare roles simply 
to participate in a clinical trial.  However, some volunteers may have attended hospital for 
non-infectious indications, visited a relative in hospital or undergone university placement 
in a hospital before screening.  All of our screenings took place well after PCV7 had been 
introduced and during the period when PCV13 was being introduced, limiting our ability to 
identify vaccine-induced trends over time.   
Molecular testing may be more sensitive than culture for detection of community-acquired 
colonisation, particularly if the oropharyngeal niche is sampled in addition to the 
nasopharynx (47).  However, this would not allow confirmation of antimicrobial resistance.  
Phenotypic resistance testing is an important strength of our study, as the evidence base 
for genotypic-phenotypic correlation of AMR in pneumococci is poor (215).    
Nasal wash is not commonly performed in epidemiological colonisation studies. However, it 
has been recognised as being better tolerated than nasopharyngeal swab while maintaining 
equal sensitivity for pathogen detection (36, 37).  Nasal wash may in fact be a strength of 
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our study if it explains why we found higher-than-expected rates of colonisation in our 
population—nasopharyngeal swabs of UK adults who shared a household with children 
only identified colonisation in 2.8% (223).  Nasal wash is technically challenging for 
participants, but all participants in this study had (by definition) performed a successful 
nasal wash on their first attempt.  Child-friendly nasal-wash methods have also been 
reported (235).  It should be noted that nasal wash requires near-patient laboratory 
facilities, as the pneumococcal yield falls if kept in saline for >1 hour; this limits the 
potential for widespread nasal wash use in community colonisation studies. To overcome 
this limitation, basic near-patient facilities to centrifuge samples and re-suspend them in 
STGG media would be needed, or else investigators would need to rely on molecular 
testing methods.   
6.4.4 Implications of this study 
Using nasal wash culture in healthy adults, our study—admittedly a pilot—found a similar 
rate of colonisation to a Dutch study of a similar population that relied on combined oral 
and nasal sampling, analysed by both culture and qPCR (47).   Our methodology had the 
advantage of allowing full serotyping and antimicrobial susceptibility testing on every 
isolate, maximising the utility of our samples.    
Our results suggest that serotype replacement is well-established among young adults and 
that vaccine-type circulation is mostly controlled with the important exceptions of 
serotypes 3, 19F and 19A.  The relatively high rates of colonisation and of AMR were 
surprising, given that our study population was specifically selected to lack important risk 
factors for pneumococcal colonisation (smoking, contact with children < 5) and exposure to 
healthcare (caring roles, recent antibiotics).   
Surveillance of invasive pneumococcal disease by Public Health England has found an 
overall reduction in IPD in the UK population since the introduction of PCV7, but also that 
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serotype replacement has cancelled out any additional benefit from PCV13 (5).  The failure 
of herd protection is most apparent in the over-65 population.  We have identified ongoing 
carriage of epidemiologically important serotypes—e.g. 3, 8, 15A, 19F and 19A—in young 
adults, which might be contributing to ongoing disease in older adults independent of 
paediatric colonisation dynamics.  In addition, the adult reservoir of serotypes 19A/F could 
re-colonise the paediatric population after the abridged 1 + 1 PCV13 schedule is 
implemented.   
The emergence of AMR in the last three years of our study is concerning, representing a 
reservoir of antimicrobial resistance genes in the community.  As discussed above, AMR in 
young colonised adults could be driven by both clonal expansion and mobile genetic 
elements (although whole-genome sequencing would be required to confirm this).  Our 
study population was generally healthy and subjects were excluded if they had recently 
received antibiotics—i.e. there was low selective pressure for AMR.  The AMR we identified 
probably represents transmitted resistance, reflecting the background population rate of 
pneumococcal AMR; it is therefore likely that rates of AMR are higher in populations with 
greater antibiotic exposure.  The rates of resistance to individual drug classes are not high 
enough to warrant changes to treatment guidelines for pneumococcal disease.  However, 
ongoing vigilance for AMR in colonisation at the population level is warranted, to detect 
trends and increases in rates of AMR as early as possible.  Resistant isolates were mostly 
from non-vaccine serotypes, suggesting that the childhood PCV13 programme is unlikely to 
further reduce rates of AMR.   
The serotype distributions and rates of antimicrobial resistance in young adults were 
broadly similar to those seen in studies of invasive disease (5, 225).  The yield from 
screening for colonisation in adults is lower than in children, and studies of invasive disease 
can avail of routinely-collected clinical samples rather than the dedicated research 
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sampling programme needed for a colonisation study.  However, nasopharyngeal sampling 
of adults is quick and well-tolerated. The BμG@S molecular serotyping methods used on 
our samples could potentially be adapted for saliva samples, increasing the yield further 
(albeit without concomitant phenotypic AMR measurement).   Colonisation studies of 
young adults could augment the ongoing surveillance for trends in pneumococcal serotype 
distributions and susceptibility profiles in communities.   
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7 Conclusions 
In this thesis, we have established that adults aged 50—80 years develop experimental 
colonisation at similar rates to those seen in young adults.  We have also demonstrated 
that the immune response to colonisation in older adults is different to that of young 
adults, with no serotype-specific immune boosting following colonisation, and a drop in 
serotype-specific antibody levels following pneumococcal challenge.  This observation, 
coupled with the finding that prior PPV23 did not protect against experimental 
colonisation, adds to the existing body of evidence that anti-CPS immunity is deficient in 
older adults.   
Our comparison of different diagnostic strategies within the EHPC model confirmed that 
nasal wash was the most sensitive method for detecting pneumococcal colonisation within 
our cohort of older adults.  We did not find any evidence for a change of “niche” with 
aging, or to support the addition of oropharyngeal or saliva samples when assessing 
pneumococcal colonisation in older adults.  These findings come with the caveat that they 
may not be generalisable from experimental to community colonisation. However, our 
study of community-acquired pneumococcal colonisation in young adults supported the 
high diagnostic yield of nasal wash, as well as reaffirming the advantages of culture-based 
pneumococcal detection methods for serotyping and antimicrobial susceptibility testing.   
Our findings present 3 avenues for future research: 
1. The use of the EHPC model in older adults 
2. Antibody-based anti-capsular immunity in older adults 
3. The role of colonisation surveys to inform vaccination policy 
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7.1 Future EHPC studies in older adults 
Our EHPC study established that this model has excellent safety, tolerability and rates of 
colonisation in older adults.  This study generated a wealth of samples and data, including 
nasal lining fluid samples, nasal microbiopsies and peripheral blood mononuclear cells, 
many of which have yet to be analysed.  Future studies may pursue in-depth analysis of 
putative biomarkers or correlates of protection identified by these secondary analyses.  
Candidate vaccines—designed by our team based on these findings, or from external 
partners—could be trialled in older adults using the EHPC model.  A negative outcome of 
such a trial would efficiently down-select candidates at Phase II level, avoiding the logistical 
and financial challenges of a Phase III efficacy trial.  A positive outcome at Phase II level, 
preventing experimental colonisation in an at-risk population (rather than a pure 
immunogenicity study or an EHPC study of young adults) would give vaccine developers 
and funding agencies confidence in progressing to Phase III.   
EHPC could also be used to explore ongoing unanswered questions regarding 
pneumococcal biology and ecology in older adults.  We found that saliva qPCR had poor 
sensitivity for detecting colonisation in older adults, in marked contrast to community-
based studies.  A future EHPC study employing alternative saliva collection methods would 
help explore this conundrum further.  In addition, alternative inoculation methods could 
explore whether the route of exposure influences the pneumococcal niche.   
Our cohort was not representative of the general older population: the exclusion of 
participants with chronic cardiac, respiratory or immunosuppressive conditions, while 
necessary for safety, is the main limitation of our study.  Under-representation of the 
“oldest old” (over-70s) within the study population is a further limitation.  These limitations 
may explain some of the discrepancies between our findings and other published studies—
for example, we did not demonstrate falling anti-CPS antibody titres with age, while others 
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have done so (65).  However, even in a particularly healthy cohort of older adults, we 
identified antibody responses to pneumococcal challenge that are different to those of 
younger adults.  EHPC was safe and well-tolerated in our cohort, meaning that future 
studies could consider adopting less restrictive inclusion criteria for older adults; indeed, an 
EHPC study recruiting volunteers with chronic obstructive pulmonary disease is due to 
commence in 2019.  Future studies could also focus specifically on enrolling over-70s, and 
using biomarkers of biological rather than chronological age (236, 237) either as inclusion 
criteria or to guide sub-group analyses.   
7.2 Anti-capsular immunity in older adults 
Anti-CPS immunity is the mechanism underpinning current pneumococcal vaccines.  We did 
not find evidence that pre-existing anti-CPS antibodies confer protection against 
colonisation.  Other researchers have found that PCV13 confers partial protection against 
vaccine-serotype CAP, IPD and colonisation in older adults.  We found that anti-CPS 
antibodies may contribute to control of pneumococcal density in older adults; however, 
evidence linking lower pneumococcal density with reductions in pneumococcal disease 
incidence, morbidity or mortality is lacking.  Higher pneumococcal nasopharyngeal density 
has been found in HIV-infected patients with pneumococcal pneumonia compared with 
controls with either non-pneumococcal pneumonia or asymptomatic HIV infection (24), 
while another study found higher nasopharyngeal pneumococcal density was measured in 
patients with more severe pneumococcal pneumonia (204).  Neither of these studies was 
sufficient to establish a prospective causal relationship between colonisation density and 
subsequent clinical outcomes.   
We did not find any indication that nasopharyngeal pneumococcal exposure improved anti-
capsular immunity in older adults, with static anti-CPS IgG levels in colonised participants 
and decreased levels in non-colonised participants.  Therefore, if a mucosal vaccination 
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strategy is pursued in older adults, an alternative antigen would have a greater likelihood 
of success.   
However, until an appropriate antigen, adjuvant, delivery system and correlate of 
protection are identified, polysaccharide vaccination—and particularly protein-conjugated 
polysaccharide vaccination—remains the only proven method for improving anti-
pneumococcal immunity and preventing pneumococcal disease in older adults.  The 
limitations of this strategy lie partially with its imperfect efficacy, but more with its 
suboptimal effectiveness in “real-world” settings.  Although PCV13 confers a degree of 
protection against vaccine-type CAP and IPD in older adults, there are no plans to add it to 
the adult vaccination schedule in the UK. Given the high rates of serotype replacement in 
pneumococcal disease in the UK, there is no reason to revisit this decision, unless a vaccine 
with greater (or more relevant) serotype coverage is introduced.   
7.3 Colonisation surveys to inform vaccine policy 
Herd immunity, conferred via the childhood PCV13 programme, has become a cornerstone 
of protection against pneumococcal disease in older adults.  However, our study of 
community-acquired colonisation in young adults in Liverpool found ongoing colonisation 
of the vaccine serotypes 3 and 19A.  This raises the possibility of an adult colonisation 
reservoir of these serotypes, since they continue to cause IPD in the general adult 
population.  Nonetheless, this incomplete herd protection is restricted to a small number of 
serotypes, and would not be sufficient in itself to justify expanding PCV13 coverage to older 
adults.   
In any case, herd protection is currently being diminished by serotype replacement. This 
was borne out by our community colonisation study, with the majority of isolates being 
NVTs.  We also identified the emergence of antimicrobial resistance in recent years, again 
clustered in NVTs, representing a further pneumococcal threat to the population.   
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Our study showed that nasal wash has a reasonable yield in young adults—higher than 
achieved by nasopharyngeal swab in comparable populations—and our findings 
complement existing surveillance data on circulating pneumococcal dynamics.  Colonisation 
surveys are a valuable measure of vaccine impact. However, they could have even greater 
public health benefit if they could inform future vaccine serotype composition.   
7.4 A roadmap towards colonisation survey-driven vaccine policy 
For colonisation surveys to truly inform vaccine policy, an adaptive pneumococcal vaccine 
design for older adults would be required.  With such a strategy, a system of pneumococcal 
serotype surveillance would identify trends in serotype replacement and inform the 
serotype composition of the adult vaccine in as close to real time as possible.  The vaccine 
itself could maintain the current protein-conjugated polysaccharide backbone but would 
target serotypes more relevant in adult disease.  Others have proposed such a strategy 
before (238), and adaptive vaccine strategies driven by circulating pathogen strains already 
exist for influenza, with data provided by the Global Influenza Surveillance and Response 
System (239).   
Pneumococcal serotype replacement does not occur at the same rate as influenza virus 
genetic drift, and therefore annual vaccine updates would not be required.  The key 
unanswered question remains: to what degree does serotype replacement in carriage 
precede and predict serotype replacement in disease? Mathematical modelling could 
combine our longitudinal colonisation data, historic childhood colonisation surveys and 
disease surveillance to address this question, although larger-scale adult colonisation 
surveys might be needed for statistical power.  If models establish the relationship 
between colonisation serotypes in different age groups and subsequent serotype-specific 
invasive disease rates, then colonisation surveys at regular intervals could be combined 
with disease surveillance to determine the serotype composition of the next vaccine. 
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Superior in-hospital diagnostics (for example, techniques to identify the serotypes in non-
bacteraemic pneumonia (240)) would enhance disease surveillance.   
Rapid reformulation of vaccines in response to colonisation and disease surveys would 
potentially require vaccine manufacturers to license their methodologies to other 
producers, in order to meet global demand for vaccines with different serotype 
combinations.  In addition, it would require pre-licensure studies demonstrating that 
introducing new serotypes into a standardised manufacturing process would consistently 
result in vaccines that are immunogenic in the target population.  EHPC studies in older 
adults could play a role in such studies, especially if new serotypes were successfully 
introduced into the EHPC model.  In the meantime, the impetus for novel, serotype-
independent, “universal” pneumococcal vaccines would remain, and EHPC studies, feasible 
in adults of all ages, could continue contributing to the pursuit of this goal.   
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Participant information sheet 
Research: working towards a nasal vaccine for pneumonia  
Exploring the effect of age on immunity against pneumonia 
Would you like to take part in our research? 
This information leaflet tells you how you 
could take part. A member of our team will 
also discuss it with you: please ask us if you 
have questions. You may want to talk to 
other people about the study: please do so. 
Take your time to decide if you want to be 
involved. 
What is the purpose of the study? 
We are developing a new vaccine to protect 
against bacteria called Pneumococcus. 
Small numbers of these bacteria are often 
found in the nose. Usually, the carrier does 
not know the bacteria are there. In most 
adults this is present at least once per year 
and more often in children. We think that 
small numbers of bacteria present in the 
nose (“nasal carriage”) can help to protect 
people against disease. 
Mild infections with pneumococcus are very 
common, such as ear infections in children. 
But pneumococcus can also infect the lung 
(causing pneumonia) or the brain (causing 
meningitis) or the blood (causing sepsis). 
These severe infections are very uncommon 
in healthy adults: about 50 cases in Liverpool 
per year. Very young children and adults who 
are elderly (mainly those who have other 
illnesses) are more likely to become ill.  
We may be able to protect people against 
severe disease from pneumococcus using a 
vaccine which could be sprayed into the 
nose. We don’t yet know if this will work. 
To test the idea, our research team want to 
study what happens when small numbers of 
the bacteria are put up the nose of healthy 
volunteers. We have already studied this 
using more than 400 volunteers, and have 
found this type of study to be safe. 
All of the volunteers we have studied so 
far have been less than fifty years of age.  
In order to develop a vaccine that will protect 
older people, we need to understand the 
immune responses to bacteria in adults aged 
over fifty. 
Do I have to take part? 
No. Taking part in this study is voluntary. 
Why have I been asked to take part? 
We are looking for volunteers who are fit and 
healthy. We check for reasons which may put 
you at higher risk from the study. We also 
make sure that your participation will provide 
helpful information to us. If we find any 
reason you may be at higher risk of infection, 
then we will not invite you to take part.  
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You will not be eligible if: 
• You are aged less than 50 years 
• You are a regular smoker or have a 
significant history of daily smoking 
• You are in close contact with those who 
have lower immune levels (such as young 
children and people with chronic ill 
health) 
• You have taken part in similar research 
before 
• You are allergic to penicillin 
• You have heart or lung disease 
• The study doctor thinks that a health 
condition, or medication means that you 
are at increased risk of infection 
What happens if I choose to take part? 
1. Health check – for safety, we check that 
you are healthy. This includes a clinical 
assessment and checklist (as above).  
2. Consent –We ask you to sign a consent 
form when you are sure you want to take 
part. 
3. Taking samples – We take samples from 
the nose, throat and blood (see below).  
We also do a heart tracing (ECG) and 
breathing test (spirometry)—again this is 
to check that you are healthy 
4. Being given drops of pneumococcus in 
the nose - We put a few drops with a 
small numbers of bacteria up your nose  
5. Monitoring– we will ask you to contact us 
daily (by phone or text) to make sure you 
are well  
6. Monitoring visits – We take samples from 
your nose to see whether the bacteria is 
present. 
Part one takes less than four weeks then 
after three to six months we will invite some 
participants to repeat this for part two.  
What kind of samples do you take? 
Samples from the nose: To collect cells from 
your nose we place a small piece of blotting 
paper inside your nostril for a few minutes 
(“nasosorption”), and also run a small plastic 
rod along the inside of each nostril (“nasal 
probe”). We also perform a “nasal wash”, 
where we squirt a little salty water into your 
nose. After a few seconds the water runs out 
into a sample bowl. This will tell us about the 
bacteria in your nose and your immunity. 
Throat swab:  we wipe the back of your 
mouth with a sterile swab (like a cotton bud). 
The laboratory can use this to find out if 
there are any bacteria or viruses. 
Saliva samples: we will ask you spit into a 
small tube or to chew on a small sponge for 
two minutes. We can then test the saliva in 
the sponge for bacteria.  
Blood samples:  We take blood samples from 
a vein in your arm (using a needle). We will 
never take more than 50 mL (about the same 
as 10 teaspoons). 
You may choose to allow the researchers to 
study the DNA from your blood sample.  If 
you choose not to donate your DNA you may 
still take part in the study. 
Some participants will also be asked to 
collect four nasosorption papers and eight 
saliva samples over 48 hours at home (or 
workplace etc).  This is an additional option 
which would be discussed with you in greater 
detail at the start of the study. If you choose 
to take home samples they must be collected 
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within 15 minutes of a set time. Therefore we 
will ask you to send a photograph of the 
sample to confirm the time taken.     
 
What will happen to my samples? 
We will process your samples in laboratories 
at the Liverpool School of Tropical Medicine 
(LSTM) and at the Royal Liverpool University 
Hospital. We will measure the levels of 
bacteria and viruses in your nose, and we will 
look in detail at how your immune system 
responds to the pneumococcus bacteria. 
To make full use of your samples, we will 
store the remainder. In the future, we can 
then go back to them with new tests to 
answer new questions. For some specialist 
tests, we may send samples to laboratories in 
the UK and abroad. 
What will happen at each visit of Stage 1? 
Visits 1 - 3: 
Consent and 
screening check 
(spread over about 
two weeks) 
First we will explain the study in detail, obtain your signed consent if you are 
happy to take part in the study, and ask some basic questions to ensure that you 
are eligible.  We will also write to your GP to confirm some aspects of your 
medical history (e.g. what medications you are taking, and which vaccinations 
you have had before).  
At the next visit, we make sure you are fit to take part in the study. We ask 
routine questions about your medical health, check your blood pressure, 
temperature and listen to your heart and lungs, perform a heart tracing (ECG), 
breathing test (spirometry) and blood test.  
If you are well enough to take part in the study, we do the throat swab, saliva 
collection, nasal swab, the nasal wash, nasal probe and another blood test.  
We then book your next appointments. If you have problems and can’t come at 
a specific time, we can be flexible to accommodate you. 
 Between one to seven days after Visit 3: 
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Visit 4: 
Being given 
pneumococcus up 
the nose 
We collect a sample from your nose using blotting paper.  We then use a 
dropper to put a small amount of water containing a small number of bacteria 
into each nostril. Usually, volunteers have no symptoms afterwards. There will 
be a doctor or nurse available by telephone 24 hours a day to answer questions. 
We will give you a course of antibiotics to keep with you, in case you are unwell, 
as well as a thermometer to check your temperature at home. Every day for the 
next week, we will need to be in contact with you by phone or text to check 
that all is well. 
 Up to six visits over the next five weeks 
Visits 5 - 10: 
Monitoring 
At each visit, a number of samples will be taken, which may include throat swab, 
saliva collection, nasal swab, nasal wash, nasal probe and blood tests 
   
End of Part 1 
of the study 
If our laboratory test finds that the pneumococcus bacteria stays in your nose, at 
this stage we will ask you to take a course of antibiotics to clear it, and we may 
ask you to be in part 2 of our study. 
 
 What about Part 2? 
We think that having small number of bacteria in your nose—even for a short time—might protect 
you against illness from this bacteria, possibly for a long time. But we cannot be certain. To test 
this, we may ask you to have the pneumococcus put into your nose a second time, after 3 to 6 
months. You do not have to take part in Part 2 if you do not want to. In total, Part 2 visits will take 
about 2 to 3 weeks. 
What will happen at each visit of Part 2? 
Visit 1: 
Screening check, 
consent, and taking 
samples 
We make sure you are still fit to take part in the study, by repeating the 
questions and examination done at Part 1. 
We do the throat swab, saliva collection, nasal wash, nasal probe and blood 
test. 
 1-7 days later 
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Visit 2: 
Being given 
pneumococcus up 
the nose 
We use a dropper to put a small amount of water containing a small number 
of bacteria into each nostril, just like before. 
Each day for the next week we will ask you to contact the research team by 
phone or text for seven days to ensure that all is well and to check your 
temperature reading (again, antibiotics and a thermometer are provided in 
the study).  
 Daily phone call or text message. 2 days later: 
Visit 3: Monitoring Throat swab, saliva collection, nasal wash, nasal probe and blood test 
 Daily phone call or text message. 5 days later: 
Visit 4: Monitoring Throat swab, saliva collection, nasal wash and nasal probe 
 Up to 7 days later 
Visit 5: End of the 
study 
At the end of Part 2, after a final throat swab, saliva collection, nasal wash, 
nasal probe and blood test, if our laboratory confirm that you have had 
pneumococcus in your nose, we will ask you to take the antibiotic course to 
clear it. 
 
What are the risks of being in the study? 
Risks of being given live bacteria   
Because the bacteria are alive, there is a very 
small risk of infection to you or your close 
contacts. We do not expect anyone to 
develop an infection but this is why we 
choose participants carefully, and why we 
monitor them closely. We provide a 
thermometer and antibiotics that treat these 
bacteria. We give you a separate leaflet 
which explains the safety precautions, and 
what to do if you feel unwell. If you carry the 
pneumococcus bacteria in your nose at the 
end of the study, we will ask you to take the 
antibiotics to kill the bacteria. 
Risks of medical tests during the study  
The only side effect of nasal sampling is a 
little discomfort.  Some people experience a 
runny nose.  Some people can feel light-
headed after blood tests, and sometimes 
may have a bruise. 
What if there is a problem? 
You can contact the research team 24 hours-
a-day by phone. They will answer any 
questions, and an emergency service will be 
available day and night, including visits to 
your home if you are unwell and unable to 
come in to see us. Any medical care you need 
will be provided by the NHS. 
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What if I wish to complain? 
If you wish to complain about any aspect of 
the study, you can contact the study doctor. 
The NHS complaints procedures are also 
available to you. Complaining will not affect 
the medical care you receive now or in the 
future. 
What if I change my mind, or want to 
stop? 
Even if you do start in the study, you are free 
to stop at any time and without giving a 
reason. If you decide not to take part, or to 
withdraw from the study, this will have no 
effect on your future health care. 
If you decide to stop, we will continue to use 
the samples and information that we have 
already collected unless you tell us not to. 
You will be paid for the visits completed up to 
that point.  
Will my details be kept confidential? 
Yes. For safety, we collect information about 
your medical history and contact details 
before you take part. The clinical research 
team use this information to check you are 
healthy, and to contact you when needed.  
We will ask your permission to ask your GP to 
share some of your medical history with us.   
We will also collect information which allows 
us to understand more about the samples, 
for example, you age or sex. However, those 
outside of the clinical team are never given 
information that can identify you. Your 
samples are given a unique number, and your 
name is not used. 
We do not expect to find anything which 
would affect your health care. If we do, we 
will let you and your GP know about it. 
All data will be collected and stored at the 
Royal Liverpool University Hospital and the 
Liverpool School of Tropical Medicine. It will 
be stored for a minimum period of 10 years.  
Your medical notes and research data are 
may be looked at by those who monitor the 
research. 
What are the benefits of taking part? 
There are no direct benefits to you. You will 
be a part of what we believe is a valuable 
research study that may help us to improve 
medical care for others. 
How much will I get paid? 
The money you are paid is compensation for 
inconvenience, loss of income, and possible 
discomfort of taking part. The first payment 
will be made at the end of part one. If you 
are eligible and choose to take part in the 
second study you will receive a second 
payment at the end of part two. Our 
payments are listed below: 
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Part 1  Visit length  
Visit 1: Study information, signing consent 45 min - 
Visit 2: Health check, screening and samples  60 min £40 
Visit 3: Screening and samples  30 min £30 
Visit 4: Having pneumococcus put up your nose. This includes you 
making daily telephone/text message contact for the first 7 days.  
(We will withhold £5 per day if you do not contact us) 
30 min £50 
Visits 5 and 6: Nasal samples, throat swab and blood samples 30 min £20 
Visit 7: Nasal samples and throat swab 20 min £15 
Visits 8 and 9: Nasal wash and throat swab (not all participants will be 
called for visit 9) 
15 min £10 
Visit 10: Nasal samples, throat swab and blood samples 25 min £20 
Optional home samples (for a subset of participants) 8 timepoints 
over 48 hours 
£48 
Part 2    
Visit 1: Screening and samples from the nose and blood 45 min £30 
Visit 2: Having pneumococcus put up your nose, and follow-up, as 
above 
60 min £50 
Visits 3, 4 and 5: Nasal samples, saliva collection, blood tests and throat 
swab 
15 min £15  
 
Contact details  
General questions: please contact the research team on 0151 706 3381 during normal working 
hours. Web site: www.lstmed.ac.uk/pneumoniavaccine 
 
The Chief Investigator for this study is Dr Jamie Rylance. You may contact him at the Liverpool 
School of Tropical Medicine, Pembroke Place, Liverpool, L3 5QA, UK. Telephone: 0151 705 3775. 
This research is sponsored by the Liverpool School of Tropical Medicine and the Royal Liverpool and 
Broadgreen University Hospitals. It is funded by the Medical Research Council. The research has 
been reviewed for scientific content by an external panel. 
The National Research Ethics Service Committee (16/NW/0031) has reviewed the study and given 
approval for it to take place. 
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Appendix 4: Letter of invitation from primary care 
 
<To be printed on GP Letter Headed Paper>  
 
 
<Insert Patient Title and Name> 
<Insert Patient Address1> 
<Insert Patient Address2> 
<Insert Patient Address3> 
<Insert Patient Address4>      <Insert Date> 
 
 
Dear <Insert Patient Title and Name> 
 
We’d like to introduce you to ground-breaking research looking at ways to prevent 
pneumonia. The researchers are based in the Liverpool School of Tropical Medicine and 
Royal Liverpool University Hospital, and they study the immune response to a bacteria 
placed in the nose.  A better understanding of these immune responses could help them 
develop a new vaccine which could be used to protect children and other vulnerable 
populations all over the world.   
 
The team have been working on this for five years and have extensive experience in carrying 
out similar studies in over 500 volunteers. 
 
As part of our commitment to medical research, we have agreed to assist the research team 
at the hospital in identifying potential people registered at our practice who may be 
interested in taking part in their studies. Our records indicate that you may be eligible to 
take part in a study for non-smoking, healthy people who are between 50 and 84 years of 
age.  The study will involve a full medical assessment followed by the placement of bacteria 
in the nose and regular follow-up with doctors and nurses.  All volunteers are paid for their 
time and inconvenience.   
 
 
This study has been reviewed and approved by the National Research Ethics Service 
Committee to ensure the safety of the people taking part.  
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Taking part in a study can be an enjoyable experience where you get to meet like-minded 
people in a relaxing environment with a host of facilities and an opportunity to learn more 
about research—and about your own health—from medical experts. 
 
To find out more about the study please:  
 
- Call 0151  706 4856 
- Text 2VOL to 88802 
- Email: 2volresearch@lstmed.ac.uk 
- Website: ***************** 
 
Yours Sincerely, 
<Insert GP Signature> 
 
 
 
Dr <Insert GP Title and Name> 
< Insert Name of Practice > 
 
Experimental Human Pneumococcal Carriage (EHPC): Effect of age on immune 
function 
Letter to patients Version 1: 23rd February 2016 
REC Ref: xx/xx/xxxx 
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Appendix 5: General practitioner questionnaire 
 
 
    
 
GP questionnaire 
 
Dear Dr ______________________ 
Your patient _______________________________________________,  
DOB _______________, address  __________________________ has 
agreed to participate in the following study: Experimental Human 
Pneumococcal Carriage: Effect of age on immune function. This study 
involves inoculation with pneumococcal bacteria and monitoring over 4 
weeks for experimental carriage of the bacteria.  
To ensure that your patient is eligible and safe to participate, we require 
some background information. We appreciate that your practice is 
extremely busy, and therefore a printed patient summary, including current 
medication, past medical history and previous immunisation and 
allergies would suffice.  Alternatively, please would you complete, sign, 
date and stamp the attached questionnaire at your earliest convenience. 
Please return the completed forms by fax to Helen Hill on (0151) 706 4856.  
Thank you very much for your kind assistance in our research project.  If 
you have any concerns or questions regarding this study please feel free to 
contact us.  
Sister Helen Hill 
helen.hill@lstmed.ac.uk 
Tel (0151) 706 4856 
Fax (0151) 706 4856 
Please tick one box 
 
1. Printed patient summary attached 
 
2. Questionnaire completed 
 
3. This patient is not registered at my practice 
191 
 
 
 
    
 
Medical Report to be completed by the General Practitioner 
 
General Medical 
History 
Please 
Circle 
Please Provide Details 
   
Does the patient 
have cardiovascular 
and/or respiratory 
disease? 
 
YES 
 
NO 
 
Details 
 
_________________________________ 
 
Does the patient 
have an 
immunosuppressive 
condition? 
(Including diabetes, 
active malignancy, 
immunosuppression 
secondary to 
medications etc) 
 
YES 
 
NO 
 
Details 
 
 
_________________________________ 
Is the patient 
allergic to penicillin/ 
amoxicillin? 
 
YES 
 
NO 
 
 
 
Has the patient 
been prescribed 
any regular 
medications? 
 
YES 
 
NO 
Details (or please attach copy of latest 
prescription) 
 
___________________________________ 
 
 
Has the patient ever 
been 
microbiologically 
diagnosed with 
pneumococcal 
disease? (Culture-
proven or molecular 
diagnosis) 
 
YES 
 
NO 
Details 
 
 
 
Has the patient 
received a 
pneumococcal 
vaccine at any 
point? (Prevenar/ 
pneumovax) 
 
YES 
 
NO 
 
Vaccine and date 
 
_________________________________ 
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Please provide any additional relevant information: 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Date 
 
 
Practice stamp 
GP signature 
 
 
Print name 
 
 
 
 
Please fax these forms back to the Research nurses at the Royal Liverpool 
University Hospital on 0151 706 4856 (safe haven fax). 
 
For office use only 
 
Review of GPQ by study physician (please sign box below) 
Eligible to proceed with 
study based on GPQ 
YES NO  (please circle) 
 
 
 
 
Name 
 
 
 
Signature 
 
 
 
Date 
 
 
 
EHPC and Aging: GP Questionnaire Version 2: 18 March 2016  
REC Ref: 16/NW/0031 
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Appendix 6: Post-inoculation safety leaflet 
 
EXPERIMENTAL HUMAN PNEUMOCCAL CARRIAGE MODEL 
Working towards a nasal vaccine for pneumonia: 
The effect of age on immune function 
                      
 
                                
 
                                  
                                              Information Sheet  
                                     EMERGENCY RESEARCH TEAM  
                                               XXXXX XXX XXX  
                                                7 days a week 
                                                      OR CALL  
                                                  0151 706 2000  
                                            Hospital Switchboard  
                                           Ask for XXXXXXXXXXXXX 
 
 
 
 
Experimental Human Pneumococcal Carriage: The effect of age on immune function 
Emergency inoculation leaflet V1 18th March 2016                     REC Ref 16/NW/0031 
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 Do you have any of the following?  
 
 
 
 
 
 
 
 
 
  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
• Fever (>37.5 ˚C)  
• Headache  
• Drowsiness  
• Cough  
• Shortness of breath 
• Earache  
• Generally Unwell  
 
NO 
Contact Research Team 
by 12noon every day for 
first 7 days on  
Xxxxx xxx xxx 
 
YES 
Call the Emergency Research 
Team on XXXXX XXX XXX 7 
days a week 
Or Call 0151 706 2000 and 
Ask for XXXXXXXXXXX  
If you are unable to get to a 
telephone start taking your 
antibiotics immediately  
 
Experimental Human Pneumococcal Carriage: The effect of age on immune function 
Emergency inoculation leaflet V1 18th March 2016                     REC Ref 16/NW/0031 
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What should I do?  
If you have any of the above symptoms we would ask that you should contact 
the research team on the following numbers without delay  
Xxxxx xxx xxx 7 days a week  
0151 706 2000 Hospital switchboard - ask for xxxxxxxxxxxxx who will be 
available by telephone 7 days a week for advice.  
 
What if I feel very unwell?  
In the unlikely event you feel very unwell, the research team emergency 
number (xxxxx xxx xxx) is available seven days a week. If for any reason you are 
unable to make contact with the team (or are not able to access a phone) we 
recommend that you start taking the antibiotics immediately (one tablet 
(500mg) of AMOXICILLIN to be taken three times per day) and attend your 
nearest Emergency department.  
 
 
What do I tell the doctor?  
If, for any reason you have to attend your doctor or the hospital you need to 
inform them that: You have had live Streptococcus pneumoniae inoculated into 
your nose on ___/___/_______ as part of a clinical study. The bacteria you 
carry are fully sensitive to amoxicillin and you have no history of allergy to this 
antibiotic.  
 
Do I need to do anything if I feel well?  
We ask that for the first 7 days you text or phone the research nurse by 
12noon every day on the following number: xxxxx xxx xxx. .  
This is to ensure that you are not experiencing any problems. If we do not hear 
from you by 12noon we will contact you to make sure you are not experiencing 
any problems. In the event that we cannot contact you, your next of kin will be 
contacted. 
 
 
 
 
 
 
Experimental Human Pneumococcal Carriage: The effect of age on immune function 
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Things you should know........  
Following inoculation with pneumococcus  
After the pneumococcus is put into your nose it is possible that it may cause an 
infection. Although this is very unlikely it is sensible that you familiarise 
yourself with symptoms or signs that may indicate infection to make sure they 
are recognised and treated early.  
Keep your thermometer, antibiotics and contact numbers with you at all times 
during the study.  
WHAT SHOULD I LOOK OUT FOR?  
If you feel generally unwell or have any of the following:  
• Fever (temp>37.5 ˚C)  
• Shivering  
• Headache  
• Drowsiness  
• Shortness of breath 
• Cough  
• Earache  
 
If you have any of the symptoms or signs marked in bold please call the 
emergency number immediately.  
                                                   Xxxxx xxx xxx  
                                                   7 days a week  
                         OR Phone 0151 706 2000 and ask for xxxxxxxxxxxxx 
 
Experimental Human Pneumococcal Carriage: The effect of age on immune function 
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Appendix 7: Poster presented at the International Symposium 
on Pneumococci and Pneumococcal Diseases, 2016 
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Appendix 8: Abstract presented at the British Infection 
Association Spring Meeting, 2017 
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Appendix 9: Poster presented at the LSTM Postgraduate 
Researcher Conference, 2018  
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Appendix 10: Review article published in Clinical and Vaccine 
Immunology, 2017 
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Appendix 11: Research paper published in the Journal of 
Infectious Diseases, 2019 
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